<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006576.pub2" GROUP_ID="PROSTATE" ID="790506111715151848" MERGED_FROM="" MODIFIED="2011-03-30 15:12:17 +0200" MODIFIED_BY="Paolo Rosati" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;/p&gt;" NOTES_MODIFIED="2011-02-24 13:22:30 -0600" NOTES_MODIFIED_BY="James Tacklind" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.1">
<COVER_SHEET MODIFIED="2011-03-30 15:12:17 +0200" MODIFIED_BY="Paolo Rosati">
<TITLE>Antibiotic prophylaxis for transrectal prostate biopsy</TITLE>
<CONTACT MODIFIED="2011-02-28 16:34:39 +0100" MODIFIED_BY="James Tacklind"><PERSON ID="F2AA229282E26AA2005EBC6EC24F60D0" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Emerson</FIRST_NAME><MIDDLE_INITIALS>L.</MIDDLE_INITIALS><LAST_NAME>Zani</LAST_NAME><EMAIL_1>emersonzani@ig.com.br</EMAIL_1><ADDRESS><ORGANISATION>State University of Campinas (UNICAMP)</ORGANISATION><ADDRESS_1>Av. Bosque da Saude, 655, Apto 153</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04142-091</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 115 585 0677</PHONE_1><PHONE_2>+55 118 274 6444</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-02-28 16:34:39 +0100" MODIFIED_BY="James Tacklind"><PERSON ID="F2AA229282E26AA2005EBC6EC24F60D0" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Emerson</FIRST_NAME><MIDDLE_INITIALS>L.</MIDDLE_INITIALS><LAST_NAME>Zani</LAST_NAME><EMAIL_1>emersonzani@ig.com.br</EMAIL_1><ADDRESS><ORGANISATION>State University of Campinas (UNICAMP)</ORGANISATION><ADDRESS_1>Av. Bosque da Saude, 655, Apto 153</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04142-091</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 115 585 0677</PHONE_1><PHONE_2>+55 118 274 6444</PHONE_2></ADDRESS></PERSON><PERSON ID="13680" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Otavio</FIRST_NAME><MIDDLE_INITIALS>Augusto Camara</MIDDLE_INITIALS><LAST_NAME>Clark</LAST_NAME><POSITION>Chief of Oncology Service</POSITION><EMAIL_1>clark@evidencias.com.br</EMAIL_1><EMAIL_2>otavioclark@uol.com.br</EMAIL_2><ADDRESS><DEPARTMENT>EVIDENCIAS</DEPARTMENT><ORGANISATION>Scientific Solutions in Healthcare</ORGANISATION><ADDRESS_1>Av. Dr. Luis de Tella</ADDRESS_1><ADDRESS_2>Campinas</ADDRESS_2><CITY>San Paolo</CITY><ZIP>1570</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 193 287 8310</PHONE_1></ADDRESS></PERSON><PERSON ID="B89177C682E26AA2007D5B6E9D85C7FF" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Nelson</FIRST_NAME><LAST_NAME>Rodrigues Netto Jr</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>nrnetto@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Division of Urology</DEPARTMENT><ORGANISATION>State University of Campinas (UNICAMP)</ORGANISATION><ADDRESS_1>R. Augusta, 2347, 3º andar</ADDRESS_1><CITY>Campinas, São Paulo</CITY><ZIP>01413-000</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 113 082 6030</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-30 15:12:17 +0200" MODIFIED_BY="Paolo Rosati">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="30" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="3" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-07-25 19:58:01 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-07-19 20:30:50 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-07-19 20:30:50 -0500" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-07-25 19:58:01 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-07-25 19:58:01 -0500" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-02-10 09:56:22 -0600" MODIFIED_BY="James Tacklind">
<SUMMARY MODIFIED="2010-10-17 21:12:35 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-07-18 18:56:03 -0500" MODIFIED_BY="[Empty name]">Antibiotic prophylaxis for transrectal prostate biopsy</TITLE>
<SUMMARY_BODY MODIFIED="2010-10-17 21:12:35 -0500" MODIFIED_BY="[Empty name]">
<P>Prostate cancer is the second most commonly diagnosed cancer in men and transrectal prostate biopsy is the procedure to obtain tissue for the histological diagnosis of carcinoma of the prostate. Despite the fact that infective complications after transrectal prostate biopsy are well known, there is uncertainty about the necessity and effectiveness of routine prophylactic antibiotics and a clear lack of standardization in antibiotic prophylaxis for transrectal prostate biopsy. In nine trials we observed that antibiotic prophylaxis is effective in preventing infectious complications (bacteriuria, bacteremia, fever, urinary tract infection, sepsis) and hospitalization following prostate biopsy. Several classes of antibiotics are effective for prophylaxis in prostate biopsy, with the quinolones the best analysed class. There are no definitive data to confirm that antibiotic for long-course is superior to short-course treatment, or that multiple-dose treatment is superior to single-dose treatment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-02-10 09:38:29 -0600" MODIFIED_BY="James Tacklind">
<ABS_BACKGROUND MODIFIED="2010-11-10 09:58:26 -0600" MODIFIED_BY="James Tacklind">
<P>Transrectal prostate biopsy (TRPB) is a well established procedure used to obtain tissue for the histological diagnosis of carcinoma of the prostate. Despite the fact that TRPB is generally considered a safe procedure, it may be accompanied by traumatic and infective complications, including asymptomatic bacteriuria (bacteria in the urine), urinary tract infection (UTI), transitory bacteremia (bacteria in the blood), fever episodes, and sepsis (pathogenic microorganisms or their toxins in the blood). Although infective complications after TRPB are well known, there is uncertainty about the necessity and effectiveness of routine prophylactic antibiotics and their adverse effects, as well as a clear lack of standardization.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-03-12 10:33:57 -0600" MODIFIED_BY="James Tacklind">
<P>To evaluate the effectiveness and adverse effects of prophylactic antibiotic treatment in TRPB.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-11 20:30:44 -0500" MODIFIED_BY="[Empty name]">
<P>The search covered the principal electronic databases: MEDLINE, EMBASE, LILACS and the Cochrane Central Register of Controlled Trials (CENTRAL). Experts were consulted and references from the relevant articles were scanned.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-10 09:59:20 -0600" MODIFIED_BY="James Tacklind">
<P>All randomized, controlled trials (RCTs) of men who underwent TRPB and received prophylactic antibiotics or placebo/no treatment, were selected, and all RCTs looking at one type of antibiotic versus another, including comparable dosages, routes of administration, frequency of administration, and duration of antibiotic treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-11 20:40:30 -0500" MODIFIED_BY="[Empty name]">
<P>Two reviewers (ELZ, OACC) independently selected included trials and extracted study data. Any disagreements were resolved by a third party (NRNJ).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-10 09:38:29 -0600" MODIFIED_BY="James Tacklind">
<P>Overall, more than 3500 references were considered and 19 original reports with a total of 3599 patients were included.</P>
<P>There were 9 trials analysing antibiotics versus placebo/no treatment, with all outcomes significantly favouring antibiotic use (P &lt; 0.05) (I<SUP>2 </SUP>= 0%), including bacteriuria (risk ratio (RR) 0.25 (95% confidence interval (CI) 0.15 to 0.42), bacteremia (RR 0.67, 95% CI 0.49 to 0.92), fever (RR 0.39, 95% CI 0.23 to 0.64), urinary tract infection (RR 0.37, 95% CI 0.22 to 0.62), and hospitalization (RR 0.13, 95% CI 0.03 to 0.55). Several classes of antibiotics were effective prophylactically for TRPB, while the quinolones, with the highest number of studies (5) and patients (1188), were the best analysed. For 'antibiotics versus enema', we analysed four studies with a limited number of patients. The differences between groups for all outcomes were not significant. For 'antibiotic versus antibiotic + enema', only the risk of bacteremia (RR 0.25, 95% CI 0.08 to 0.75) was diminished in the 'antibiotic + enema group'. Seven trials reported the effects of short-course (1 day) versus long-course (3 days) antibiotics. Long course was significantly better than short-course treatment only for bacteriuria (RR 2.09, 95% CI 1.17 to 3.73). For 'single versus multiple dose', there was significantly greater risk of bacteriuria for single-dose treatment (RR 1.98, 95% CI 1.18 to 3.33). Comparing oral versus systemic administration - intramuscular injection (IM), or intravenous (IV) - of antibiotics, there were no significant differences in the groups for bacteriuria, fever, UTI and hospitalization.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-11-10 10:02:48 -0600" MODIFIED_BY="James Tacklind">
<P>Antibiotic prophylaxis is effective in preventing infectious complications following TRPB. There is no definitive data to confirm that antibiotics for long-course (3 days) are superior to short-course treatments (1 day), or that multiple-dose treatment is superior to single-dose.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-02-10 09:56:22 -0600" MODIFIED_BY="James Tacklind">
<BACKGROUND MODIFIED="2010-11-10 11:01:18 -0600" MODIFIED_BY="James Tacklind">
<CONDITION MODIFIED="2010-11-10 10:26:44 -0600" MODIFIED_BY="James Tacklind">
<P>Prostate cancer (PCa) is the second most commonly diagnosed cancer in men and represents a significant health problem. Worldwide, more than 900,000 men are diagnosed with prostate cancer every year with an estimated 258,000 deaths in 2008 (<LINK REF="REF-Ferlay-2010" TYPE="REFERENCE">Ferlay 2010</LINK>). Incidence rates of prostate cancer vary by more than 25-fold worldwide and nearly three-quarters of the registered cases occur in economically developed countries (658,000 cases). The highest incidence rates are in Australia/New Zealand (104.2 per 100,000), Western and Northern Europe and North America, largely because the widespread use of prostate-specific antigen (PSA) testing in those regions (<LINK REF="REF-Ferlay-2010" TYPE="REFERENCE">Ferlay 2010</LINK>). In these countries prostate cancer is the most frequently diagnosed cancer among men (<LINK REF="REF-ACS-2010" TYPE="REFERENCE">ACS 2010</LINK>; <LINK REF="REF-Ferlay-2007" TYPE="REFERENCE">Ferlay 2007</LINK>).<BR/>
</P>
<P>While screening - by digital rectal examination (DRE) and PSA analysis - has increased detection of early stage prostate cancer, it is not yet known whether early detection and subsequent treatment improves disease-specific morbidity and mortality (<LINK REF="REF-Andriole-2009" TYPE="REFERENCE">Andriole 2009</LINK>). The American Cancer Society and American Urological Association recommend annual screening (<LINK REF="REF-ACS-2009" TYPE="REFERENCE">ACS 2009</LINK>; <LINK REF="REF-AUA-2009" TYPE="REFERENCE">AUA 2009</LINK>), while in contrast, the United States Preventive Task Force believes that there is insufficient scientific evidence to recommend it (<LINK REF="REF-US-Task-Force-2008" TYPE="REFERENCE">US Task Force 2008</LINK>).</P>
<P>Two recent studies evaluated the influence of screening on the rate of death from PCa and obtained different results. The first (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial), conducted in 10 centers in the United States, recruited 76,693 men who underwent PSA tests and DRE versus usual clinical care (which could include screening for PCa) (<LINK REF="REF-Andriole-2009" TYPE="REFERENCE">Andriole 2009</LINK>). With 7 years of follow up, more men in the screening group were diagnosed with PCa (7.4% versus 6.1%), but cancer mortality was low and equal in both groups (0.13% and 0.11%). The second study, the European Randomized Study of Screening for Prostate Cancer (ERSPC), was conducted in 7 European countries and included 162,243 men followed for a median of 9 years. The men were randomized into two groups: screening (an average of once per 4 years) versus no screening (<LINK REF="REF-Schr_x00f6_der-2009" TYPE="REFERENCE">Schröder 2009</LINK>). In the screening group the rate of PCa diagnosis was higher (8.2% versus 4.8%) and mortality was 20% lower (0.29% versus 0.36%) relative to the no-screening group, but at the cost of a high rate of overdiagnosis and overtreatment.</P>
<P>The prostate biopsy has evolved from the digitally guided biopsy to the current standard of the transrectal ultrasound-guided systematic biopsy (TRPB) method. The TRPB is a well established out-patient procedure performed to obtain tissue for the histological diagnosis of carcinoma of the prostate in men with either an elevated, or rising, PSA, or an abnormal DRE that raises suspicions of prostate cancer (<LINK REF="REF-Hodge-1989a" TYPE="REFERENCE">Hodge 1989a</LINK>; <LINK REF="REF-Sruogis-2005" TYPE="REFERENCE">Sruogis 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-11-10 10:50:56 -0600" MODIFIED_BY="James Tacklind">
<P>Despite the fact that TRPB is generally considered a safe procedure, it may be accompanied by traumatic and infective complications, the latter including asymptomatic bacteriuria, urinary tract infection, transitory bacteremia, fever episodes, and sepsis (<LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>). Although infective complications after TRPB are well known and rarely fatal (<LINK REF="REF-Breslin-1978" TYPE="REFERENCE">Breslin 1978</LINK>; <LINK REF="REF-Brewster-1993" TYPE="REFERENCE">Brewster 1993</LINK>; <LINK REF="REF-Borer-1999" TYPE="REFERENCE">Borer 1999</LINK>), there is no agreement that their treatment by antibiotic prophylaxis is really necessary. </P>
<P>There is significant variability in the reported infection rates after TRPB. Historically, the use of larger gauge needles (14 gauge) to perform the biopsy was associated with infection rates of 2% to 79%, but, with thinner needles, rates from 0% to 37%, irrespective of the use of antibiotics (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="REF-Enlud-1997" TYPE="REFERENCE">Enlud 1997</LINK>; <LINK REF="STD-Roach-1991" TYPE="STUDY">Roach 1991</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Shigemura-2005" TYPE="STUDY">Shigemura 2005</LINK>). </P>
<P>The need for prophylaxis has been questioned by several authors, who note the incidence of post-procedural bacteremia is relatively low, usually transient, and resolves without additional therapy (<LINK REF="REF-Enlud-1997" TYPE="REFERENCE">Enlud 1997</LINK>; <LINK REF="REF-Wendel-1967" TYPE="REFERENCE">Wendel 1967</LINK>; <LINK REF="REF-Astraldi-1937" TYPE="REFERENCE">Astraldi 1937</LINK>). In one prospective study (N = 415), patients who underwent TRPB with no antibiotic prophylaxis had an infection complication rate of 2.9% (<LINK REF="REF-Enlud-1997" TYPE="REFERENCE">Enlud 1997</LINK>).</P>
<P>Even among those who use antibiotic prophylaxis there is much variability in the type, dose, frequency of administration, and duration of treatment. Some reviews that surveyed radiology and urology departments that regularly undertook TRPB have shown a total of 48 different regimens utilizing 13 different antibiotics (<LINK REF="REF-Taylor-1997" TYPE="REFERENCE">Taylor 1997</LINK>; <LINK REF="REF-Shandera-1998" TYPE="REFERENCE">Shandera 1998</LINK>), ranging from a single oral dose of ciprofloxacin before TRPB, to intravenous cefuroxime and rectal metronidazole before the procedure, followed by oral cephalexin for 5 days.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-10 10:52:18 -0600" MODIFIED_BY="James Tacklind">
<P>Recent studies, including randomized, controlled trials comparing the use of antibiotic versus placebo/no treatment in TRPB, have shown that antibiotic prophylaxis results in a lower incidence of post-biopsy febrile episodes, positive urine cultures, and bacteremia (<LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>).<BR/>Several prospective, randomized trials have examined the value of different types of antibiotics and different regimens of antibiotic prophylaxis in TRPB, with variable results (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Sabbagh-2004" TYPE="STUDY">Sabbagh 2004</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>). These data confirm that there is a clear lack of standardization in antibiotic prophylaxis for transrectal prostate biopsy with widely varying costs for each of the different regimens.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-11-10 11:01:18 -0600" MODIFIED_BY="James Tacklind">
<P>The need for prophylaxis has been questioned by some authors (<LINK REF="REF-Enlud-1997" TYPE="REFERENCE">Enlud 1997</LINK>; <LINK REF="REF-Wendel-1967" TYPE="REFERENCE">Wendel 1967</LINK>) and several studies included a placebo group versus use of antibiotic (<LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>), demonstrating doubt about the effectiveness of prophylactic antibiotics. Among studies that used antibiotic prophylaxis there is much variability in the type, dose, frequency of administration, and duration of treatment of antibiotics, with conflicting results. Therefore, a systematic review is necessary to evaluate whether antibiotic prophylaxis is necessary for TRPB, and if so, what is the most effective and safest method.</P>
<P>This systematic review evaluated the effectiveness of antibiotic prophylaxis in reducing the risk of infective complications following TRPB, with no restriction of language. The review also evaluated what should be the antibiotic of choice for prophylaxis in TRPB.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-03-10 13:33:03 -0600" MODIFIED_BY="James Tacklind">
<P>The objectives of this review were:<BR/>
</P>
<UL>
<LI>to evaluate the effectiveness of antibiotic prophylaxis in reducing the risk of infective complications following TRPB (bacteriuria, bacteremia, fever, urinary tract infection);</LI>
<LI>to evaluate what should be the antibiotic of choice for prophylaxis in transrectal prostate biopsy, including dosage, route of administration, frequency of administration and duration of treatment.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-10 13:05:59 -0600" MODIFIED_BY="James Tacklind">
<SELECTION_CRITERIA MODIFIED="2010-11-10 13:00:22 -0600" MODIFIED_BY="James Tacklind">
<CRIT_STUDIES MODIFIED="2010-11-10 13:00:22 -0600" MODIFIED_BY="James Tacklind">
<P>All randomized, controlled trials (RCT) in which patients received TRPB and prophylactic antibiotics versus placebo/no treatment, and all RCTs looking at one type of antibiotic versus another, compared dosage, route of administration, frequency of administration, or duration of treatment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-17 20:14:54 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Male patients who required TRPB and received prophylactic antibiotics or placebo/no treatment.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>history of hypersensitivity to antibiotic in study</LI>
<LI>significant gastrointestinal disease or inability to tolerate oral medication</LI>
<LI>presence of culture-proven urinary tract infection prior to intervention</LI>
<LI>presence of indwelling bladder catheters</LI>
<LI>history of endoscopic manipulation of the urinary tract within 7 days prior to the study enrollment</LI>
<LI>antibiotic(s) given during the preceding 10 days</LI>
<LI>patients with prostheses (e.g. hip replacement, prosthetic cardiac valves) and congenital heart disease requiring prophylactic antibiotics</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroups</HEADING>
<P>Patients with co-morbid conditions potentially immunosuppressive (and thus prone to infections), such as diabetes, renal failure, chronic corticosteroids use, and immunodeficiency conditions.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-08-06 10:34:39 -0500" MODIFIED_BY="James Tacklind">
<UL>
<LI>antibiotic versus placebo or no treatment</LI>
<LI>antibiotic class A (quinolones, sulfonamides, aminoglycosides, cephalosporins, &#946;-lactamase inhibitors, metronidazole) versus class B (quinolones, sulfonamides, aminoglycosides, cephalosporins, &#946;-lactamase inhibitors, metronidazole)</LI>
<LI>single-dose versus multiple-dose treatment</LI>
<LI>short-course (one day) versus long-course treatment (three days)</LI>
<LI>oral versus systemic administration (intravenous (IV) and intramuscular (IM))</LI>
<LI>antibiotic versus enema</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-12-30 18:30:17 -0600" MODIFIED_BY="[Empty name]">
<P>Therapeutic response according to the definition by the authors of each study, analyzing the following variables.</P>
<OL>
<LI>Sepsis: SIRS caused by infection (SIRS - defined as two or more of the following: temperature &#8805; 38<SUP>o</SUP> C (centigrade) or less than 36<SUP>o </SUP>C; heart rate more than 90 beats/minute; respiratory rate more than 20 breaths/minute or respiratory alkalosis; white blood cell count more than 12,000 or immature forms more than 4000 or more than 10%) (<LINK REF="REF-Levy-2002" TYPE="REFERENCE">Levy 2002</LINK>)</LI>
<LI>Fever (temperature &gt; 37.5<SUP>o</SUP> C)</LI>
<LI>Bacteremia: defined as the presence of bacteria in blood culture, accessed due to protocol blood collection, irrespective of clinical signs</LI>
<LI>Bacteriuria: the presence of bacteria in the urine in the post-procedure period and/or culture proven (presence of any uropathogen not present previously and/or colony forming units (CFU) &gt; 100,000/mL) (millilitres) in the absence of clinical signs of infection, diagnosed due to protocol urine collection</LI>
<LI>UTI: bacteriuria on post-procedure period associated with clinical signs of UTI (dysuria, frequency, urgency)</LI>
</OL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-21 19:40:46 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Bacteriuria</LI>
<LI>Bacteremia</LI>
<LI>Fever</LI>
<LI>Urinary tract infection</LI>
<LI>Sepsis</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-08-21 19:38:39 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Mortality</LI>
<LI>Hospitalization due to infective complications</LI>
<LI>Adverse effects of antibiotics (gastrointestinal, allergic)</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-10 13:03:28 -0600" MODIFIED_BY="James Tacklind">
<ELECTRONIC_SEARCHES MODIFIED="2010-11-10 13:03:28 -0600" MODIFIED_BY="James Tacklind">
<P>Strategies of search for electronic databases: for MEDLINE we used the methodological search strategy for RCTs, previously reported (<LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK>); for EMBASE we used adaptations of this same strategy, previously reported (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>); for LILACS we used the methodological search strategy previously reported by one of the reviewers (<LINK REF="REF-Castro-1999" TYPE="REFERENCE">Castro 1999</LINK>).</P>
<P>There was no restrictions for language.</P>
<P>Relevant trials were obtained from the following sources:</P>
<UL>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> (Issue 1, 2008 to Issue 1, 2010);</LI>
<LI>MEDLINE (1966 to 2010);</LI>
<LI>EMBASE (1980 to 2010);</LI>
<LI>LILACS (1980 to 2010).</LI>
</UL>
<P>To the methodological search strategy of each database we added the specific terms pertinent to this review as free text and MeSH terms.</P>
<OL>
<LI>methodological search strategy</LI>
<LI>PROSTATE/ all subheadings</LI>
<LI>prostat*</LI>
<LI>#2 or #3</LI>
<LI>BIOPSY/ all subheadings</LI>
<LI>biops*</LI>
<LI>#5 or #6</LI>
<LI>#4 and #7</LI>
<LI>ANTI-INFECTIVE AGENTS/ all subheadings</LI>
<LI>ANTI-INFECTIVE AGENTS, LOCAL/</LI>
<LI>ANTIPARASITIC AGENTS/</LI>
<LI>ANTIVIRAL AGENTS/</LI>
<LI>DISINFECTANTS/</LI>
<LI>ANTIFUNGAL AGENTS/</LI>
<LI>#10 or #11 or #12 or #13 or #14</LI>
<LI>#9 not #15</LI>
<LI>ANTIBIOTIC-PROPHYLAXIS/ all subheadings</LI>
<LI>antibiot*</LI>
<LI>antimicr*</LI>
<LI>prophyla*</LI>
<LI>prevent*</LI>
<LI>#16 or #17 or #18 or #19 or #20 or #21</LI>
<LI>#8 and #22</LI>
<LI>#1 and #23</LI>
<LI>INFECTION/ all subheadings</LI>
<LI>infect*</LI>
<LI>#25 or #26</LI>
<LI>#8 and #27</LI>
<LI>#1 and #28</LI>
<LI>FEVER/ all subheadings</LI>
<LI>pyrex*</LI>
<LI>#30 or #31</LI>
<LI>#8 and #32</LI>
<LI>#1 and #33</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-06 10:24:02 -0500" MODIFIED_BY="James Tacklind">
<UL>
<LI>reference lists of urology textbooks, review articles and relevant trials (All references of relevant articles were scanned and all additional articles of potential interest were retrieved for further analysis.)</LI>
<LI>reference lists of abstracts from urology scientific meetings</LI>
<LI>letters seeking information about unpublished or incomplete trials to investigators known to be involved in previous studies</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-10 13:05:59 -0600" MODIFIED_BY="James Tacklind">
<STUDY_SELECTION MODIFIED="2010-10-15 21:05:21 -0500" MODIFIED_BY="[Empty name]">
<P>All potential trials' titles and abstracts were read by two reviewers independently, and were selected for eligibility according to the criteria specified in the protocol. Each of these articles was read by reviewers who evaluated for inclusion. If the article did not fit the inclusion criteria, the reasons for exclusion were detailed (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables). Any discrepancies were resolved by discussion, or by input of a third party.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-03-10 13:40:10 -0600" MODIFIED_BY="James Tacklind">
<P>For each included article a careful analysis and an attentive reading was done to extract data. A specific formulary for data extraction was created and submitted to a pre-test with three studies of the same area, but not included in this review. There was no detection of any failure or ambiguity and the formulary was approved for use in the major search.<BR/>Two of the reviewers independently extracted the data from the articles (ELZ, OACC). Data were extracted on the selected clinical outcomes, methodological characteristics, and demographics of participants.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-11-10 13:05:12 -0600" MODIFIED_BY="James Tacklind">
<P>The methodological quality of each selected trial was assessed by the same two reviewers (ELZ, OACC). Criteria assessed were the generation and concealment of the sequence of randomization, blinding (investigators, participants, outcome assessors and data analysis), intention-to-treat analysis, use of placebo, completeness of follow up and source of funding.<BR/>Trials were assessed for methodological quality using the standard Cochrane criteria for allocation concealment.<BR/>A - Adequate: randomization method described that does not allow investigator/participant to know or influence the intervention group before an eligible participant entered into the study.<BR/>B - Unclear: randomization stated but no information on method used is available.<BR/>C - Inadequate: method of randomization used such as alternate medical record numbers or unsealed envelopes; any information in the study which indicated that investigators or participants could influence intervention group.<BR/>Only RCTs with allocation concealment classified as score A and B were used in this review.</P>
<P>To assess the possibility of publication bias (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>) we performed a funnel-plot test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-11-10 13:05:59 -0600" MODIFIED_BY="James Tacklind">
<P>For dichotomous outcome (bacteriuria, bacteremia, fever, UTI, sepsis, hospitalization, death) results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Data were pooled using the fixed-effects model. Heterogeneity was analysed using an I<SUP>2</SUP> test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When there was considerable heterogeneity among the studies (I<SUP>2 </SUP>&gt; 50%), the random-effects model was utilized. When possible, the risk difference with 95% CI was calculated for each adverse effect, either compared to no treatment . If "considerable" heterogeneity was detected (I<SUP>2 </SUP>&gt; 50%), a possible explanation was pursued. If a reasonable cause was found, a separate analysis was performed. If the cause was not apparent and heterogeneity was caused by divergent data in terms of direction of results (i.e. data favouring one or other treatment), we did not pool the data. The studies were included in a meta-analysis using the outcomes presented above. The meta-analysis was performed using the Review Manager 5 package. In case it was not possible to perform a meta-analysis of the data, the results were presented in a descriptive form with individual evaluation of the results of each study.</P>
</EFFECT_MEASURES>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-02-10 09:56:22 -0600" MODIFIED_BY="James Tacklind">
<STUDY_DESCRIPTION MODIFIED="2011-02-10 09:56:22 -0600" MODIFIED_BY="James Tacklind">
<P>A total of 3599 men were randomized. Weighted mean age was 66.6 (14 trials), which ranged from 40 to 94 years (12 trials). Three trials reported racial data, with 81.4% White and 11.3% Black. Nineteen trials reported trial origination (India = 1, China = 1, Turkey = 3, Greece = 1, Italy = 1, France = 1, United Kingdom = 3, United States = 4, Canada = 1, Brazil = 2, multinational = 1). Study discontinuations ranged from 0% to 25%, with an overall mean of 4.7%. Weighted mean follow up was 13.5 days, and ranged from 4 to 28 days. </P>
<P>Nine placebo controlled trials described the effects of antibiotics versus placebo/no treatment in preventing infectious complications following TRPB (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). Five trials (1229 patients) compared quinolones to placebo (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). Two studies compared quinolones to nitroimidazoles (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK> and <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK> = tinidazole; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK> and <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK> = metronidazole). Two trials (189 patients) compared sulfonamides to placebo (<LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>). Two trials (129 patients) compared penicillins to placebo (<LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK> = piperacillin; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK> = carbenicillin). One trial (40 patients) compared gentamicin to placebo (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>). The majority of trials (eight) utilized pre-biopsy enema, except one (<LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>). Three trials were three-armed studies (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). One trial (<LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>) compared data of two different antibiotics versus placebo, and two trials compared antibiotic short-course and long-course versus placebo (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). Included patients in both groups were low risk patients; excluded patients had predisposing factors for infection (see 'Exclusion criteria').</P>
<P>Four trials (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>) described the effects of antibiotics compared to enemas in preventing infectious complications. Three trials (280 patients) were designed to compared antibiotic versus enema versus antibiotic + enema versus placebo/no treatment (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK> = gentamicin, povidone iodine enema; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK> = piperacillin, povidone iodine enema; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK> = ciprofloxacin, rifampicin enema). One trial (120 patients) (<LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>) compared antibiotic (ciprofloxacin) for 2 days versus antibiotic for 7 days versus antibiotic (2 days) + enema versus enema (sodium biphosphate).</P>
<P>Six trials reported the effects of short-course versus long-course antibiotics (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). All studies (1693 patients) compared quinolones for one day versus three days. Five trials (1588 patients) utilized ciprofloxacin (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK> = ciprofloxacin extended release; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>), and in two studies quinolones were compared to a nitroimidazole antibiotics (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK> and <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK> = tinidazole; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK> and <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK> = metronidazole). One trial utilized norfloxacin (<LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>).</P>
<P>Seven trials reported the effects of single-dose versus multiple-dose treatment (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Bates-1998" TYPE="STUDY">Bates 1998</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). Five trials (1588 patients) utilized ciprofloxacin (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK> = ciprofloxacin extended release; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>), and in two studies quinolones were compared to nitroimidazole antibiotics (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK> and <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK> = tinidazole; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK> and <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK> = metronidazole). One trial utilized norfloxacin (<LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>) and one trial utilized co-amoxiclav (<LINK REF="STD-Bates-1998" TYPE="STUDY">Bates 1998</LINK>).</P>
<P>Seven trials compared different classes of antibiotics (<LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK>). We performed three subgroup analyses: quinolones versus other antibiotics, sulfonamide versus other antibiotics and piperacillin tazobactam versus other antibiotics.</P>
<P>Quinolones were compared to other antibiotics in three studies (648 patients) (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK> = ceftriaxone; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK> = piperacillin tazobactam; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK> = sulfonamide). Sulfonamide were compared to other antibiotics in three studies (326 patients) (<LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK> = netilmicin-metronidazole; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK> = ofloxacin; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK> = gentamicin). Piperacillin tazobactam were compared to other antibiotics in two studies (247 patients) (<LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK> = cefuroxime; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK> = ciprofloxacin).</P>
<P>Four trials compared oral versus systemic administration with 754 patients (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK> = ceftriaxone versus ciprofloxacin; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK> piperacillin-tazobactam versus ciprofloxacin; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK> = netilmicin+metronidazole versus sulfonamide; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK> = gentamicin versus sulfonamide).</P>
<SEARCH_RESULTS MODIFIED="2010-10-25 11:13:46 -0500" MODIFIED_BY="James Tacklind">
<P>Overall, more than 3500 references were scanned and updated to March 2010. Fifty-six were selected for full text analysis and were retrieved. Of these, 37 were excluded for various reasons (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table). Nineteen original reports of trials on the role of antibiotic in transrectal prostate biopsy with a total of 3599 patients were included in the final analysis (see the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-11-10 13:34:30 -0600" MODIFIED_BY="James Tacklind">
<P>See '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-02-10 09:56:22 -0600" MODIFIED_BY="James Tacklind">
<P>Thirty seven studies were excluded (<LINK REF="STD-Akay-2006" TYPE="STUDY">Akay 2006</LINK>; <LINK REF="STD-Anjum-1996" TYPE="STUDY">Anjum 1996</LINK>; <LINK REF="STD-Argyropoulos-2007" TYPE="STUDY">Argyropoulos 2007</LINK>; <LINK REF="STD-Aus-1993" TYPE="STUDY">Aus 1993</LINK>; <LINK REF="STD-Aus-1996" TYPE="STUDY">Aus 1996</LINK>; <LINK REF="STD-Bjerklund-2004" TYPE="STUDY">Bjerklund 2004</LINK>; <LINK REF="STD-Bosquet-Sanz-2006" TYPE="STUDY">Bosquet Sanz 2006</LINK>; <LINK REF="STD-Carey-2001" TYPE="STUDY">Carey 2001</LINK>; <LINK REF="STD-Eaton-1981" TYPE="STUDY">Eaton 1981</LINK>; <LINK REF="STD-Eggert-1999" TYPE="STUDY">Eggert 1999</LINK>; <LINK REF="STD-Ferreira-1985" TYPE="STUDY">Ferreira 1985</LINK>; <LINK REF="STD-Herranz-Amo-1996" TYPE="STUDY">Herranz Amo 1996</LINK>; <LINK REF="STD-Hosokawa-2005" TYPE="STUDY">Hosokawa 2005</LINK>; <LINK REF="STD-Hotta-2001" TYPE="STUDY">Hotta 2001</LINK>; <LINK REF="STD-Huang-2006" TYPE="STUDY">Huang 2006</LINK>; <LINK REF="STD-Ito-2002" TYPE="STUDY">Ito 2002</LINK>; <LINK REF="STD-Janoff-2000" TYPE="STUDY">Janoff 2000</LINK>; <LINK REF="STD-Jeon-2003" TYPE="STUDY">Jeon 2003</LINK>; <LINK REF="STD-Khan-1984" TYPE="STUDY">Khan 1984</LINK>; <LINK REF="STD-Lindert-2000" TYPE="STUDY">Lindert 2000</LINK>; <LINK REF="STD-Lindstedt-2006" TYPE="STUDY">Lindstedt 2006</LINK>; <LINK REF="STD-Mari-2007" TYPE="STUDY">Mari 2007</LINK>; <LINK REF="STD-Meyer-1987" TYPE="STUDY">Meyer 1987</LINK>; <LINK REF="STD-Otrock-2004" TYPE="STUDY">Otrock 2004</LINK>; <LINK REF="STD-Peters-2003" TYPE="STUDY">Peters 2003</LINK>; <LINK REF="STD-Puig-2006" TYPE="STUDY">Puig 2006</LINK>; <LINK REF="STD-Rees-1980" TYPE="STUDY">Rees 1980</LINK>; <LINK REF="STD-Roach-1991" TYPE="STUDY">Roach 1991</LINK>; <LINK REF="STD-Sabbagh-2004" TYPE="STUDY">Sabbagh 2004</LINK>; <LINK REF="STD-Saleem-2001" TYPE="STUDY">Saleem 2001</LINK>; <LINK REF="STD-Sharpe-1982" TYPE="STUDY">Sharpe 1982</LINK>; <LINK REF="STD-Shigemura-2005" TYPE="STUDY">Shigemura 2005</LINK>; <LINK REF="STD-Thompson-1982" TYPE="STUDY">Thompson 1982</LINK>; <LINK REF="STD-Tobias_x002d_Machado-2003" TYPE="STUDY">Tobias-Machado 2003</LINK>; <LINK REF="STD-Vaz-1994" TYPE="STUDY">Vaz 1994</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>; <LINK REF="STD-Yamamoto-2008" TYPE="STUDY">Yamamoto 2008</LINK>). See '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for details. The major causes of exclusion were:</P>
<UL>
<LI>studies not randomized - <LINK REF="STD-Anjum-1996" TYPE="STUDY">Anjum 1996</LINK>; <LINK REF="STD-Aus-1993" TYPE="STUDY">Aus 1993</LINK>; <LINK REF="STD-Carey-2001" TYPE="STUDY">Carey 2001</LINK>; <LINK REF="STD-Eaton-1981" TYPE="STUDY">Eaton 1981</LINK>; <LINK REF="STD-Eggert-1999" TYPE="STUDY">Eggert 1999</LINK>; <LINK REF="STD-Hosokawa-2005" TYPE="STUDY">Hosokawa 2005</LINK>; <LINK REF="STD-Huang-2006" TYPE="STUDY">Huang 2006</LINK>; <LINK REF="STD-Janoff-2000" TYPE="STUDY">Janoff 2000</LINK>; <LINK REF="STD-Jeon-2003" TYPE="STUDY">Jeon 2003</LINK>; <LINK REF="STD-Lindstedt-2006" TYPE="STUDY">Lindstedt 2006</LINK>; <LINK REF="STD-Otrock-2004" TYPE="STUDY">Otrock 2004</LINK>; <LINK REF="STD-Puig-2006" TYPE="STUDY">Puig 2006</LINK>; <LINK REF="STD-Rees-1980" TYPE="STUDY">Rees 1980</LINK>;</LI>
<LI>inadequate randomization - <LINK REF="STD-Akay-2006" TYPE="STUDY">Akay 2006</LINK>; <LINK REF="STD-Hotta-2001" TYPE="STUDY">Hotta 2001</LINK>; <LINK REF="STD-Roach-1991" TYPE="STUDY">Roach 1991</LINK>; <LINK REF="STD-Shigemura-2005" TYPE="STUDY">Shigemura 2005</LINK>; <LINK REF="STD-Tobias_x002d_Machado-2003" TYPE="STUDY">Tobias-Machado 2003</LINK>;</LI>
<LI>single studies of a determined intervention - <LINK REF="STD-Argyropoulos-2007" TYPE="STUDY">Argyropoulos 2007</LINK>; <LINK REF="STD-Ferreira-1985" TYPE="STUDY">Ferreira 1985</LINK>; <LINK REF="STD-Vaz-1994" TYPE="STUDY">Vaz 1994</LINK>; <LINK REF="STD-Yamamoto-2008" TYPE="STUDY">Yamamoto 2008</LINK>;</LI>
<LI>lack of adequate exclusion criteria of patients - <LINK REF="STD-Bosquet-Sanz-2006" TYPE="STUDY">Bosquet Sanz 2006</LINK>; <LINK REF="STD-Herranz-Amo-1996" TYPE="STUDY">Herranz Amo 1996</LINK>; <LINK REF="STD-Ito-2002" TYPE="STUDY">Ito 2002</LINK>; <LINK REF="STD-Mari-2007" TYPE="STUDY">Mari 2007</LINK>; <LINK REF="STD-Meyer-1987" TYPE="STUDY">Meyer 1987</LINK>; <LINK REF="STD-Peters-2003" TYPE="STUDY">Peters 2003</LINK>; <LINK REF="STD-Sabbagh-2004" TYPE="STUDY">Sabbagh 2004</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK> (We tried to contact the authors of these studies for more informations but to no avail.);</LI>
<LI>different definitions of short-course and long-course treatment than considered in review protocol - <LINK REF="STD-Aus-1996" TYPE="STUDY">Aus 1996</LINK>; <LINK REF="STD-Ito-2002" TYPE="STUDY">Ito 2002</LINK>; <LINK REF="STD-Mari-2007" TYPE="STUDY">Mari 2007</LINK>.</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-10 13:49:56 -0600" MODIFIED_BY="James Tacklind">
<P>See '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies'</LINK> table, '<LINK REF="FIG-37" TYPE="FIGURE">Figure 37</LINK>', '<LINK REF="FIG-38" TYPE="FIGURE">Figure 38</LINK>' and '<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>', '<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>', '<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>', '<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>' for details.</P>
<ALLOCATION MODIFIED="2010-10-25 11:13:57 -0500" MODIFIED_BY="James Tacklind">
<P>Ten of the included studies described adequate randomization (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>) and five reported an adequate allocation concealment (<LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-11-10 13:49:56 -0600" MODIFIED_BY="James Tacklind">
<P>Six trials were double blinded (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>)</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-10-25 11:13:57 -0500" MODIFIED_BY="James Tacklind">
<P>All included studies apparently addressed incomplete outcome data.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-10-25 11:13:57 -0500" MODIFIED_BY="James Tacklind">
<P>All included studies were apparently free of selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-10-25 11:13:58 -0500" MODIFIED_BY="James Tacklind">
<P>The majority of included studies were apparently free of other potential sources of bias.</P>
<P>Ten trials were placebo controlled (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). A sample size was pre-planned in two studies (<LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>). An intention-to-treat analysis was performed in ten trials (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). Four papers referred to multicentric studies (<LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>). Three studies had industry funding (<LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>). </P>
<P>Publication bias was unlikely according to the funnel plots inspection.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-12-15 14:54:59 -0600" MODIFIED_BY="James Tacklind">
<P>Our analysis included 19 trials with a total of 3599 patients. Not all articles allowed data extraction for all end points (See '<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>' for a more detailed description of the extractable end point of each article and '<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>' for included studies in each category of comparison). The outcomes were analysed in each subgroup of intervention.</P>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic versus placebo or no treatment</HEADING>
<P>Nine trials compared antibiotic to placebo or no treatment (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). The majority of trials (eight) utilized pre-biopsy enema, except one (<LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>). Three trials were three-armed studies. One trial (<LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>) presented and compared data of two different antibiotics versus placebo, and two trials presented and compared data of antibiotic short-course and long-course versus placebo (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>Data on bacteriuria could be extracted from 7 trials with 870 patients (1 trial subdivided) (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>). There were 61 events of bacteriuria among 412 patients randomized to receive placebo and 18 among 458 patients randomized to receive antibiotics. The meta-analysis was significant and favoured antibiotic use (RR 0.25, 95% CI 0.15 to 0.42, P &lt; 0.05). No heterogeneity was detected in the analysis (I<SUP>2 </SUP>= 0%) ('<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>'). Analysing only trials with pre-biopsy enema, the results were similar (RR 0.28, 95% CI 0.17 to 0.46; I<SUP>2 </SUP>= 0%) ('<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>We collect data on bacteremia from 5 trials with 494 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>). There were 45 events of bacteremia among 237 patients randomized to placebo and 34 events among 257 patients randomized to receive antibiotic. The comparison was significant and favoured antibiotic use (RR 0.67, 95% CI 0.49 to 0.92, P &lt; 0.05) (I<SUP>2 </SUP>= 40%) ('<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>'). Analysing only trials with pre-biopsy enema, the results also favoured antibiotics (RR 0.44, 95% CI 0.22 to 0.87 ;I<SUP>2 </SUP>= 32%) ('<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>Data on fever was extracted from 7 trials with 820 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). There were 43 events of fever among 397 patients randomized to placebo and 17 among 423 patients randomized to receive antibiotic. The comparison was significant and favoured antibiotic use (RR 0.39, 95% CI 0.23 to 0.64). No heterogeneity was detected in the analysis (I<SUP>2 </SUP>= 0%) ('<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>'). Analysing only trials with pre-biopsy enema, the results were similar and favoured antibiotics (RR 0.34, 95% CI 0.20 to 0.61). No heterogeneity was detected (I<SUP>2</SUP> = 0%) ('<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urinary tract infection</HEADING>
<P>('<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>')<BR/>We collected data on UTI from 3 trials with 1077 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>). There were 48 events among 534 patients randomized to placebo, and 18 among 543 randomized to receive antibiotic. The meta-analysis was significant and favoured antibiotics (RR 0.37, 95% CI 0.22 to 0.62). No heterogeneity was detected in the analysis (I<SUP>2 </SUP>= 0%). All trials used pre-biopsy enemas.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sepsis</HEADING>
<P>This endpoint was reported in only one study (<LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>). There were 3 events of sepsis among 25 patients randomized to placebo and 1 event among 23 randomized to antibiotic use (RR 0.36, 95% CI 0.04 to 3.24).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalization</HEADING>
<P>('<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>')<BR/>Data on hospitalization could be collect from 2 trials (1 trial subdivided) with 650 patients (<LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>). There were 10 hospitalizations among the 306 patients randomized to placebo and only 1 among the 344 patients randomized to antibiotics. The comparison was significant and favoured antibiotics (RR 0.13, 95% CI 0.03 to 0.55). No heterogeneity was detected (I<SUP>2 </SUP>= 0%). All trials used pre-biopsy enemas.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>('<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>')<BR/>This endpoint (nausea and abdominal cramps in <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>, pruritis and diarrhea in <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>) was poorly reported among the included studies, and was extracted from only two studies with 127 patients. The comparison was not significant (RR 1.62, 95% CI 0.23 to 11.56), and no heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>There were no cases of mortality reported in the included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quinolones versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>')</P>
<P>Three trials were included with 628 patients (<LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>); the meta-analysis favoured quinolones (RR 0.33, 95% CI 0.17 to 0.64; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>('<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>')</P>
<P>One trial was included (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>), with two subgroups (antibiotic short-course and long-course) with 306 patients. The comparison between the groups (quinolones versus placebo) was not significant (RR 0.32, 95% CI 0.05 to 2.01; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>')</P>
<P>Three trials (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>) (two with subgroups) were included with 640 patients. The comparison between the groups (quinolones x placebo) was not significant (RR 0.48, 95% CI 0.22 to 1.06; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">UTI</HEADING>
<P>('<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>')</P>
<P>Three trials were included (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Aron-2000b" TYPE="STUDY">Aron 2000b</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>;<LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Yang-2001b" TYPE="STUDY">Yang 2001b</LINK>) with 1077 patients; the comparison favoured quinolones (RR 0.37, 95% CI 0.22 to 0.62; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalization</HEADING>
<P>('<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>')</P>
<P>Two trials were included with 582 patients (<LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>) and favoured quinolones (RR 0.16, 95% CI 0.03 to 0.87; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sulfonamide versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>')</P>
<P>Two studies were included with 133 patients (<LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>; <LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>) and use of sulfonamide lowered risk relative to placebo (RR 0.17, 95% CI 0.05 to 0.57; I<SUP>2 </SUP>= 0%); only one trial (<LINK REF="STD-Ruebush-1979" TYPE="STUDY">Ruebush 1979</LINK>) reported data for bacteremia (26 events in 37 patients in the placebo group versus 25 events in 42 antibiotic patients (RR 0.85 95% CI 0.61 to 1.17), fever (5 events in 33 in the placebo group versus 4 in 38 patients in antibiotic group (RR 0.69 CI 0.20 to 2.38) and adverse events (1 in 37 in placebo versus 1 in 42 in antibiotic group (RR 0.88 95% CI 0.06 to 13.59) and only one trial reported data for hospitalization (<LINK REF="STD-Isen-1999b" TYPE="STUDY">Isen 1999b</LINK>) (3 events among 23 randomized to placebo versus 0 in 45 randomized to antibiotic (RR 0.07, 95% CI 0.00 to 1.38).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other classes of antibiotics (except quinolones and sulfonamides)</HEADING>
<P>The outcomes analysed were bacteriuria, bacteremia and fever. For adverse events only one trial reported (<LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>). There was 1 event among 23 patients randomized to antibiotic use (diarrhea, nausea and abdominal cramps) versus 0 among 25 randomized to placebo.</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>')</P>
<P>Three studies were included with 109 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>) and favoured antibiotic use (RR 0.20, 95% CI 0.07 to 0.54; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>('<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>')</P>
<P>Three studies were included with 109 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>). The comparison was significant and favoured "other classes" (RR 0.47, 95% CI 0.22 to 0.98, P &lt; 0.05), but with considerable heterogeneity (I<SUP>2 </SUP>= 63%). The heterogeneity is caused by one trial (<LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>), but the reason was not apparent. We then re-analysed the data utilizing random effects, but heterogeneity was still 63%. By eliminating Crawford we eliminated the heterogeneity (fixed effect RR 0.20, 95% CI 0.06 to 0.62; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>')</P>
<P>Three studies were included with 109 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Crawford-1982" TYPE="STUDY">Crawford 1982</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>). Use of antibiotics lowered risk of fever (RR 0.23, 95% CI 0.10 to 0.54; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic versus enema</HEADING>
<P>Antibiotic was compared with enema in four studies (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>')<BR/>Data on bacteriuria were extracted from 3 trials with 139 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>). There were 5 events of bacteriuria among 68 patients randomized to enema and 9 among 71 randomized to receive antibiotic. The comparison between the groups was not significant (RR 1.71, 95% CI 0.61 to 4.79; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>('<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>')<BR/>Data on bacteremia were collected from 2 trials with 60 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>). There were 5 events of bacteremia among 28 patients randomized to enema and 11 among 32 randomized to receive antibiotics. The comparison between the groups was not significant (RR 1.89, 95% CI 0.40 to 8.93) (I<SUP>2 </SUP>= 61%) using a random-effects model. There was no explicit cause for the heterogeneity, and the limited number of studies made a sensitivity analysis unviable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>')<BR/>Four trials with 197 patients reported data on fever (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>). There were 15 events of fever among 96 patients randomized to enema and 10 among 101 randomized to receive antibiotic. The comparison between groups was not significant (RR 0.89, 95% CI 0.16 to 5.05) (I<SUP>2 </SUP>= 66%) using a random-effects model. No apparent cause was identified for the heterogeneity and a sensitivity analysis was not viable due to the limited number of studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">UTI, sepsis and hospitalization</HEADING>
<P>These endpoints were reported in only one study (<LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>). There were 11 events of UTI among 28 patients randomized to enema versus 2 events among 30 randomized to antibiotic use (RR 0.17, 95% CI 0.04 to 0.70); 2 events of sepsis and 2 events of hospitalization in 28 patients in the group taking enemas versus 0 events in the antibiotic group (P &gt; 0.05).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic versus antibiotic + enema</HEADING>
<P>This intervention was reported for four trials (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>')</P>
<P>Data on bacteriuria were extracted from 3 trials with 147 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>). There were 9 events of bacteriuria among 71 patients randomized to antibiotic and 4 among 76 randomized to receive antibiotic + enema. The comparison between the groups was not significant (RR 0.42, 95% CI 0.13 to 1.29; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>('<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>')<BR/>Data on bacteremia were collected from 2 trials with 68 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>). There were 11 events of bacteremia among 32 patients randomized to antibiotic and 3 among 36 randomized to receive antibiotic + enema. Combination therapy lowered risk relative to monotherapy (RR 0.25, 95% CI 0.08 to 0.75; I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>')<BR/>Data on fever were collected from 4 trials with 209 patients (<LINK REF="STD-Brown-1981" TYPE="STUDY">Brown 1981</LINK>; <LINK REF="STD-Freitas-1999" TYPE="STUDY">Freitas 1999</LINK>; <LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Tekdogan-2006" TYPE="STUDY">Tekdogan 2006</LINK>). There were 10 events of fever among 101 patients randomized to enema and 5 among 108 randomized to receive antibiotic. The comparison between the groups was not significant (RR 0.53, 95% CI 0.21 to 1.34; I<SUP>2 </SUP>= 38%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Short-course (one day) versus long-course treatment (three days)</HEADING>
<P>This intervention was reported in six trials (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>')<BR/>Data on bacteriuria were extracted from 3 trials with 869 patients (<LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>). There were 32 events of bacteriuria among 428 patients randomized to short-course treatment and 16 among 441 randomized to long-course treatment. The comparison favoured long-course treatment (RR 2.09, 95% CI 1.17 to 3.73; I<SUP>2</SUP> = 34%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>Data on bacteremia were collected from 1 trial with 156 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>). There was no events among 79 patients randomized to short-course treatment and 1 among 77 randomized to long-course treatment (RR 0.33, 95% CI 0.01 to 7.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>')<BR/>Data on fever were collected from 4 trials with 652 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>). There were 12 events of fever among 324 patients randomized to short-course treatment and 4 among 328 randomized to long-course treatment. The comparison between the groups was not significant (RR 2.84, 95% CI 0.99 to 8.16), and with no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urinary tract infection</HEADING>
<P>('<LINK REF="FIG-18" TYPE="FIGURE">Figure 18</LINK>')<BR/>From 5 trials that included 1312 patients were collected data on UTI (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>). There were 21 events of UTI among 651 patients randomized to short-course treatment and 15 among 661 randomized to long-course treatment. The comparison between the groups was not significant (RR 1.40, 95% CI 0.73 to 2.68) and no heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalization</HEADING>
<P>('<LINK REF="FIG-19" TYPE="FIGURE">Figure 19</LINK>')<BR/>Data on hospitalization was extracted from 2 trials with 366 patients (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>). There were 3 events among 181 patients randomized to short-course treatment and 0 among 185 randomized to long-course treatment. The comparison between the groups was not significant (RR 4.14, 95% CI 0.47 to 36.46) and with no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Single dose versus multiple dose treatment</HEADING>
<P>This intervention was reported in 7 trials (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Bates-1998" TYPE="STUDY">Bates 1998</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-20" TYPE="FIGURE">Figure 20</LINK>')<BR/>We were able to collect data on bacteriuria from 4 trials with 944 patients (<LINK REF="STD-Bates-1998" TYPE="STUDY">Bates 1998</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>). There were 38 events among 465 patients randomized to single-dose treatment and 20 among 479 randomized to multiple-dose treatment. The comparison favoured multiple-dose treatment (RR 1.98; 95% CI 1.18 to 3.33) (I<SUP>2</SUP> = 7%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bacteremia</HEADING>
<P>Data on bacteremia could be extracted from 1 trial with 156 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>). There were no events among 79 patients randomized to single-dose treatment and 1 among 77 of those randomized to multiple-dose treatment (RR 0.33, 95% CI 0.01 to 7.86).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-21" TYPE="FIGURE">Figure 21</LINK>')<BR/>We collected data on fever from 4 trials with 652 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>). There were 12 events among 324 patients randomized to single-dose treatment and 4 among 328 of those randomized to multiple-dose treatment. The comparison between the groups was not significant (RR 2.84, 95% CI 0.0.99 to 8.16) and with no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urinary tract infection</HEADING>
<P>('<LINK REF="FIG-22" TYPE="FIGURE">Figure 22</LINK>')<BR/>Data on UTI was extracted from 5 trials with 1312 patients (<LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Briffaux-2009" TYPE="STUDY">Briffaux 2009</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Schaeffer-2007" TYPE="STUDY">Schaeffer 2007</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>). There were 21 events among 651 patients randomized to single-dose treatment and 15 among 661 of those randomized to multiple-dose treatment. The comparison between the groups was not significant (RR 1.40, 95% CI 0.73 to 2.68), and no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sepsis</HEADING>
<P>This endpoint was reported in only one study (<LINK REF="STD-Bates-1998" TYPE="STUDY">Bates 1998</LINK>). There were 2 events of sepsis among 37 patients in single dose group versus 1 event of sepsis among 38 in group multiple dose treatment (P &gt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalization</HEADING>
<P>('<LINK REF="FIG-23" TYPE="FIGURE">Figure 23</LINK>')<BR/>Data on hospitalization was collected from 3 trials with 441 patients (<LINK REF="STD-Bates-1998" TYPE="STUDY">Bates 1998</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>). There were 5 hospitalizations among 218 patients randomized to single-dose treatment and 1 among those 223 patients randomized to multiple-dose treatment. The comparison between the groups was not significant (RR 3.10, 95% CI 0.64 to 15.06), and no heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotic class A versus B</HEADING>
<P>Included in this section were studies that compared different types of antibiotics, subdivided into classes of antibiotics. We performed three subgroup analyses: quinolone versus other antibiotics; sulfonamide versus other antibiotics; and piperacillin tazobactam versus other antibiotics.</P>
<SUBSECTION>
<HEADING LEVEL="4">Quinolones versus other antibiotics</HEADING>
<P>The outcomes analysed were bacteriuria, fever, UTI, sepsis and hospitalization. The comparisons between the groups (quinolone and other antibiotics) were not significant for all outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="5">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-24" TYPE="FIGURE">Figure 24</LINK>')</P>
<P>Two trials with 225 patients (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>) compared quinolone versus sulfonamide and quinolone versus piperacillin tazobactam (RR 0.93, 95% CI 0.28 to 3.10); no heterogeneity was detected (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fever</HEADING>
<P>('<LINK REF="FIG-25" TYPE="FIGURE">Figure 25</LINK>')</P>
<P>Two trials ( <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>) with 561 patients compared quinolone versus piperacillin tazobactam and ceftriaxone (RR 0.56, 95% CI 0.07 to 4.16). There was no heterogeneity (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">UTI</HEADING>
<P>('<LINK REF="FIG-26" TYPE="FIGURE">Figure 26</LINK>')</P>
<P>Two trials with 407 patients compared quinolone versus piperacillin-tazobactam and ceftriaxone (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>) (RR 0.72, 95% CI 0.18 to 2.88). Moderate heterogeneity was detected (I<SUP>2</SUP> = 25%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sepsis</HEADING>
<P>This endpoint was reported in only one study (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>). There was one event among 66 randomized to quinolone and 0 events in group piperacillin/tazobactam (P &gt; 0.05)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalization</HEADING>
<P>('<LINK REF="FIG-27" TYPE="FIGURE">Figure 27</LINK>')</P>
<P>Two trials with 407 patients (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>) compared quinolone versus piperacillin-tazobactam and ceftriaxone (RR 0.56, 95% CI 0.07 to 4.16); no heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sulfonamide versus other antibiotics</HEADING>
<P>The outcomes analysed were bacteriuria, bacteremia and UTI. For bacteriuria ('<LINK REF="FIG-28" TYPE="FIGURE">Figure 28</LINK>'), three trials were included (<LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK>) with 303 patients comparing sulfonamide to gentamicin, netilmicin-metronidazole and quinolone. There were 5 events among 161 patients using sulfonamide and 15 events among 142 randomized to other antibiotics. The comparison between these groups was not significant (RR 3.10, 95% CI 0.60 to 16.13; I<SUP>2 </SUP>= 53%), using a random-effects model. There was no apparent reason for heterogeneity. Bacteremia and UTI were reported in only one study (<LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>). There were 13 events of bacteremia and 2 events of UTI among 47 patients randomized to the netilmicin-metronidazole group and 20 events of bacteremia and 0 events of UTI among 54 randomized to sulfonamide (P &gt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Piperacillin tazobactam versus other antibiotics</HEADING>
<P>The outcomes analysed were bacteriuria, bacteremia, fever, UTI, sepsis, hospitalization and adverse events.</P>
<P>For bacteriuria, UTI, sepsis and hospitalization, two trials were included (<LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>) with 247 patients. The comparisons between the groups were not significant for all outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="5">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-29" TYPE="FIGURE">Figure 29</LINK>')</P>
<P>The RR was 1.03, 95% CI 0.31 to 3.46 and no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">UTI</HEADING>
<P>('<LINK REF="FIG-30" TYPE="FIGURE">Figure 30</LINK>')</P>
<P>The risk ratio was 1.01, 95% CI 0.32 to 3.15, but with heterogeneity (I<SUP>2 </SUP>= 44%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sepsis</HEADING>
<P>('<LINK REF="FIG-31" TYPE="FIGURE">Figure 31</LINK>')</P>
<P>The risk ratio was 3.10, 95% CI 0.33 to 29.40, and no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalization</HEADING>
<P>('<LINK REF="FIG-32" TYPE="FIGURE">Figure 32</LINK>')</P>
<P>The RR was 3.10, 95% CI 0.33 to 29.40, P &gt; 0.05, and no heterogeneity was detected (I<SUP>2 </SUP>= 0%).<BR/>For bacteremia and adverse events only one trial reported (<LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK>). There were 0 events of bacteremia and 16 adverse events (diarrhea) among 54 patients randomized to piperacillin-tazobactam (P &lt; 0.05) and 1 event of bacteremia (P &gt; 0.05) and 2 of adverse events (diarrhea) among 55 randomized to cefuroxime (P &lt; 0.05); fever was reported in one trial (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>). There was 1 event of fever among 66 patients randomized to quinolone and 0 events in 72 patients randomized to piperacillin-tazobactam (P &gt; 0.05)</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus systemic administration</HEADING>
<P>The outcomes analysed were bacteriuria, fever, UTI and hospitalization. Bacteremia and sepsis were reported in only one study and meta-analysis was not realized. There were 13 events of bacteremia among 47 patients randomized to systemic antibiotic versus 20 events of bacteremia among 54 randomized to oral antibiotic (P &gt; 0.05) (<LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>). There was 1 event of sepsis among 66 patients randomized to oral antibiotic versus 0 events among 72 randomized to systemic antibiotic (P &gt; 0.05) (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria</HEADING>
<P>('<LINK REF="FIG-33" TYPE="FIGURE">Figure 33</LINK>')<BR/>Data on bacteriuria was extracted from 3 trials with 354 patients (<LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK>). There were 5 events of bacteriuria among 182 patients randomized to oral treatment and 15 among 172 randomized to systemic treatment. The comparison between groups was not significant (RR 0.34, 95% CI 0.06 to 1.93; I<SUP>2 </SUP>= 58%, using the random-effects model). There was no explicit cause to justify heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever</HEADING>
<P>('<LINK REF="FIG-34" TYPE="FIGURE">Figure 34</LINK>')<BR/>Data on fever was collected from 3 trials with 522 patients (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Shivde-2002" TYPE="STUDY">Shivde 2002</LINK>). There were 2 events of bacteriuria among 258 patients randomized to oral treatment and 1 among 264 randomized to systemic treatment. The comparison between the groups was not significant (RR 1.80, 95% CI 0.24 to 13.45). No heterogeneity was detected (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">UTI</HEADING>
<P>('<LINK REF="FIG-35" TYPE="FIGURE">Figure 35</LINK>')<BR/>We collected data on UTI from 3 trials with 508 patients (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>). There were 4 events of UTI among 250 patients randomized to oral treatment and 5 among 258 randomized to systemic treatment. The comparison between the groups was not significant (RR 0.85, 95% CI 0.27 to 2.70). Heterogeneity was detected (I<SUP>2</SUP> = 22%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalization</HEADING>
<P>('<LINK REF="FIG-36" TYPE="FIGURE">Figure 36</LINK>')<BR/>Data on hospitalization was extracted from 2 trials with 407 patients (<LINK REF="STD-Cam-2008" TYPE="STUDY">Cam 2008</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>). There were 2 events of hospitalization among 196 patients randomized to oral treatment and 1 among 211 randomized to systemic treatment. The comparison between the groups was not significant (RR 1.80, 95% CI 0.24 to 13.45). No heterogeneity was detected (I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<SUMMARY_OF_RESULTS MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>This systematic review addressed the totality of the evidence for antibiotic prophylaxis for transrectal prostate biopsy. The results favoured the use of antibiotics in transrectal prostate biopsy to prevent infectious complications. In the analysis antibiotic versus placebo/no treatment, all outcomes significantly favored antibiotics versus placebo. Nine trials compared antibiotic to placebo or no treatment, and eight trialsutilized pre-biopsy enemas. These results confirm the necessity of antibiotic prophylaxis for transrectal prostate biopsy and emphasize substantial infection and hospitalization rates without antibiotic prophylaxis (bacteriuria 14.8% without antibiotics versus 3.9% with antibiotics; bacteremia 8.6% versus 2.1%; fever 10.8% versus 4.0%; UTI 9.0% versus 3.3%; hospitalization 3.3% versus 0.3%) (see '<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>').</P>
<P>Analysing the different classes of antibiotics versus placebo/no treatment, in the quinolones group the results favoured the use of antibiotics to prevent bacteriuria, UTI and hospitalization, and there was a tendency toward fever reduction as well; in 'other antibiotics', the use of antibiotics prevented bacteriuria and fever. In analysing studies that directly compared different classes of antibiotics, there was no difference between quinolones and 'other classes of antibiotics' (sulfonamides, piperacillin tazobactam and ceftriaxone). Comparing sulfonamide to 'other classes of antibiotics' and comparing piperacillin tazobactam with 'other antibiotics', there were no differences for any outcome. The quinolones were the most analysed, with the largest number of patients and trials included, and therefore indicate the best evidence for the use of antibiotic prophylaxis for prostate biopsy.</P>
<P>For 'antibiotic versus enema and antibiotic versus antibiotic + enema', only four trials were analysed, with a limited number of patients. The difference between the groups was not significant for any outcome, and all had some heterogeneity. In the analysis 'antibiotic versus antibiotic + enema', only the risk of bacteremia was diminished for the group antibiotic + enema, and with no differences in the outcomes for bacteriuria and fever.</P>
<P>Comparing 'antibiotic short-course versus long-course', there was a significant difference favouring long-course treatment only for bacteriuria. For bacteremia, fever, UTI and hospitalization, the differences between the groups were not significant. (see '<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>').</P>
<P>For the analysis 'multiple-dose versus single-dose treatment' there was a significant reduction only in the risk of bacteriuria with the multiple-dose treatment arm; for the outcome fever, the comparison favoured the multiple-dose treatment arm, but it was not significant (P = 0.06). (see '<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>').</P>
<P>Comparing the different ways of administering antibiotics (oral versus systemic), the comparisons were not significant for bacteriuria, fever, UTI and hospitalization (see '<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>').</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-11-10 14:07:45 -0600" MODIFIED_BY="James Tacklind">
<P>The information provided by this review are relevant and fairly robust, especially regarding effectiveness of antibiotic prophylaxis in reducing the risk of infective complications following TRPB in low risk patients (see 'Exclusion criteria'). Regarding what should be the antibiotic of choice for prophylaxis in TRPB, the data are insufficient to confirm that antibiotic use for long course is superior to short course or that multiple-dose is superior to single-dose treatment.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-10-25 11:13:58 -0500" MODIFIED_BY="James Tacklind">
<P>For the analysis antibiotic versus placebo/no treatment, the quality of the evidence was moderate, especially due to unclear allocation concealment and lack of blinding in several studies. Nine studies were included (see '<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>'). </P>
<P>For the analysis antibiotic short-course versus long-course six trials were included. The quality of the evidence was moderate, especially due to unclear allocation concealment in several studies, with good numbers of patients and no heterogeneity (see '<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>').</P>
<P>For the analysis 'multiple-dose versus single-dose treatment' the quality of the evidence is moderate to low, specially due unclear allocation concealment and wide confidence interval in several studies, with good numbers of patients and no heterogeneity. Seven trials were included (see '<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>'). </P>
<P>For 'antibiotic versus enema' and 'antibiotic versus antibiotic + enema', the quality of the evidence is poor because of a limited number of studies (4), patients and events.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-10-25 11:13:58 -0500" MODIFIED_BY="James Tacklind">
<P>This systematic review probably identified all relevant studies and all relevant data about interventions and outcomes could be obtained. The methods used for review process were rigorous and probably free of bias. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-11-10 14:03:16 -0600" MODIFIED_BY="James Tacklind">
<P>A systematic review of literature (<LINK REF="REF-Bootsma-2008" TYPE="REFERENCE">Bootsma 2008</LINK>) was conducted to address antibiotic prophylaxis in urologic procedures, and included articles searched in the electronic databases MEDLINE, EMBASE and <I>The Cochrane Library</I>, and with some language restrictions (English, French, Spanish, German). Only the transurethral resection of the prostate and prostate biopsy sections were well researched and had a high and moderate-to-high level of evidence, respectively, in favour of using antibiotic prophylaxis. The authors presented a narrative review, without meta-analysis, and the results were presented in a descriptive form. They showed a significant decrease of bacteriuria after prostate biopsy with the use of antibiotic prophylaxis compared to no use of antibiotics (moderate to high evidence); nevertheless, no conclusive evidence was found regarding the effect of antibiotic prophylaxis on symptomatic UTIs and other infectious complications.</P>
<P>A meta-analysis of antibiotic prophylaxis use in transrectal prostatic biopsy was published recently (<LINK REF="REF-Yang-2009" TYPE="REFERENCE">Yang 2009</LINK>), but examined only English and Chinese medical literature. Twelve trials with 1987 patients were included (<LINK REF="STD-Melekos-1990" TYPE="STUDY">Melekos 1990</LINK>; <LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Brewster-1995" TYPE="STUDY">Brewster 1995</LINK>; <LINK REF="STD-Aus-1996" TYPE="STUDY">Aus 1996</LINK>; <LINK REF="STD-Kapoor-1998" TYPE="STUDY">Kapoor 1998</LINK>; <LINK REF="STD-Isen-1999a" TYPE="STUDY">Isen 1999a</LINK>; <LINK REF="STD-Aron-2000a" TYPE="STUDY">Aron 2000a</LINK>; <LINK REF="STD-Yang-2001a" TYPE="STUDY">Yang 2001a</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002</LINK>; <LINK REF="STD-Tobias_x002d_Machado-2003" TYPE="STUDY">Tobias-Machado 2003</LINK>; <LINK REF="STD-Akay-2006" TYPE="STUDY">Akay 2006</LINK>). The authors proposed to compare an antibiotic-treated group versus a control group with the outcomes bacteriuria, bacteremia and fever. In the methodology section the control group was defined as "receiving placebo or no agent"; however, included in this group were studies comparing two different types of antibiotics (<LINK REF="STD-Fong-1991" TYPE="STUDY">Fong 1991</LINK>; <LINK REF="STD-Cormio-2002" TYPE="STUDY">Cormio 2002</LINK>; <LINK REF="STD-Tobias_x002d_Machado-2003" TYPE="STUDY">Tobias-Machado 2003</LINK>), studies comparing antibiotic short course versus long course (<LINK REF="STD-Aus-1996" TYPE="STUDY">Aus 1996;</LINK> <LINK REF="STD-Petteffi-2002" TYPE="STUDY">Petteffi 2002;</LINK> <LINK REF="STD-Tobias_x002d_Machado-2003" TYPE="STUDY">Tobias-Machado 2003</LINK>), and all without placebo comparators. Therefore, the authors "created" a control group that was not completely a no treatment or placebo group. There were also two studies with inadequate randomization (<LINK REF="STD-Akay-2006" TYPE="STUDY">Akay 2006</LINK>; <LINK REF="STD-Tobias_x002d_Machado-2003" TYPE="STUDY">Tobias-Machado 2003</LINK>). Yang's use of poor methodology resulted in limited validity, and should be consulted with caution.</P>
<P>Compared to the two reviews presented above, our systematic review is wider ranging, by comparing not only antibiotics to placebo, but also comparing different classes of antibiotics, doses, and duration of treatment.</P>
<P>The sextant biopsy scheme significantly improved cancer detection over digitally directed biopsy of palpable nodules and ultrasound-guided biopsy of specific hypoechoic lesions (<LINK REF="REF-Hodge-1989a" TYPE="REFERENCE">Hodge 1989a</LINK>; <LINK REF="REF-Hodge-1989b" TYPE="REFERENCE">Hodge 1989b</LINK>) and remained the gold standard for several years. Numerous groups have published series showing improved cancer detection rates by incorporating additional laterally directed cores into the standard systematic sextant technique, ultimately taking anywhere from 8 to 13 cores (<LINK REF="REF-Eskew-1997" TYPE="REFERENCE">Eskew 1997</LINK>; <LINK REF="REF-Naughton-2000a" TYPE="REFERENCE">Naughton 2000a</LINK>; <LINK REF="REF-Babaian-2000" TYPE="REFERENCE">Babaian 2000</LINK>; <LINK REF="REF-Presti-2000" TYPE="REFERENCE">Presti 2000</LINK>). At present, the six-cores scheme is considered inadequate for routine prostate biopsy for cancer detection because it may miss over 20% of cancers. Extended biopsy protocols do not result in increased complications compared to sextant biopsy (<LINK REF="REF-Mariappan-2004" TYPE="REFERENCE">Mariappan 2004</LINK>; <LINK REF="REF-Naughton-2000b" TYPE="REFERENCE">Naughton 2000b</LINK>; <LINK REF="REF-Naughton-2001" TYPE="REFERENCE">Naughton 2001</LINK>; <LINK REF="REF-Paul-2004" TYPE="REFERENCE">Paul 2004</LINK>; <LINK REF="REF-Paul-2005" TYPE="REFERENCE">Paul 2005</LINK>).</P>
<P>Many of the studies included in this analysis are from when 6-core biopsies were standard. Currently, 12 to 16 core biopsies are being performed. Nevertheless, as discussed above, extended biopsy protocols do not result in increased complications compared to sextant biopsy technique. There was no randomized controlled study comparing different antibiotics regimens for different number of cores on biopsy.<B> </B>
</P>
<P>The rule of saturation biopsy is most often applied to patients with previous negative biopsies and patients who have been diagnosed with prostate cancer and remain on active surveillance protocols or are considering focal therapy (<LINK REF="REF-Jones-2006" TYPE="REFERENCE">Jones 2006</LINK>). The safety and efficacy of saturation biopsy has been well established, but further studies are needed to validate these strategies over extended biopsy schemes (<LINK REF="REF-Patel-2009" TYPE="REFERENCE">Patel 2009</LINK>). Complications with saturation biopsy were similar to extended biopsy technique.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-10 14:05:37 -0600" MODIFIED_BY="James Tacklind">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-10 14:04:35 -0600" MODIFIED_BY="James Tacklind">
<P>Antibiotic prophylaxis is effective in preventing infectious complications following prostate biopsy. Several classes of antibiotics are effective for prophylaxis in prostate biopsy and the quinolones was the best analysed class, with higher numbers of studies and patients. There is no definitive data to confirm that antibiotic use for long course (3 days) is superior to antibiotic for short course (1 day), or that multiple-dose is superior to single-dose treatment. There is no significant difference between different ways of administering antibiotics (oral versus IM or IV) to prevent infectious complications.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-10 14:05:37 -0600" MODIFIED_BY="James Tacklind">
<P>Following these results, it is unlikely that future trials will feature a no-treatment control group for antibiotic prophylaxis in prostate biopsy. Trials comparing different classes of antibiotics, short-course versus long-course treatment and multiple-dose versus single-dose treatment are necessary to confirm or deny our findings.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-09-14 15:20:10 -0500" MODIFIED_BY="James Tacklind">
<P>Thanks to the Prostatic Diseases and Urologic Cancers Group for the opportunity to conduct a systematic review and by their support of the review, especially James Tacklind, Timothy J. Wilt and Roderick MacDonald. Thanks also to the Brazilian Cochrane Centre for their technical support, and to Tony Burson for his dedication in helping to write an English-language review. Thanks to authors who kindly sent information of their studies, contributing to the improvement of data on this review: Anthony J. Schaeffer, E. David Crawford, Haydar Kamil Cam, Marcos Tobias Machado, Simon Brewster, Subodh Shivde.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-25 14:19:13 -0500" MODIFIED_BY="James Tacklind">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-08-06 10:50:15 -0500" MODIFIED_BY="James Tacklind">
<P>ELZ: trial selection, quality assessment, data extraction, data entry, data analysis, writing of protocol and review<BR/>OACC: trial selection, quality assessment, data extraction, data entry, data analysis, writing of protocol, revision of protocol and review<BR/>NRN Jr: data analysis, writing of protocol, resolution of disagreements, revision of protocol and review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2009-08-25 14:19:34 -0500" MODIFIED_BY="James Tacklind"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-10-13 21:49:56 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-10-13 21:49:56 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-08-06 09:34:26 -0500" MODIFIED_BY="James Tacklind">
<STUDY DATA_SOURCE="PUB" ID="STD-Aron-2000a" MODIFIED="2009-09-26 21:54:31 -0500" MODIFIED_BY="[Empty name]" NAME="Aron 2000a" YEAR="2000">
<REFERENCE MODIFIED="2009-09-26 21:54:31 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aron M, Rajeev TP, Gupta NP</AU>
<TI>Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study</TI>
<SO>BJU International</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>6</NO>
<PG>682-5</PG>
<IDENTIFIERS MODIFIED="2009-07-19 20:46:11 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 20:46:11 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10759665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-30 20:11:59 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aron-2000b" MODIFIED="2009-09-26 21:54:41 -0500" MODIFIED_BY="[Empty name]" NAME="Aron 2000b" YEAR="2000">
<REFERENCE MODIFIED="2009-09-26 21:54:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aron M, Rajeev TP, Gupta NP</AU>
<TI>Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study</TI>
<SO>BJU International</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>6</NO>
<PG>682-5</PG>
<IDENTIFIERS MODIFIED="2009-07-19 20:46:20 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 20:46:20 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10759665"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bates-1998" MODIFIED="2009-09-26 21:41:58 -0500" MODIFIED_BY="[Empty name]" NAME="Bates 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-09-26 21:41:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bates TS, Porter T, Gingell JC</AU>
<TI>Prophylaxis for transrectal prostatic biopsies: a randomized controlled study of intravenous co-amoxiclav given as a single dose compared with an intravenous dose followed by oral co-amoxiclav for 24h</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>81</VL>
<PG>529-31</PG>
<IDENTIFIERS MODIFIED="2009-07-19 20:51:52 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 20:51:52 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9598622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brewster-1995" MODIFIED="2009-09-26 21:42:52 -0500" MODIFIED_BY="[Empty name]" NAME="Brewster 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-09-26 21:42:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brewster SF, Macgowan AP, Gingell JC</AU>
<TI>Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective randomized trial of cefuroxime versus piperacillin/tazobactam</TI>
<SO>British Journal of Urology</SO>
<YR>1995</YR>
<VL>76</VL>
<PG>351-4</PG>
<IDENTIFIERS MODIFIED="2009-07-25 20:08:45 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-25 20:08:45 -0500" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1995278252"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Briffaux-2009" MODIFIED="2010-08-06 09:33:06 -0500" MODIFIED_BY="James Tacklind" NAME="Briffaux 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-08-06 09:33:06 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Briffaux R, Coloby P, Bruyere F, Ouaki F, Pires C, Dore C, et al</AU>
<TI>Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomised study</TI>
<TO>Antibioprophylaxie courte versus longue pour les biopsies prostatiques. Etude prospective randomisée multicentrique</TO>
<SO>Progrès en Urologie</SO>
<YR>2009</YR>
<VL>19</VL>
<PG>39-46</PG>
<IDENTIFIERS MODIFIED="2009-03-06 20:24:33 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-06 20:24:33 -0600" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19135641"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1981" MODIFIED="2009-09-26 21:52:48 -0500" MODIFIED_BY="[Empty name]" NAME="Brown 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-09-26 21:52:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown RW, Warner JJ, Turner BI, Harris LF, Alford RH</AU>
<TI>Bacteremia and bacteriuria after transrectal prostatic biopsy</TI>
<SO>Urology</SO>
<YR>1981</YR>
<VL>18</VL>
<NO>2</NO>
<PG>145-8</PG>
<IDENTIFIERS MODIFIED="2009-07-25 20:18:46 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-25 20:18:46 -0500" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1981194038"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cam-2008" MODIFIED="2009-09-26 21:53:40 -0500" MODIFIED_BY="[Empty name]" NAME="Cam 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-26 21:53:40 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cam K, Kayikci A, Akman Y, Erol A</AU>
<TI>Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy</TI>
<SO>International Journal of Urology</SO>
<YR>2008</YR>
<VL>15</VL>
<PG>997-1001</PG>
<IDENTIFIERS MODIFIED="2009-07-19 20:56:25 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 20:56:25 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18721198"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cormio-2002" MODIFIED="2009-08-06 11:08:49 -0500" MODIFIED_BY="James Tacklind" NAME="Cormio 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-06 11:08:49 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cormio L, Berardi B, Callea A, Fiorentino N, Sblendorio D, Zizzi V, Traficante A</AU>
<TI>Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam</TI>
<SO>BJU International</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>7</NO>
<PG>700-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12410751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crawford-1982" MODIFIED="2009-12-04 14:05:01 -0600" MODIFIED_BY="James Tacklind" NAME="Crawford 1982" YEAR="1982">
<REFERENCE MODIFIED="2009-12-04 14:05:01 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crawford ED, Haynes AL Jr, Story MW, Borden TA</AU>
<TI>Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy</TI>
<SO>The Journal of Urology</SO>
<YR>1982</YR>
<VL>127</VL>
<NO>3</NO>
<PG>449-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6895918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fong-1991" MODIFIED="2009-12-04 14:04:53 -0600" MODIFIED_BY="James Tacklind" NAME="Fong 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-12-04 14:04:53 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fong IW, Struthers N, Honey RJ, Simbul M, Boisseau DA</AU>
<TI>A randomized comparative study of the prophylactic use of trimethoprim-sulfamethoxazole versus netilmicin-metronidazole in transrectal prostatic biopsy</TI>
<SO>The Journal of Urology</SO>
<YR>1991</YR>
<VL>146</VL>
<NO>3</NO>
<PG>794-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1908529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Freitas-1999" MODIFIED="2010-08-06 09:34:26 -0500" MODIFIED_BY="James Tacklind" NAME="Freitas 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-06 09:34:26 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Freitas DG, Srougi M</AU>
<TI>Preparation for transrectal prostatic biopsy. A random and prospective study</TI>
<TO>Preparo para biópsia prostática transrectal. Estudo prospectivo e randomizado</TO>
<SO>Tese de Mestrado - Escola Paulista de Medicina (EPM - UNIFESP)</SO>
<YR>1999</YR>
<CY>São Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isen-1999a" MODIFIED="2009-09-26 21:57:14 -0500" MODIFIED_BY="[Empty name]" NAME="Isen 1999a" YEAR="1999">
<REFERENCE MODIFIED="2009-09-26 21:57:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isen K, Kupeli B, Sinik Z, Sozen S, Bozkirli I</AU>
<TI>Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole</TI>
<SO>International Urology and Nephrology</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>4</NO>
<PG>491-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10668944"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isen-1999b" MODIFIED="2009-09-26 21:57:56 -0500" MODIFIED_BY="[Empty name]" NAME="Isen 1999b" YEAR="1999">
<REFERENCE MODIFIED="2009-09-26 21:57:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isen K, Kupeli B, Sinik Z, Sozen S, Bozkirli I</AU>
<TI>Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole</TI>
<SO>International Urology and Nephrology</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>4</NO>
<PG>491-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10668944"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapoor-1998" MODIFIED="2009-12-04 14:06:07 -0600" MODIFIED_BY="James Tacklind" NAME="Kapoor 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-12-04 14:06:07 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al</AU>
<TI>Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy</TI>
<SO>Urology</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>4</NO>
<PG>552-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9763070"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melekos-1990" MODIFIED="2009-09-26 21:59:19 -0500" MODIFIED_BY="[Empty name]" NAME="Melekos 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-09-26 21:59:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melekos MD</AU>
<TI>Efficacy of prophylactic antimicrobial regimens in preventing infectious complications after transrectal biopsy of the prostate</TI>
<SO>International Urology and Nephrology</SO>
<YR>1990</YR>
<VL>22</VL>
<NO>3</NO>
<PG>257-62</PG>
<IDENTIFIERS MODIFIED="2009-07-25 20:16:07 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-25 20:16:07 -0500" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1990271873"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petteffi-2002" MODIFIED="2010-04-08 13:17:11 -0500" MODIFIED_BY="James Tacklind" NAME="Petteffi 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-04-08 13:17:11 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petteffi L, Toniazzo GP, Sander GB, Stein AC, Koff WJ</AU>
<TI>Efficiency of short and long term antimicrobial therapy in transrectal ultrasound-guided prostate biopsies</TI>
<SO>International Brazian Journal of Urology</SO>
<YR>2002</YR>
<VL>28</VL>
<NO>6</NO>
<PG>526-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15748401"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruebush-1979" MODIFIED="2009-12-04 14:06:30 -0600" MODIFIED_BY="James Tacklind" NAME="Ruebush 1979" YEAR="1979">
<REFERENCE MODIFIED="2009-12-04 14:06:30 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruebush TK, McConville JH, Calia FM</AU>
<TI>A double-blind study of trimethoprim-sulfamethoxazole prophylaxis in patients having transrectal needle biopsy of the prostate</TI>
<SO>The Journal of Urology</SO>
<YR>1979</YR>
<VL>122</VL>
<NO>4</NO>
<PG>492-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="384025"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaeffer-2007" MODIFIED="2009-12-04 14:06:45 -0600" MODIFIED_BY="James Tacklind" NAME="Schaeffer 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-12-04 14:06:45 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaeffer AJ, Montorsi F, Scattoni V, Perroncel R, Song J, Haverstock DC, et al</AU>
<TI>Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate</TI>
<SO>BJU International</SO>
<YR>2007</YR>
<VL>100</VL>
<PG>51-7</PG>
<IDENTIFIERS MODIFIED="2009-07-19 20:59:10 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 20:59:10 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17552953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shivde-2002" MODIFIED="2009-09-26 22:04:30 -0500" MODIFIED_BY="[Empty name]" NAME="Shivde 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-09-26 22:04:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shivde SR, Cooke RPD, O'Neill WA, Cowie AGA, Lawrence WT, Watson GM</AU>
<TI>Trimethoprim versus Gentamicin for the prevention of bacteriuria following transrectal biopsy of the prostate - do patients need additional anaerobic cover?</TI>
<SO>Urologia Internationalis</SO>
<YR>2002</YR>
<VL>69</VL>
<PG>106-10</PG>
<IDENTIFIERS MODIFIED="2009-07-25 20:14:04 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-25 20:14:04 -0500" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2002317472"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tekdogan-2006" MODIFIED="2009-09-26 22:06:46 -0500" MODIFIED_BY="[Empty name]" NAME="Tekdogan 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-26 22:06:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tekdogan U, Tuncel A, Eroglu M, Unsal A, Atan A, Balbay MD</AU>
<TI>The efficiency of prophylactic antibiotic treatment in patients without risk factor who underwent transrectal</TI>
<TO>Transrektal prostat igne biyopsi yapilan risk faktorsuz hastalarda koruyucu antibiyotik tedavisinin etkinligi</TO>
<SO>Türk Üroloji Dergisi</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>2</NO>
<PG>261-7</PG>
<IDENTIFIERS MODIFIED="2009-07-25 20:20:44 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-25 20:20:44 -0500" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2006393248"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001a" MODIFIED="2009-09-26 22:10:11 -0500" MODIFIED_BY="[Empty name]" NAME="Yang 2001a" YEAR="2001">
<REFERENCE MODIFIED="2009-09-26 22:10:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang L, Hu J, Wei H, Wang L, Zhong H</AU>
<TI>Clinical significance of antibiotic prophylaxis for transrectal prostate biopsy</TI>
<SO>Zhonghua wai ke za zhi [Chinese Journal of Surgery]</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>12</NO>
<PG>940-2</PG>
<IDENTIFIERS MODIFIED="2009-07-19 21:01:58 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 21:01:58 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16201177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2001b" MODIFIED="2009-09-26 22:11:20 -0500" MODIFIED_BY="[Empty name]" NAME="Yang 2001b" YEAR="2001">
<REFERENCE MODIFIED="2009-09-26 22:11:20 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang L, Hu J, Wei H, Wang L, Zhong H</AU>
<TI>Clinical significance of antibiotic prophylaxis for transrectal prostate biopsy</TI>
<SO>Zhonghua wai ke za zhi [Chinese Journal of Surgery]</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>12</NO>
<PG>940-2</PG>
<IDENTIFIERS MODIFIED="2009-07-19 21:04:37 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-19 21:04:37 -0500" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16201177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-10-13 21:49:56 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akay-2006" MODIFIED="2010-04-08 13:19:34 -0500" MODIFIED_BY="James Tacklind" NAME="Akay 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-08 13:19:34 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akay AF, Akay H, Aflay U, Sahin H, Bircan K</AU>
<TI>Prevention of pain and infective complications after transrectal prostate biopsy: a prospective study</TI>
<SO>International Urology and Nephrology</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>1</NO>
<PG>45-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anjum-1996" MODIFIED="2010-04-08 13:19:54 -0500" MODIFIED_BY="James Tacklind" NAME="Anjum 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-08 13:19:54 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anjum M, Palmer JH, Mufti G, Brewster SF, MacGowan AP, Gingell JC</AU>
<TI>Antimicrobial prophylaxis for transrectal prostatic biopsy</TI>
<SO>British Journal of Urology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>4</NO>
<PG>618-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argyropoulos-2007" MODIFIED="2010-04-08 13:20:06 -0500" MODIFIED_BY="James Tacklind" NAME="Argyropoulos 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 13:20:06 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argyropoulos AN, Doumas K, Farmakis A, Liakatas I, Gkialas I, Lykourinas M</AU>
<TI>Time of administration of a single dose of oral levofloxacin and its effect in infectious complications from transrectal prostate biopsy</TI>
<SO>International Urology and Nephrology</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>3</NO>
<PG>897-903</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:29:18 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aus-1993" MODIFIED="2010-04-08 13:20:21 -0500" MODIFIED_BY="James Tacklind" NAME="Aus 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-04-08 13:20:21 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aus G, Hermansson CG, Hugosson J, Pedersen KV</AU>
<TI>Transrectal ultrasound examination of the prostate: complications and acceptance by patients</TI>
<SO>British Journal of Urology</SO>
<YR>1993</YR>
<VL>71</VL>
<NO>4</NO>
<PG>457-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aus-1996" MODIFIED="2010-04-08 13:20:33 -0500" MODIFIED_BY="James Tacklind" NAME="Aus 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-08 13:20:33 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aus G, Ahlgren G, Bergdahl S, Hugosson J</AU>
<TI>Infection after transrectal core biopsies of the prostate - risk factors and antibiotic prophylaxis</TI>
<SO>British Journal of Urology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>6</NO>
<PG>851-5</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:29:42 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjerklund-2004" MODIFIED="2009-10-29 20:25:58 -0500" MODIFIED_BY="[Empty name]" NAME="Bjerklund 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-10-29 20:25:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjerklund Johansen T</AU>
<TI>Bacteriuria and prophylaxis</TI>
<SO>EAU Update Series</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>3</NO>
<PG>136-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosquet-Sanz-2006" MODIFIED="2010-04-08 13:20:58 -0500" MODIFIED_BY="James Tacklind" NAME="Bosquet Sanz 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-08 13:20:58 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosquet Sanz M, Gimeno Argente V, Arlandis Guzman S, Bonillo Garcia MA, Trassierra Villa M, Jimenez Cruz JF</AU>
<TI>Comparative study between tobramycin and tobramycin plus ciprofloxacin in transrectal prostate biopsy prophylaxis</TI>
<SO>Actas Urologicas Españolas</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>9</NO>
<PG>866-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carey-2001" MODIFIED="2010-04-08 13:21:07 -0500" MODIFIED_BY="James Tacklind" NAME="Carey 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-08 13:21:07 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carey JM, Korman HJ</AU>
<TI>Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications?</TI>
<SO>The Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>1</NO>
<PG>82-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eaton-1981" MODIFIED="2010-04-08 13:21:21 -0500" MODIFIED_BY="James Tacklind" NAME="Eaton 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-04-08 13:21:21 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eaton AC</AU>
<TI>The safety of transrectal biopsy of the prostate as an out-patient investigation</TI>
<SO>British Journal of Urology</SO>
<YR>1981</YR>
<VL>53</VL>
<NO>2</NO>
<PG>144-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eggert-1999" MODIFIED="2009-10-29 20:33:48 -0500" MODIFIED_BY="[Empty name]" NAME="Eggert 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-10-29 20:33:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eggert T, Hammerer P, Graefen M, Haese A, Huland H</AU>
<TI>Complications of TRUS-guided systematic sextant biopsy of the prostate: A prospective study</TI>
<SO>Der Urologe B</SO>
<YR>1999</YR>
<VL>39</VL>
<NO>3</NO>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-1985" MODIFIED="2010-04-08 13:21:42 -0500" MODIFIED_BY="James Tacklind" NAME="Ferreira 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-04-08 13:21:42 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferreira U, Rodrigues Netto N Jr, Villaca CJ, Palma PC, Jerschov V</AU>
<TI>Comparative study of the local and systemic use of sulfamethoxazole-trimethoprim in transrectal biopsy of the prostate</TI>
<SO>Archivos Espanoles de Urologia</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>3</NO>
<PG>301-4</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:29:59 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herranz-Amo-1996" MODIFIED="2010-04-08 13:15:33 -0500" MODIFIED_BY="James Tacklind" NAME="Herranz Amo 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-08 13:15:33 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herranz Amo F, Rodriguez Fernandez E, Diez Cordero JM, Lledo Garcia E, Verdu Tartajo F, Gonzalez Chamorro F, et al</AU>
<TI>Morbidity of and tolerance to ultrasonography-guided transrectal biopsy of the prostate</TI>
<SO>Actas Urologicas Españolas</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>10</NO>
<PG>858-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hosokawa-2005" MODIFIED="2009-10-29 20:37:54 -0500" MODIFIED_BY="[Empty name]" NAME="Hosokawa 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-10-29 20:37:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hosokawa Y, Kishino T, Ono T, Oyama N, Momose H</AU>
<TI>Antibiotic prophylaxis for transrectal needle biopsy of the prostate</TI>
<SO>Journal of Nara Medical Association</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>1</NO>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hotta-2001" MODIFIED="2009-10-29 20:40:15 -0500" MODIFIED_BY="[Empty name]" NAME="Hotta 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-10-29 20:40:15 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hotta H, Matsukawa M, Kunishima Y, Nishiyama N, Shimizu T, Takahashi S, et al</AU>
<TI>Efficacy of prophylactic single intravenous administration of antimicrobials for patients receiving systematica transrectal prostate biopsy</TI>
<SO>Japanese Journal of Chemotherapy</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>11</NO>
<PG>642-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2006" MODIFIED="2010-04-08 13:22:25 -0500" MODIFIED_BY="James Tacklind" NAME="Huang 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-08 13:22:25 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang YC, Ho DR, Wu CF, Shee JJ, Lin WY, Chen CS</AU>
<TI>Modified bowel preparation to reduce infection after prostate biopsy</TI>
<SO>Chang Gung Medical Journal</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-2002" MODIFIED="2009-08-06 11:13:41 -0500" MODIFIED_BY="James Tacklind" NAME="Ito 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-08-06 11:13:41 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito Y, Deguchi T, Kawada Y</AU>
<TI>Antimicrobial prophylaxis for transrectal prostate biopsy: A prospective randomized trial using levofloxacin</TI>
<SO>Japanese Journal of Chemotherapy</SO>
<YR>2003</YR>
<VL>50</VL>
<NO>12</NO>
<PG>870-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janoff-2000" MODIFIED="2010-04-08 13:22:48 -0500" MODIFIED_BY="James Tacklind" NAME="Janoff 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-04-08 13:22:48 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janoff DM, Skarecky DW, McLaren CE, Ahlering TE</AU>
<TI>Prostate needle biopsy infection after four or six dose ciprofloxacin</TI>
<SO>Canadian Journal of Urology</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>4</NO>
<PG>1066-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeon-2003" MODIFIED="2009-10-29 20:42:15 -0500" MODIFIED_BY="[Empty name]" NAME="Jeon 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-10-29 20:42:15 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeon SS, Woo SH, Hyun JH, Choi HY, Chai SE</AU>
<TI>Bisacodyl rectal preparation can decrease infectious complications of transrectal ultrasound-guided prostate biopsy</TI>
<SO>Urology</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>3</NO>
<PG>461-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-1984" MODIFIED="2009-10-29 20:42:28 -0500" MODIFIED_BY="[Empty name]" NAME="Khan 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-10-29 20:42:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan SA, Hu KN, Smith N</AU>
<TI>Intraoperative preparation of rectum with povidone-iodine-saturated gauze in transrectal biopsy of prostate</TI>
<SO>Urology</SO>
<YR>1984</YR>
<VL>23</VL>
<NO>5 Spec No</NO>
<PG>104-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindert-2000" MODIFIED="2010-10-13 21:49:56 -0500" MODIFIED_BY="[Empty name]" NAME="Lindert 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-04-08 13:23:08 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindert KA, Kabalin JN, Terris MK</AU>
<TI>Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy</TI>
<SO>The Journal of Urology</SO>
<YR>2000</YR>
<VL>164</VL>
<NO>1</NO>
<PG>76-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindstedt-2006" MODIFIED="2010-04-08 13:23:20 -0500" MODIFIED_BY="James Tacklind" NAME="Lindstedt 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-08 13:23:20 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindstedt S, Lindstrom U, Ljunggren E, Wullt B, Grabe M</AU>
<TI>Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors</TI>
<SO>European Urology</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>4</NO>
<PG>832-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mari-2007" MODIFIED="2010-04-08 13:23:37 -0500" MODIFIED_BY="James Tacklind" NAME="Mari 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-08 13:23:37 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mari M</AU>
<TI>Single dose versus 5-day course of oral prulifloxacin in antimicrobial prophylaxis for transrectal prostate biopsy</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>2007</YR>
<VL>51</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1987" MODIFIED="2009-10-29 20:48:16 -0500" MODIFIED_BY="[Empty name]" NAME="Meyer 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-10-29 20:48:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer W, Huland H, Becker H</AU>
<TI>The incidence of fever and sepsis after treatment with antibiotics</TI>
<SO>Aktuelle Urologie</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>1</NO>
<PG>22-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otrock-2004" MODIFIED="2010-04-08 13:24:17 -0500" MODIFIED_BY="James Tacklind" NAME="Otrock 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-08 13:24:17 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otrock ZK, Oghlakian GO, Salamoun MM, Haddad M, Bizri AR</AU>
<TI>Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>10</NO>
<PG>873-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-2003" MODIFIED="2010-04-08 13:26:12 -0500" MODIFIED_BY="James Tacklind" NAME="Peters 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-04-08 13:26:12 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peters HJ, Breitling P</AU>
<TI>Antibiotic prophylaxis in transrectal prostate biopsy. Short-term vs. long-term therapy</TI>
<SO>Urologe - Ausgabe A</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1</NO>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puig-2006" MODIFIED="2010-04-08 13:26:28 -0500" MODIFIED_BY="James Tacklind" NAME="Puig 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-08 13:26:28 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puig J, Darnell A, Bermudez P, Malet A, Serrate G, Bare M, Prats J</AU>
<TI>Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?</TI>
<SO>European Radiology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>4</NO>
<PG>939-43</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:30:25 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1980" MODIFIED="2010-04-08 13:26:44 -0500" MODIFIED_BY="James Tacklind" NAME="Rees 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-04-08 13:26:44 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees M, Ashby EC, Pocock RD, Dowding CH</AU>
<TI>Povidone-iodine antisepsis for transrectal prostatic biopsy</TI>
<SO>British Medical Journal</SO>
<YR>1980</YR>
<VL>281</VL>
<NO>6241</NO>
<PG>650</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roach-1991" MODIFIED="2009-11-10 18:30:39 -0600" MODIFIED_BY="[Empty name]" NAME="Roach 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-11-10 18:30:39 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roach MB, Figueroa TE, McBride D, George WJ, Neal DE Jr</AU>
<TI>Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy</TI>
<SO>Urology</SO>
<YR>1991</YR>
<VL>38</VL>
<NO>1</NO>
<PG>84-7</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:30:39 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabbagh-2004" MODIFIED="2010-08-06 09:39:35 -0500" MODIFIED_BY="James Tacklind" NAME="Sabbagh 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-08-06 09:39:35 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabbagh R, McCormack M, Peloquim F, Faucher R, Perreault JP, Perrotte P, et al</AU>
<TI>A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy</TI>
<SO>Canadian Journal of Urology</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>2</NO>
<PG>2216-9</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:30:52 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saleem-2001" MODIFIED="2010-04-08 13:28:02 -0500" MODIFIED_BY="James Tacklind" NAME="Saleem 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-08 13:28:02 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saleem W, Singh P, Dwivedi U</AU>
<TI>Current role of transrectal ultrasonography (TRUS) of prostate</TI>
<SO>JK Practitioner</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>133-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharpe-1982" MODIFIED="2010-04-08 13:28:12 -0500" MODIFIED_BY="James Tacklind" NAME="Sharpe 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-04-08 13:28:12 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharpe JR, Sadlowski RW, Finney RP, Branch WT, Hanna JE</AU>
<TI>Urinary tract infection after transrectal needle biopsy of the prostate</TI>
<SO>The Journal of Urology</SO>
<YR>1982</YR>
<VL>127</VL>
<NO>2</NO>
<PG>255-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shigemura-2005" MODIFIED="2010-08-06 09:40:02 -0500" MODIFIED_BY="James Tacklind" NAME="Shigemura 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-08-06 09:40:02 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shigemura K, Tanaka K, Yasuda M, Ishihara S, Muratani T, Deguchi T, et al</AU>
<TI>Efficacy of 1-day prophylaxis medication with fluoroquinolone for prostate biopsy</TI>
<SO>World Journal of Urology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>5</NO>
<PG>356-60</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:31:10 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1982" MODIFIED="2010-04-08 13:15:12 -0500" MODIFIED_BY="James Tacklind" NAME="Thompson 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-04-08 13:15:12 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson PM, Pryor JP, Williams JP, Eyers DE, Dulake C, Scully MF, et al</AU>
<TI>The problem of infection after prostatic biopsy: the case for the transperineal approach</TI>
<SO>British Journal of Urology</SO>
<YR>1982</YR>
<VL>54</VL>
<NO>6</NO>
<PG>736-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tobias_x002d_Machado-2003" MODIFIED="2010-08-06 09:41:00 -0500" MODIFIED_BY="James Tacklind" NAME="Tobias-Machado 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-08-06 09:41:00 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tobias-Machado M, Correa TD, De Barros EL, Wroclawski ER</AU>
<TI>Antibiotic prophylaxis in prostate biopsy. A comparative randomized clinical assay between ciprofloxacin, norfloxacin and chloramphenicol</TI>
<SO>International Brazilian Journal of Urology</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>4</NO>
<PG>313-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15745554"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaz-1994" MODIFIED="2010-04-08 13:31:43 -0500" MODIFIED_BY="James Tacklind" NAME="Vaz 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-04-08 13:31:43 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaz F, Muglia R, Tostes H, Torres H</AU>
<TI>The use of lomefloxacin in the prophylaxis of transrectal prostate biopsy</TI>
<SO>Revista Brasileira de Medicina</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>11</NO>
<PG>1709-10</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:31:20 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2010-04-08 13:32:20 -0500" MODIFIED_BY="James Tacklind" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-08 13:32:20 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Zhou X, Chen S, Zhu C, Yu X</AU>
<TI>Investigation of infection risk and the value of antibiotic prophylaxis during transrectal biopsy of the prostate by endotoxin determination</TI>
<SO>Zhonghua Nan Ke Xue [National Journal of Andrology]</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>7</NO>
<PG>496-8, 502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-2008" MODIFIED="2010-04-08 13:32:36 -0500" MODIFIED_BY="James Tacklind" NAME="Yamamoto 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-08 13:32:36 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto S, Ishitoya S, Segawa T, Kamoto T, Okumura K, Ogawa O</AU>
<TI>Antibiotic prophylaxis for transrectal prostate biopsy: a prospective randomized study of tosufloxacin versus levofloxacin</TI>
<SO>International Journal of Urology</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>7</NO>
<PG>604-6</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:31:29 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-09-22 21:35:33 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-09-22 21:35:33 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACS-2009" MODIFIED="2010-09-07 11:26:42 -0500" MODIFIED_BY="James Tacklind" NAME="ACS 2009" TYPE="OTHER">
<AU>American Cancer Society</AU>
<TI>American Cancer Society recommendations for prostate cancer early detection</TI>
<SO>Prostate Cancer: Early Detection.</SO>
<YR>2009</YR>
<VL>Accessed at www.cancer.org/acs/groups/cid/documents/webcontent/003182-pdf.pdf on August 27, 2010</VL>
<IDENTIFIERS MODIFIED="2010-08-26 20:45:35 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-ACS-2010" MODIFIED="2010-08-31 19:46:48 -0500" MODIFIED_BY="[Empty name]" NAME="ACS 2010" TYPE="BOOK">
<AU>American Cancer Society</AU>
<SO>Cancer Facts &amp; Figures 2010</SO>
<YR>2010</YR>
<PB>Atlanta: American Cancer Society</PB>
<IDENTIFIERS MODIFIED="2009-11-10 18:42:26 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andriole-2009" MODIFIED="2010-08-06 09:42:00 -0500" MODIFIED_BY="James Tacklind" NAME="Andriole 2009" TYPE="JOURNAL_ARTICLE">
<AU>Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al</AU>
<TI>Mortality results from a randomized prostate-cancer screening trial</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>13</NO>
<PG>1310-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Astraldi-1937" MODIFIED="2010-04-08 13:34:51 -0500" MODIFIED_BY="James Tacklind" NAME="Astraldi 1937" TYPE="JOURNAL_ARTICLE">
<AU>Astraldi A</AU>
<TI>Diagnosis of cancer of the prostate: biopsy by rectal route</TI>
<SO>Urologic and Cutaneous Review</SO>
<YR>1937</YR>
<VL>41</VL>
<PG>421</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-AUA-2009" MODIFIED="2010-09-07 11:27:19 -0500" MODIFIED_BY="James Tacklind" NAME="AUA 2009" TYPE="OTHER">
<AU>AUA Foundation</AU>
<TI>What you should know about prostate cancer screening</TI>
<SO>Patient guide series</SO>
<YR>2009</YR>
<VL>Accessed at www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/patient-guides/psa.pdf on August 27, 2010</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babaian-2000" MODIFIED="2010-06-20 19:51:55 -0500" MODIFIED_BY="[Empty name]" NAME="Babaian 2000" TYPE="JOURNAL_ARTICLE">
<AU>Babaian RJ</AU>
<TI>Extended field prostate biopsy enhances cancer detection</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>4</NO>
<PG>453-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bootsma-2008" MODIFIED="2010-04-08 13:35:01 -0500" MODIFIED_BY="James Tacklind" NAME="Bootsma 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bootsma AMJ, Pes MPL, Geerlings SE, Goossens A</AU>
<TI>Antibiotic prophylaxis in urologic procedures: a systematic review</TI>
<SO>European Urology</SO>
<YR>2008</YR>
<VL>54</VL>
<PG>1270-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borer-1999" MODIFIED="2010-04-08 13:36:17 -0500" MODIFIED_BY="James Tacklind" NAME="Borer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Borer A, Gilad J, Sikuler E, Riesenberg K, Schlaeffer F, Buskila D</AU>
<TI>Fatal Clostridium sordellii ischio-rectal abscess with septicaemia complicating ultrasound-guided transrectal prostate biopsy</TI>
<SO>Journal of Infection</SO>
<YR>1999</YR>
<VL>38</VL>
<NO>2</NO>
<PG>128-9</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:33:26 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Breslin-1978" MODIFIED="2010-04-08 13:36:25 -0500" MODIFIED_BY="James Tacklind" NAME="Breslin 1978" TYPE="JOURNAL_ARTICLE">
<AU>Breslin JA, Turner BI, Faber RB, Rhamy RK</AU>
<TI>Anaerobic infection as a consequence of transrectal prostatic biopsy</TI>
<SO>The Journal of Urology</SO>
<YR>1978</YR>
<VL>120</VL>
<NO>4</NO>
<PG>502-3</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:34:42 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Brewster-1993" MODIFIED="2010-04-08 13:36:38 -0500" MODIFIED_BY="James Tacklind" NAME="Brewster 1993" TYPE="JOURNAL_ARTICLE">
<AU>Brewster SF, Rooney N, Kabala J, Feneley RC</AU>
<TI>Fatal anaerobic infection following transrectal biopsy of a rare prostatic tumour</TI>
<SO>British Journal of Urology</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>6</NO>
<PG>977-8</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:35:48 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Castro-1999" MODIFIED="2010-04-08 13:36:53 -0500" MODIFIED_BY="James Tacklind" NAME="Castro 1999" TYPE="JOURNAL_ARTICLE">
<AU>Castro AA, Clark OAC, Atallah AN</AU>
<TI>Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS database): update</TI>
<SO>São Paulo Medical Journal</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>3</NO>
<PG>138-9</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:38:28 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-09-07 11:28:35 -0500" MODIFIED_BY="James Tacklind" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2010-09-22 21:35:33 -0500" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK_SECTION">
<AU>Egger M, Smith GD, Altman D</AU>
<TI>Systematic reviews in health care. Metaanalysis in context</TI>
<SO>British Medical Journal Books</SO>
<YR>2001</YR>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enlud-1997" MODIFIED="2010-04-08 13:37:04 -0500" MODIFIED_BY="James Tacklind" NAME="Enlud 1997" TYPE="JOURNAL_ARTICLE">
<AU>Enlud AL, Varenhorst E</AU>
<TI>Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases</TI>
<SO>British Journal of Urology</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>5</NO>
<PG>777-80</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:38:50 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Eskew-1997" MODIFIED="2010-06-20 19:53:22 -0500" MODIFIED_BY="[Empty name]" NAME="Eskew 1997" TYPE="JOURNAL_ARTICLE">
<AU>Eskew LA, Bare RL, McCullough DL</AU>
<TI>Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate</TI>
<SO>The Journal of Urology</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>1</NO>
<PG>199-202; discussion -3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2007" MODIFIED="2009-11-10 18:39:09 -0600" MODIFIED_BY="[Empty name]" NAME="Ferlay 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ferlay F, Autier P, Boniol M, Heanue M, Colombet M, Boyle P</AU>
<TI>Estimates of the cancer incidence and mortality in Europe in 2006</TI>
<SO>Annals of Oncology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>3</NO>
<PG>581-92</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:39:09 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2010" MODIFIED="2010-08-06 09:44:43 -0500" MODIFIED_BY="James Tacklind" NAME="Ferlay 2010" TYPE="BOOK">
<AU>Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM</AU>
<SO>GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [http://globocan.iarc.fr; accessed 6 August, 2010]</SO>
<YR>2010</YR>
<PB>International Agency for Research on Cancer</PB>
<CY>Lyon, France</CY>
<IDENTIFIERS MODIFIED="2009-11-10 18:43:45 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-04-08 13:37:28 -0500" MODIFIED_BY="James Tacklind" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:41:40 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hodge-1989a" MODIFIED="2010-06-20 19:19:03 -0500" MODIFIED_BY="[Empty name]" NAME="Hodge 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Hodge KK, McNeal JE, Stamey TA</AU>
<TI>Ultrasound guided transrectal core biopsies of the palpably abnormal prostate</TI>
<SO>The Journal of Urology</SO>
<YR>1989</YR>
<VL>142</VL>
<NO>1</NO>
<PG>66-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hodge-1989b" MODIFIED="2010-06-20 19:18:34 -0500" MODIFIED_BY="[Empty name]" NAME="Hodge 1989b" TYPE="JOURNAL_ARTICLE">
<AU>Hodge KK, McNeal JE, Terris MK, Stamey TA</AU>
<TI>Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate</TI>
<SO>The Journal of Urology</SO>
<YR>1989</YR>
<VL>142</VL>
<NO>1</NO>
<PG>71-4; discussion 4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006" MODIFIED="2010-08-06 09:45:19 -0500" MODIFIED_BY="James Tacklind" NAME="Jones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C</AU>
<TI>Saturation technique does not improve cancer detection as an initial prostate biopsy strategy</TI>
<SO>The Journal of Urology</SO>
<YR>2006</YR>
<VL>175</VL>
<NO>2</NO>
<PG>485-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" MODIFIED="2010-08-06 09:45:34 -0500" MODIFIED_BY="James Tacklind" NAME="Lefebvre 1996" TYPE="BOOK_SECTION">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of sensitive search strategy for reports of randomised controlled trials in EMBASE</TI>
<SO>Fourth International Cochrane Colloquium</SO>
<YR>1996 Oct 20-24</YR>
<PB>Cochrane</PB>
<CY>Adelaide (Australia)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2002" MODIFIED="2010-08-06 09:46:34 -0500" MODIFIED_BY="James Tacklind" NAME="Levy 2002" TYPE="OTHER">
<AU>Levy H</AU>
<TI>Promoting clear identification of sepsis, severe sepsis and septic shock</TI>
<SO>www.cdc.gov/nchs/ppt/icd9/attachment1.PPT 2002 (accessed 8 April, 2010)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mariappan-2004" MODIFIED="2010-06-20 19:56:28 -0500" MODIFIED_BY="[Empty name]" NAME="Mariappan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mariappan P, Chong WL, Sundram M, Mohamed SR</AU>
<TI>Increasing prostate biopsy cores based on volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity</TI>
<SO>BJU International</SO>
<YR>2004</YR>
<VL>94</VL>
<NO>3</NO>
<PG>307-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naughton-2000a" MODIFIED="2010-06-20 19:58:31 -0500" MODIFIED_BY="[Empty name]" NAME="Naughton 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ</AU>
<TI>A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection</TI>
<SO>The Journal of Urology</SO>
<YR>2000</YR>
<VL>164</VL>
<NO>2</NO>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naughton-2000b" MODIFIED="2010-06-20 20:00:16 -0500" MODIFIED_BY="[Empty name]" NAME="Naughton 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Naughton CK, Ornstein DK, Smith DS, Catalona WJ</AU>
<TI>Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores</TI>
<SO>The Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<NO>1</NO>
<PG>168-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naughton-2001" MODIFIED="2010-06-20 20:01:44 -0500" MODIFIED_BY="[Empty name]" NAME="Naughton 2001" TYPE="JOURNAL_ARTICLE">
<AU>Naughton CK, Miller DC, Yan Y</AU>
<TI>Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores</TI>
<SO>The Journal of Urology</SO>
<YR>2001</YR>
<VL>165</VL>
<NO>1</NO>
<PG>100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patel-2009" MODIFIED="2010-06-20 20:22:24 -0500" MODIFIED_BY="[Empty name]" NAME="Patel 2009" TYPE="JOURNAL_ARTICLE">
<AU>Patel AR, Jones JS</AU>
<TI>Optimal biopsy strategies for the diagnosis and staging of prostate cancer</TI>
<SO>Current Opinion in Urology</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>3</NO>
<PG>232-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paul-2004" MODIFIED="2010-06-20 20:03:24 -0500" MODIFIED_BY="[Empty name]" NAME="Paul 2004" TYPE="JOURNAL_ARTICLE">
<AU>Paul R, Scholer S, van Randenborgh H, Kubler H, Alschibaja M, Busch R, et al</AU>
<TI>Morbidity of prostatic biopsy for different biopsy strategies: is there a relation to core number and sampling region?</TI>
<SO>European Urology</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>4</NO>
<PG>450-5; discussion 6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paul-2005" MODIFIED="2010-06-20 20:06:28 -0500" MODIFIED_BY="[Empty name]" NAME="Paul 2005" TYPE="JOURNAL_ARTICLE">
<AU>Paul R, Scholer S, van Randenborgh H, Kubler H, Alschibaja M, Busch R, et al</AU>
<TI>Optimization of prostatic biopsy: a prospective randomized trial comparing the sextant biopsy with a 10-core biopsy. Impact of prostatic region of sampling</TI>
<SO>Urologia Internationalis</SO>
<YR>2005</YR>
<VL>74</VL>
<NO>3</NO>
<PG>203-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Presti-2000" MODIFIED="2010-06-20 20:08:23 -0500" MODIFIED_BY="[Empty name]" NAME="Presti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Presti JC, Jr., Chang JJ, Bhargava V, Shinohara K</AU>
<TI>The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial</TI>
<SO>The Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<NO>1</NO>
<PG>163-6; discussion 6-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" MODIFIED="2010-04-08 13:39:51 -0500" MODIFIED_BY="James Tacklind" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>150-3</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:45:07 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Schr_x00f6_der-2009" MODIFIED="2010-08-06 13:15:07 -0500" MODIFIED_BY="James Tacklind" NAME="Schröder 2009" TYPE="JOURNAL_ARTICLE">
<AU>Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al</AU>
<TI>Screening and prostate-cancer mortality in a randomized European study</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>13</NO>
<PG>1320-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shandera-1998" MODIFIED="2009-11-10 18:45:41 -0600" MODIFIED_BY="[Empty name]" NAME="Shandera 1998" TYPE="JOURNAL_ARTICLE">
<AU>Shandera KC, Thibault GP, Deshon GE Jr</AU>
<TI>Variability in patient preparation for prostate biopsy among American urologists</TI>
<SO>Urology</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>4</NO>
<PG>644-6</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:45:41 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sruogis-2005" MODIFIED="2009-11-10 18:46:01 -0600" MODIFIED_BY="[Empty name]" NAME="Sruogis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sruogis A, Jankevicius F, Mickys U</AU>
<TI>Prostatic biopsy technique. Historical review</TI>
<SO>Medicina (Kaunas)</SO>
<YR>2005</YR>
<VL>41</VL>
<NO>11</NO>
<PG>957-67</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:46:01 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1997" MODIFIED="2010-04-08 13:40:11 -0500" MODIFIED_BY="James Tacklind" NAME="Taylor 1997" TYPE="JOURNAL_ARTICLE">
<AU>Taylor HM, Bingham JB</AU>
<TI>The use of prophylactic antibiotics in ultrasound-guided transrectal prostate biopsy</TI>
<SO>Clinical Radiology</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>10</NO>
<PG>787-90</PG>
<IDENTIFIERS MODIFIED="2009-11-10 18:46:49 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-US-Task-Force-2008" MODIFIED="2010-09-07 11:30:06 -0500" MODIFIED_BY="James Tacklind" NAME="US Task Force 2008" TYPE="JOURNAL_ARTICLE">
<AU>U.S.Preventive Services Task Force</AU>
<TI>Screening for prostate cancer: U.S.Preventive Services Task Force recommendation statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>149</VL>
<NO>3</NO>
<PG>185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wendel-1967" MODIFIED="2010-04-08 13:40:19 -0500" MODIFIED_BY="James Tacklind" NAME="Wendel 1967" TYPE="JOURNAL_ARTICLE">
<AU>Wendel RG, Evans AT</AU>
<TI>Complications of punch biopsy of the prostate gland</TI>
<SO>The Journal of Urology</SO>
<YR>1967</YR>
<VL>97</VL>
<PG>122</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2009" MODIFIED="2010-04-08 13:41:04 -0500" MODIFIED_BY="James Tacklind" NAME="Yang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Yang M, Zhao X, Wu Z, Xiao N, Lu C</AU>
<TI>Meta-analysis of antibiotic prophylaxis use in transrectal prostatic biopsy</TI>
<SO>Zhong Nan Da Xue Xue Bao Yie Xue Ban [Journal of Central South University. Medical Sciences]</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>2</NO>
<PG>115-23</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-10 09:36:20 -0600" MODIFIED_BY="James Tacklind" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:20 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Aron-2000a">
<CHAR_METHODS MODIFIED="2009-09-21 20:55:49 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, double-blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:09 -0500" MODIFIED_BY="James Tacklind">
<P>231 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:20 -0500" MODIFIED_BY="James Tacklind">
<P>antibiotic for 1 day (Ciprofloxacin 500 mg orally + tinidazole 600 mg orally single dose) or antibiotic for 3 days (ciprofloxacin 500 mg orally 12/12h 3d + Tinidazole 600 mg orally 12/12h 3d) (with enema) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 08:53:26 -0500" MODIFIED_BY="James Tacklind">
<P>bacteremia, fever, UTI, infectious complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 10:11:09 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: bleeding diathesis, UTI, immunosuppressed patients, heart disease, indwelling catheter<BR/>TCI: urine cultures (48 hours), blood cultures (if fever)<BR/>Fever: 38<SUP>o</SUP> C</P>
<P>digitally directed TRPB; 18 gauge needle </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:30 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Aron-2000b">
<CHAR_METHODS MODIFIED="2009-09-21 20:55:55 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, double-blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:09 -0500" MODIFIED_BY="James Tacklind">
<P>231 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:30 -0500" MODIFIED_BY="James Tacklind">
<P>antibiotic for 1 day (ciprofloxacin 500 mg orally + tinidazole 600 mg orally single dose) or antibiotic for 3 days (ciprofloxacin 500 mg orally 12/12h 3d + tinidazole 600 mg orally 12/12h 3d) (with enema) or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 08:53:37 -0500" MODIFIED_BY="James Tacklind">
<P>bacteremia, fever, UTI, infectious complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:19:36 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: bleeding diathesis, UTI, immunosuppressed patients, heart disease, indwelling catheter<BR/>TCI: urine cultures (48 hours), blood cultures (if fever)<BR/>Fever: 38<SUP>o</SUP> C</P>
<P>digitally directed TRPB; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:02:31 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bates-1998">
<CHAR_METHODS MODIFIED="2009-09-21 20:56:09 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:09 -0500" MODIFIED_BY="James Tacklind">
<P>75 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:02:31 -0500" MODIFIED_BY="[Empty name]">
<P>antibiotic single dose (co-amoxiclav 1.2 g IV) or antibiotic multiple dose (co-amoxiclav 1.2g IV + co-amoxiclav 250/125 mg orally 8/8h 1 day) (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, sepsis, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:25:10 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: UTI, prostatitis, indwelling catheter, DM, steroid therapy, heart valves, penicillin hypersensibility, immunosuppression<BR/>TCI: urine sample 72 h after biopsy<BR/>Fever: &gt;37.5<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>mean of four biopsy cores (2 to 6); 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:03:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brewster-1995">
<CHAR_METHODS MODIFIED="2009-09-21 20:56:15 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:09 -0500" MODIFIED_BY="James Tacklind">
<P>111 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:03:46 -0500" MODIFIED_BY="[Empty name]">
<P>antibiotic (cefuroxime 1.5g IV single dose) or another antibiotic (piperacillin/tazobactam 4.5g IV single dose) (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, bacteremia, UTI, sepsis, hospitalization, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:25:24 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: penicillin hypersensibility, heart valve, heart murmur, rectal stenosis, concurrent ATB therapy, bleeding diathesis, anticoagulant therapy<BR/>TCI: urine and blood cultures (after 48h)<BR/>Fever: &gt; ou = 37.5<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>four biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:38 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Briffaux-2009">
<CHAR_METHODS MODIFIED="2009-09-21 20:56:21 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:09 -0500" MODIFIED_BY="James Tacklind">
<P>288 male adult submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:38 -0500" MODIFIED_BY="James Tacklind">
<P>antibiotic for 1 day (2 Ciprofloxacin 500 mg tablets orally single dose) or antibiotic for 3 days (2 Ciprofloxacin 500 mg tablets orally + ciprofloxacin 500 mg orally 12/12h 3d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-03-03 20:25:12 -0600" MODIFIED_BY="[Empty name]">
<P>bacteriuria, UTI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:25:49 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: allergy, risk factors for infection (diabetes, immunosuppression, urinary stent), ATB use in the previous week, active UTI, valvular heart disease</P>
<P>TCI: urine culture, blood cell count</P>
<P>UTI: 10.000 UFC/mL</P>
<P>at least 10 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:08:03 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-1981">
<CHAR_METHODS MODIFIED="2009-09-21 21:02:31 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:10 -0500" MODIFIED_BY="James Tacklind">
<P>40 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:08:03 -0500" MODIFIED_BY="[Empty name]">
<P>antibiotic (Gentamicin 80mg IM single dose) or enema (povidone-iodine) or ATB + enema or placebo (saline clean enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, bacteremia, fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:26:17 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: use of ATB or urologic manipulation 24h before, positive urine or blood culture, marked general debility, valvular heart disease, valvular prostheses<BR/>TCI: urine and blood cultures<BR/>Fever: &gt; 101 F (38.3<SUP>o</SUP> C)<BR/>UTI: &gt; 100.000 UFC/mL</P>
<P>2 to 4 biopsy cores (mean 2.7); 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:17:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cam-2008">
<CHAR_METHODS MODIFIED="2009-09-21 21:16:17 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:10 -0500" MODIFIED_BY="James Tacklind">
<P>400 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:17:50 -0500" MODIFIED_BY="[Empty name]">
<P>antibiotic short course (ceftriaxone 1g IM single dose) or antibiotic short course (ciprofloxacin 500 mg orally single dose) or antibiotic long course (ciprofloxacin 500 mg orally 12/12h 3d) (without enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 18:46:52 -0600" MODIFIED_BY="[Empty name]">
<P>fever, UTI, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-14 14:16:59 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: UTI, use of ATB</P>
<P>TCI: urine culture</P>
<P>fever: &gt; 38.0<SUP>o</SUP> C</P>
<P>12 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:18:58 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cormio-2002">
<CHAR_METHODS MODIFIED="2009-09-21 21:16:46 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:10 -0500" MODIFIED_BY="James Tacklind">
<P>138 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:18:58 -0500" MODIFIED_BY="[Empty name]">
<P>antibiotic (piperacillin/tazobactam 2250 mg IM 12/12h 2d) or another antibiotic (ciprofloxacin 500 mg orally 12/12h 7d) (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, fever, ITU, sepsis, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:26:49 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: indwelling catheters, ATB, immunosuppressive drugs, UTI<BR/>TCI: urine culture<BR/>Fever: 37.5<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>6-12 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:19:21 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crawford-1982">
<CHAR_METHODS MODIFIED="2009-09-21 21:21:23 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, double-blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:10 -0500" MODIFIED_BY="James Tacklind">
<P>48 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:19:21 -0500" MODIFIED_BY="[Empty name]">
<P>Antibiotic (carbenicillin 2 tablets orally 6/6h 1d) or placebo (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, bacteremia, fever, sepsis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 10:11:10 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: UTI, prosthetic devices, rheumatic valvular heart disease, allergy to penicillin, use of ATB (14 day before)<BR/>TCI: urine culture (24h before, 48h and 2 weeks after biopsy) and blood cultures (15 min after biopsy)<BR/>Fever: 38.5<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>1 to 6 biopsy cores</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:49 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Fong-1991">
<CHAR_METHODS MODIFIED="2009-09-21 21:25:16 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:11 -0500" MODIFIED_BY="James Tacklind">
<P>101 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:49 -0500" MODIFIED_BY="James Tacklind">
<P>ATB (netilmicin 1.5mg/Kg IV + metronidazole 500 mg orally - single dose) or another ATB (trimethoprim/sulfo methoxazole 320mg/1600mg orally - single dose) (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, symptomatic UTI, bacteremia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:27:28 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: allergy to drug treatment, severe constipation, indwelling catheter, antibiotic change, vomiting, failure to take the medication<BR/>TCI: blood and urine culture<BR/>Fever: 38<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>2-3 biopsy cores; 14 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:36:20 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Freitas-1999">
<CHAR_METHODS MODIFIED="2009-09-21 21:30:58 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:11 -0500" MODIFIED_BY="James Tacklind">
<P>120 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:36:20 -0600" MODIFIED_BY="James Tacklind">
<P>enema (sodium biphosphate) or ATB (Ciprofloxacin 500mg 12/12h 2d) or ATB long course (ciprofloxacin 500 mg 12/12h 7d) or ATB + enema</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, fever, sepsis, mortality, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:27:51 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: UTI, urologic instrumentation (72h), valvular heart disease or prostheses, use of ATB<BR/>TCI: urine culture<BR/>Fever: 37.5<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>6 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:52 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Isen-1999a">
<CHAR_METHODS MODIFIED="2009-09-21 21:40:25 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:11 -0500" MODIFIED_BY="James Tacklind">
<P>110 male patients submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:52 -0500" MODIFIED_BY="James Tacklind">
<P>ATB (Ofloxacin 400 mg orally single dose) or ATB (trimethoprim/sulfonamide methoxazole 160 mg/800 mg orally single dose) or placebo (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:28:06 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: artificial heart valve, indwelling catheter, diabetes, steroid use, prostatitis, ATB use 72h before<BR/>TCI: urine culture</P>
<P>6 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:55 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Isen-1999b">
<CHAR_METHODS MODIFIED="2009-09-21 21:53:51 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:11 -0500" MODIFIED_BY="James Tacklind">
<P>110 male patients submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:55 -0500" MODIFIED_BY="James Tacklind">
<P>ATB (ofloxacin 400 mg orally single dose) or ATB (trimethoprim/sulfonamide methoxazole 160 mg/800 mg orally single dose) or placebo (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:28:53 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: artificial heart valve, indwelling catheter, diabetes, steroid use, prostatitis, ATB use 72h before<BR/>TCI: urine culture</P>
<P>6 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:24:58 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Kapoor-1998">
<CHAR_METHODS MODIFIED="2009-09-21 21:55:06 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, double-blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:11 -0500" MODIFIED_BY="James Tacklind">
<P>537 male adult submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:24:58 -0500" MODIFIED_BY="James Tacklind">
<P>Antibiotic (ciprofloxacin 500 mg orally single dose) or placebo (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, bacteremia, fever, UTI, sepsis, hospitalization, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:29:09 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion: hypersensibility to ciprofloxacin, valvular heart disease, significant gastrointestinal disease, epilepsy, bacteriuria, urologic manipulation, indwelling catheter, ATB use (7d), granulocyte count &lt; 1000/mm<SUP>3</SUP>
<BR/>TCI: urine culture, urinalysis<BR/>Fever: 37.5<SUP>o</SUP> C<BR/>UTI: 10.000 UFC/mL</P>
<P>4 biopsy cores; 18 or 20 gauge needle </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-08-06 10:11:12 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Melekos-1990">
<CHAR_METHODS MODIFIED="2009-09-21 21:57:09 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:12 -0500" MODIFIED_BY="James Tacklind">
<P>81 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-12 10:12:46 -0600" MODIFIED_BY="James Tacklind">
<P>antibiotic (piperacillin 2 g IV single dose) or enema (PVPI) or ATB + enema</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, bacteremia, fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-16 18:53:48 -0600" MODIFIED_BY="[Empty name]">
<P>exclusion: general debility, heart disease, UTI, use of ATB 24 prior, urologic manipulation<BR/>TCI: MSU culture, blood culture<BR/>Fever: 38.5<SUP>o</SUP> C</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-10 09:36:20 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Petteffi-2002">
<CHAR_METHODS MODIFIED="2009-09-21 21:59:52 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:12 -0500" MODIFIED_BY="James Tacklind">
<P>105 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-10 09:36:20 -0600" MODIFIED_BY="James Tacklind">
<P>Antibiotic short-course (norfloxacin 400mg orally single dose) or antibiotic long-course (norfloxacin 400 mg orally 12/12h for 3 days) (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, fever, hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:29:44 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: allergy to norfloxacin, indwelling catheter, chronic or within less than 30 days of ATB use, leucopenia, valvular cardiac conditions or valvular prosthesis, factors that could potentially interfere in the analysis results: diabetes, neoplasty, AIDS, corticosteroids use<BR/>TCI: blood count, urine culture<BR/>UTI: 100.000 UFC/mL</P>
<P>12 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-14 15:06:45 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Ruebush-1979">
<CHAR_METHODS MODIFIED="2010-03-12 10:14:56 -0600" MODIFIED_BY="James Tacklind">
<P>randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:12 -0500" MODIFIED_BY="James Tacklind">
<P>79 male patients submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-14 15:06:45 -0500" MODIFIED_BY="James Tacklind">
<P>ATB (trimethoprim/sulfonamide metoxazole 40/200 mg orally 12/12h 7d) or placebo (no enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, bacteremia, fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:29:58 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: valvular heart disease, intravascular prosthesis, fever, use of ATB during the week before<BR/>TCI: urine culture (1d before, 2-4 hours after biopsy, 7-14 days later); blood cultures (before, during and 15 to 25 minutes after final)<BR/>Fever: 37.6<SUP>o</SUP> C<BR/>UTI: 10.000 UFC/mL</P>
<P>1 to 7 biopsy cores</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:24:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaeffer-2007">
<CHAR_METHODS MODIFIED="2010-03-12 10:16:21 -0600" MODIFIED_BY="James Tacklind">
<P>randomized, double-blind, controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:12 -0500" MODIFIED_BY="James Tacklind">
<P>497 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:24:02 -0500" MODIFIED_BY="[Empty name]">
<P>Antibiotic 1day or 3 days (ciprofloxacin extended-release 1000 mg 1x/d) (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, UTI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:30:10 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: MSU positive (&gt;10000 UFC), hypersensitivity to quinolone, valvular heart disease, renal or hepatic insufficiency, CNS disorder that might predispose do seizures, endoscopic manipulation of urinary tract in last 7 days, indwelling catheter within 48 hours, ATB within 7 days<BR/>TCI: urine culture, blood culture (if fever)<BR/>UTI: 10.000 UFC/mL</P>
<P>mean of 9.3 and 9.5 biopsy cores; 18 gauge needle </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:25:03 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Shivde-2002">
<CHAR_METHODS MODIFIED="2009-09-21 22:02:39 -0500" MODIFIED_BY="[Empty name]">
<P>randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:12 -0500" MODIFIED_BY="James Tacklind">
<P>115 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:25:03 -0500" MODIFIED_BY="James Tacklind">
<P>antibiotic (trimethoprim 200 mg orally 2 doses) or another antibiotic (gentamicin 120 mg IV single dose) (without enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:30:27 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: valvular heart diseases and protheses, symptomatic UTI, drug sensitivities, diabetes<BR/>TCI: urine sample, urine culture<BR/>UTI: 100.000 UFC/mL</P>
<P>4 to 6 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-17 19:25:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tekdogan-2006">
<CHAR_METHODS MODIFIED="2009-09-21 22:03:38 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:13 -0500" MODIFIED_BY="James Tacklind">
<P>159 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-17 19:25:45 -0500" MODIFIED_BY="[Empty name]">
<P>Antibiotic (ciprofloxacin 1000 mg/d 4d) or enema (rifampicin) or enema + ATB or none treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>bacteriuria, fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:31:04 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: previous prostatic biopsy or prostatic surgery, diabetes, abnormal blood leukocyte counts, neurogenic disease with voiding dysfunction, valvular heart disease, UTI, catheterization in last 15 days, any antibiotic - anticoagulant - immunosuppressive treatment<BR/>TCI: MSU culture 2 days after biopsy, blood culture (if fever)<BR/>Fever: 38<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>6 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:25:09 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Yang-2001a">
<CHAR_METHODS MODIFIED="2009-09-21 22:08:04 -0500" MODIFIED_BY="[Empty name]">
<P>randomized, blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:13 -0500" MODIFIED_BY="James Tacklind">
<P>192 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:25:09 -0500" MODIFIED_BY="James Tacklind">
<P>ATB short course (ciprofloxacin 500 mg orally + metronidazole 400 mg orally single dose) or ATB long course (ciprofloxacin 500 mg orally 12/12h + metronidazole 400 mg orally 12/12h 3d) or placebo (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>fever, UTI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 14:32:37 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: coagulation disturbance, acute infectious disease, severe cardiac disease<BR/>TCI: urine culture, blood culture (if fever)<BR/>Fever: 38<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>13 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-07 11:25:57 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Yang-2001b">
<CHAR_METHODS MODIFIED="2009-08-13 20:40:41 -0500" MODIFIED_BY="[Empty name]">
<P>a randomized, blinded, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-08-06 10:11:13 -0500" MODIFIED_BY="James Tacklind">
<P>192 male adults submitted to TRPB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-07 11:25:57 -0500" MODIFIED_BY="James Tacklind">
<P>ATB short course (Ciprofloxaxin 500 mg orally + Metronidazole 400 mg orally single dose) or ATB long course (ciprofloxacin 500 mg orally 12/12 hours + metronidazole 400 mg orally 12/12 hours/3 days) or placebo (with enema)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-12 21:31:50 -0500" MODIFIED_BY="[Empty name]">
<P>fever, UTI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-06 10:11:24 -0500" MODIFIED_BY="James Tacklind">
<P>exclusion criteria: coagulation disturbance, acute infectious disease, severe cardiac disease<BR/>TCI: urine culture, blood culture (if fever)<BR/>Fever: 38<SUP>o</SUP> C<BR/>UTI: 100.000 UFC/mL</P>
<P>13 biopsy cores; 18 gauge needle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>TCI: tests of control of infection. TRPB: transrectal prostate biopsy. ATB: antibiotic. UTI: urine tract infection. DM: diabetes. CNS: central nervous system.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-06 08:57:13 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Akay-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 08:57:13 -0500" MODIFIED_BY="James Tacklind">
<P>inadequate randomization - the patients were divided into two groups according to their order of arrival</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anjum-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-30 19:57:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Argyropoulos-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 19:57:14 -0500" MODIFIED_BY="[Empty name]">
<P>single study comparing time of administration of antibiotic making impossible the realization of meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aus-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-23 19:54:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aus-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-23 19:54:29 -0500" MODIFIED_BY="[Empty name]">
<P>short-course antibiotic versus long-course antibiotic, but long-course so long (7 days) - the review protocol considered long-course as 3 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 15:00:39 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Bjerklund-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 15:00:39 -0600" MODIFIED_BY="James Tacklind">
<P>doesn't have patients and interventions of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Bosquet-Sanz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>without exclusion criteria of patients - we tried to contact the authors but to no avail</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carey-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized - retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eaton-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eggert-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-30 19:59:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferreira-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 19:59:15 -0500" MODIFIED_BY="[Empty name]">
<P>single study comparing local and systemic administration of antibiotic making impossible realization of meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Herranz-Amo-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>without adequate exclusion criteria of patients (included patients with co-morbidities and with urinary catheter)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hosokawa-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hotta-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>inadequate randomization determined by preference of the urologist</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ito-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>without exclusion criteria of patients; short-course antibiotic versus long-course antibiotic, but short-course so long (3 days), that was considered long-course in the protocol review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Janoff-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jeon-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 15:00:52 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Khan-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 15:00:52 -0600" MODIFIED_BY="James Tacklind">
<P>doesn't have patients and interventions of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindert-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindstedt-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mari-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>without exclusion criteria of patients (except UTI); short-course antibiotic versus long-course antibiotic, but long-course so long (5 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Meyer-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>without exclusion criteria of patients - we tried to contact the authors but to no avail</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otrock-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Peters-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>without exclusion criteria of patients - we tried to contact the authors but to no avail</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Puig-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rees-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 08:57:37 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Roach-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 08:57:37 -0500" MODIFIED_BY="James Tacklind">
<P>inadequate randomization - by alternation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Sabbagh-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>without adequate exclusion criteria of patients (no urinalysis taken prior to the procedure) - we tried to contact the authors but to no avail</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 15:00:12 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Saleem-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 15:00:12 -0600" MODIFIED_BY="James Tacklind">
<P>doesn't have intervention of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 15:00:20 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Sharpe-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 15:00:20 -0600" MODIFIED_BY="James Tacklind">
<P>doesn't have patients and interventions of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 08:58:01 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Shigemura-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 08:58:01 -0500" MODIFIED_BY="James Tacklind">
<P>inadequate randomization by alternation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thompson-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomized- don't have patients and interventions of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-15 18:28:42 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tobias_x002d_Machado-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-15 18:28:42 -0600" MODIFIED_BY="[Empty name]">
<P>inadequate randomization - only the groups of interventions were randomized, but patients were not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 08:58:12 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Vaz-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 08:58:12 -0500" MODIFIED_BY="James Tacklind">
<P>single study comparing lomefloxacin versus lomefloxacin plus metronidazole</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Wang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:48:09 -0600" MODIFIED_BY="James Tacklind">
<P>without exclusion criteria of patients - we tried to contact the authors but to no avail</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 08:58:17 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Yamamoto-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 08:58:17 -0500" MODIFIED_BY="James Tacklind">
<P>single study comparing trovafloxacin versus levofloxacin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-10-17 21:14:15 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-29 20:48:39 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:57:47 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000a">
<DESCRIPTION>
<P>"Patients were randomized into three groups, using computer-generated random numbers."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:58:12 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000b">
<DESCRIPTION>
<P>"patients were randomized into three groups, using computer-generated random numbers."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:03:12 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Bates-1998">
<DESCRIPTION>
<P>"Patients were then randomized to receive"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:02:51 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brewster-1995">
<DESCRIPTION>
<P>"One-hundred and eleven eligible consecutive patients were randomized to receive ...."</P>
<P>Information provided by author: "utilized randomising card system"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 10:29:14 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Briffaux-2009">
<DESCRIPTION>
<P>"patients were randomized by a permutation block"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:54:06 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1981">
<DESCRIPTION>
<P>"Patients were randomized into one of four groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:02:52 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cam-2008">
<DESCRIPTION>
<P>"The patients were prospectively randomized in three groups"</P>
<P>Information provided by author: "utilized a computer program that assigned each subsequent patient into a group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:00:29 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Cormio-2002">
<DESCRIPTION>
<P>"Patients scheduled for TPB at our unit were randomized to receive"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:02:19 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Crawford-1982">
<DESCRIPTION>
<P>"Patients were assigned randomly to receive the treatment drug . . or a placebo"</P>
<P>Information provided by author: used a random generator for sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:06:02 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Fong-1991">
<DESCRIPTION>
<P>"Randomization was done by pre-selection from a table of number for regimens A and B"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 09:49:33 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Freitas-1999">
<DESCRIPTION>
<P>The patients were divided, randomly, into four groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:07:36 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999a">
<DESCRIPTION>
<P>"Patients were randomly divided into 3 groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:08:19 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999b">
<DESCRIPTION>
<P>"Patients were randomly divided into 3 groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:12:00 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Kapoor-1998">
<DESCRIPTION>
<P>"This was a prospective, randomized, double-blind, placebo controlled trial . . . ; Those patients who met enrollment criteria were assigned in a 1:1 ratio to one of the two treatment groups in accordance with a computer-generated randomization schedule."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:13:01 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Melekos-1990">
<DESCRIPTION>
<P>"Patients were randomized into one of the following four groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:14:12 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Petteffi-2002">
<DESCRIPTION>
<P>"patients randomly separated in two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:15:43 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Ruebush-1979">
<DESCRIPTION>
<P>"Each patient was assigned randomly to a coded bottle containing 16 tablets of a combination"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 20:48:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schaeffer-2007">
<DESCRIPTION>
<P>"patients were randomized to receive oral ciprofloxacin"</P>
<P>Information provided by author: "The randomization was 1:1, with a block size of 4"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:18:14 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Shivde-2002">
<DESCRIPTION>
<P>"The patients recruited in this study were randomised to receive"</P>
<P>Contact with author: "we employed the 'Blocked randomisation' process"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:20:23 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Tekdogan-2006">
<DESCRIPTION>
<P>"Patients were randomized into four groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:24:40 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P>Patients were randomly divided into three groups by computer generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:25:37 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001b">
<DESCRIPTION>
<P>Patients were randomly divided into three groups by computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-06-29 20:51:12 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:51 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Aron-2000a">
<DESCRIPTION>
<P> No information provided<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:51 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Aron-2000b">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:49:59 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Bates-1998">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:51 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Brewster-1995">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:51 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Briffaux-2009">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:13 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1981">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:52 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Cam-2008">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:00:40 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Cormio-2002">
<DESCRIPTION>
<P>"Patients scheduled for TPB at our unit were randomized to receive"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:52 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Crawford-1982">
<DESCRIPTION>
<P> Information provided by author: "Used a random generator"; "the study nurse let informed the pharmacy know and they delivered the drug"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:06:11 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Fong-1991">
<DESCRIPTION>
<P>"pre-selection from a table of number for regimens A and B. Numbered and coded envelopes contained the specific regimens"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:26 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Freitas-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:02:52 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:29 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:52 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Kapoor-1998">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:02:41 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Melekos-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:35 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Petteffi-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:37 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Ruebush-1979">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-29 20:51:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schaeffer-2007">
<DESCRIPTION>
<P>Information provided by author: "sealed code break envelopes will be provided to the investigator with each shipment of study medication"; "Study personnel directly involved in the conduct of the study will not be allowed to access the randomization list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:52 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Shivde-2002">
<DESCRIPTION>
<P> Contact with author: "employed central randomisation"; "The procedure was carried out by specialist registrars working with the respective consultants and hence the Senior Registrar, the other main investigators were blinded to the process of antibiotic prophylaxis received by the enrolled patients" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:43 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Tekdogan-2006">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:52 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-08 13:08:52 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2001b">
<DESCRIPTION>
<P> No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-09-15 09:22:27 -0500" MODIFIED_BY="James Tacklind" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:16:53 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000a">
<DESCRIPTION>
<P>Double-blinded study. "Patients in group 1 . . . received a placebo tablet twice a day for 3 days, . . . In group 2, 79 patients . . were given a single dose of ciprofloxacin (500 mg) and tinidazole (600 mg) orally at the same time, followed by placebo tablet twice a day for five more doses. In group 3, 77 patients . . were given the same combination and dose but for 3 days."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:19:19 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000b">
<DESCRIPTION>
<P>Double-blinded study. "Patients in group 1 . . received a placebo tablet twice a day for 3 days, . . . In group 2, 79 patients . . . were given a single dose of ciprofloxacin (500 mg) and tinidazole (600 mg) orally at the same time, followed by placebo tablet twice a day for five more doses. In group 3, 77 patients . . were given the same combination and dose but for 3 days."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:50:08 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Bates-1998">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:53:05 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brewster-1995">
<DESCRIPTION>
<P>Patients were not told which drug they were given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:53:32 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Briffaux-2009">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:54:23 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Brown-1981">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 09:55:42 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Cam-2008">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:02:52 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Cormio-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-08-06 14:27:05 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Crawford-1982">
<DESCRIPTION>
<P>"Patients were assigned randomly to receive the treatment drug (carbenicillin indanyl sodium) or a placebo that was indistinguishable from the study drug".</P>
<P>Information provided by author: investigators and patients were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:06:15 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Fong-1991">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:06:54 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Freitas-1999">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-10 10:46:27 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:02:52 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999b">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:11:01 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Kapoor-1998">
<DESCRIPTION>
<P>"a prospective, randomized, double-blinded, placebo-controlled trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:13:05 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Melekos-1990">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:02:53 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Petteffi-2002">
<DESCRIPTION>
<P>"A clinical trial, simple-blind, controlled"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-15 09:22:27 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Ruebush-1979">
<DESCRIPTION>
<P>"Each patient was assigned randomly to a coded bottle containing 16 tablets of a combination of 40 mg. trimethoprim and 200 mg. sulfamethoxazole or a placebo that was identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:17:21 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Schaeffer-2007">
<DESCRIPTION>
<P>"For patients in the 1-day arm the first and third doses of ciprofloxacin XR were replaced with placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-12 10:19:26 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Shivde-2002">
<DESCRIPTION>
<P>blinded evaluators, but not patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-10 10:46:44 -0600" MODIFIED_BY="James Tacklind" RESULT="NO" STUDY_ID="STD-Tekdogan-2006">
<DESCRIPTION>
<P>No blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-07 11:25:40 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P>Group A received placebo orally 2/day for 3 days; group B received ciprofloxacin and metronidazole 1x and other 5x were given oral placebo; group C received ciprofloxacin and metronidazole 2x/day for 3 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-07 11:26:01 -0500" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001b">
<DESCRIPTION>
<P>Group A received placebo orally 2x/day for 3 days; group B received ciprofloxacin and metronidazole 1x and other 5x were given oral placebo; group C received ciprofloxacin and metronidazole 2x/day for 3 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-10-17 21:14:15 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 09:17:00 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000a">
<DESCRIPTION>
<P>"No patient was excluded from the study after randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 09:49:26 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000b">
<DESCRIPTION>
<P>"No patient was excluded from the study after randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 09:50:32 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Bates-1998">
<DESCRIPTION>
<P>"Eight patients (four from each group) were found to have asymptomatic UTIs . . . ; these patients were excluded from the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 09:53:11 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brewster-1995">
<DESCRIPTION>
<P>"Of the 111 men in the study, 109 men were evaluable: one patient receiving cefuroxime failed to complete all the temperature assessments in his diary card and one patient receiving PT did not provide the 48h MSU and blood culture sample"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-11 10:33:33 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Briffaux-2009">
<DESCRIPTION>
<P>"Analysis was planned in an intention-to-treat basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 09:54:31 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brown-1981">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-10 10:46:16 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cam-2008">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 09:59:16 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cormio-2002">
<DESCRIPTION>
<P>"Six patients (two in Group 1 and four in Group 2) were excluded because of positive urine cultures before TPB"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 10:02:52 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Crawford-1982">
<DESCRIPTION>
<P>"Of 63 patients entered into the study 15 were considered nonevaluable".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 10:06:21 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Fong-1991">
<DESCRIPTION>
<P>"Of these patients 16 (14%) were excluded from the study: 11 in group 1 and 5 in group 2"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:12:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Freitas-1999">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:12:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isen-1999a">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:14:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Isen-1999b">
<DESCRIPTION>
<P>All patients analysed analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 10:11:16 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Kapoor-1998">
<DESCRIPTION>
<P>"Five hundred thirty-seven patients . . . comprised the safety (intent-to-treat) population"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:14:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1990">
<DESCRIPTION>
<P>All patients analysed analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:13:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petteffi-2002">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 10:16:05 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Ruebush-1979">
<DESCRIPTION>
<P>"Nine patients were excluded from analysis for the following reasons"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 10:17:35 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Schaeffer-2007">
<DESCRIPTION>
<P>intention-to-treat analysis. "The 'enrolled' population consisted of all patients enrolled in the study, including those who received no study medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-12 10:19:39 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Shivde-2002">
<DESCRIPTION>
<P>"a total of 128 patients were enrolled in the trial but only 115 were available for the final analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:13:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tekdogan-2006">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:14:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P>all patients analysed analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-17 21:13:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-2001b">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-03-12 10:26:24 -0600" MODIFIED_BY="James Tacklind" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:17:07 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000a">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 08:51:08 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000b">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:51:01 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Bates-1998">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:53:23 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brewster-1995">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-11 10:33:52 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Briffaux-2009">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:54:55 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brown-1981">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:58:07 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cam-2008">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:59:27 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cormio-2002">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:05:37 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Crawford-1982">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:06:31 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Fong-1991">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:07:01 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Freitas-1999">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:07:43 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Isen-1999a">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:08:25 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Isen-1999b">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:11:26 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Kapoor-1998">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:13:13 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Melekos-1990">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:14:21 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Petteffi-2002">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:16:09 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Ruebush-1979">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:17:45 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Schaeffer-2007">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:19:45 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Shivde-2002">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:20:30 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Tekdogan-2006">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:24:26 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P>apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:26:24 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001b">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-08-06 14:28:31 -0500" MODIFIED_BY="James Tacklind" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:17:10 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000a">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 08:51:13 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Aron-2000b">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:51:05 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Bates-1998">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:10 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Brewster-1995">
<DESCRIPTION>
<P>Comment: Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:12 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Briffaux-2009">
<DESCRIPTION>
<P>Comment: Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:14 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1981">
<DESCRIPTION>
<P>Imprecision - few patients and few events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:58:10 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cam-2008">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 09:59:44 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cormio-2002">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:05:40 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Crawford-1982">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:06:34 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Fong-1991">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:07:04 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Freitas-1999">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-06 14:28:31 -0500" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999a">
<DESCRIPTION>
<P>Randomization resulted in 23, 42 and 45 patients in the three groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 10:46:29 -0600" MODIFIED_BY="James Tacklind" RESULT="UNKNOWN" STUDY_ID="STD-Isen-1999b">
<DESCRIPTION>
<P>The randomization result in 23, 42 and 45 patients in the three groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:11:34 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Kapoor-1998">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:13:16 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Melekos-1990">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:14:24 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Petteffi-2002">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:16:13 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Ruebush-1979">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:17:48 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Schaeffer-2007">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:19:48 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Shivde-2002">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:20:33 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Tekdogan-2006">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:24:27 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001a">
<DESCRIPTION>
<P>apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-12 10:26:27 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Yang-2001b">
<DESCRIPTION>
<P>Apparently free</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-02-10 09:51:10 -0600" MODIFIED_BY="James Tacklind">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-04-05 21:52:52 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-04-05 21:52:37 -0500" MODIFIED_BY="Grade Profiler">Antibiotic compared to placebo for patients submitted to transrectal prostate biopsy</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Antibiotic compared to placebo for patients submitted to transrectal prostate biopsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients submitted to transrectal prostate biopsy<BR/>
<B>Settings:</B> low risk patients<BR/>
<B>Intervention:</B> Antibiotic<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antibiotic</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Bacteriuria</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.25 </B>
<BR/>(0.15 to 0.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>870<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>148 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>37 per 1000</B>
<BR/>(22 to 62)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>261 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
<BR/>(39 to 110)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Bacteremia</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.49 to 0.92)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>494<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>190 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>127 per 1000</B>
<BR/>(93 to 175)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>268 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>180 per 1000</B>
<BR/>(131 to 247)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Fever</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.39 </B>
<BR/>(0.23 to 0.64)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>820<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>108 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
<BR/>(25 to 69)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
<BR/>(15 to 43)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>UTI</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.37 </B>
<BR/>(0.22 to 0.62)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1077<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 1000</B>
<BR/>(20 to 56)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>24 per 1000</B>
<BR/>(14 to 40)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hospitalization</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.13 </B>
<BR/>(0.03 to 0.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>650<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
<BR/>(1 to 18)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>130 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(4 to 72)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse event</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.62 </B>
<BR/>(0.23 to 11.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>127<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
<BR/>(4 to 185)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>74 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>120 per 1000</B>
<BR/>(17 to 855)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> some studies with unclear allocation concealment and lack of blinding<BR/>
<SUP>2</SUP> studies with unclear allocation concealment<BR/>
<SUP>3</SUP> few patients and few events - wide confidence interval</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-04-05 21:53:21 -0500" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-04-05 21:53:15 -0500" MODIFIED_BY="Grade Profiler">Short course compared to long course treatment for patients submitted to transrectal prostate biopsy</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Short course compared to long course treatment for patients submitted to transrectal prostate biopsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients submitted to transrectal prostate biopsy<BR/>
<B>Settings:</B> low risk patients<BR/>
<B>Intervention:</B> Short course<BR/>
<B>Comparison: </B>long course treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>long course treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Short course</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Bacteriuria</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.09 </B>
<BR/>(1.17 to 3.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>869<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
<BR/>(42 to 134)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>84 per 1000</B>
<BR/>(47 to 149)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Fever</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.84 </B>
<BR/>(0.99 to 8.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>652<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
<BR/>(12 to 98)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
<BR/>(19 to 155)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>UTI</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.4 </B>
<BR/>(0.73 to 2.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1312<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(17 to 62)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>21 per 1000</B>
<BR/>(11 to 40)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hospitalization</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 4.14 </B>
<BR/>(0.47 to 36.46)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>366<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> most of the studies with unclear allocation concealment<BR/>
<SUP>2</SUP> few events - wide confidence interval</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-02-10 09:51:10 -0600" MODIFIED_BY="James Tacklind" NO="3" READONLY="YES">
<TITLE MODIFIED="2010-04-05 21:53:36 -0500" MODIFIED_BY="Grade Profiler">Single dose compared to multiple dose antibiotic for patients submitted to transrectal prostate biopsy</TITLE>
<TABLE COLS="7" ROWS="23">
<TR>
<TD COLSPAN="7">
<P>
<B>Single dose compared to multiple dose antibiotic for patients submitted to transrectal prostate biopsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients submitted to transrectal prostate biopsy<BR/>
<B>Settings:</B> low risk patients<BR/>
<B>Intervention:</B> Single dose<BR/>
<B>Comparison: </B>multiple dose antibiotic</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>multiple dose antibiotic</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Single dose</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Bacteriuria</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.98 </B>
<BR/>(1.18 to 3.33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>944<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>42 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>83 per 1000</B>
<BR/>(50 to 140)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>113 per 1000</B>
<BR/>(67 to 190)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Fever</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.84 </B>
<BR/>(0.99 to 8.16)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>652<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
<BR/>(12 to 98)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
<BR/>(19 to 155)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>UTI</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.4 </B>
<BR/>(0.73 to 2.68)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1312<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>23 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(17 to 62)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>21 per 1000</B>
<BR/>(11 to 40)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hospitalization</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.1 </B>
<BR/>(0.64 to 15.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>441<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
<BR/>(3 to 60)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> most of the studies with unclear allocation concealment<BR/>
<SUP>2</SUP> studies with large confidence interval</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2010-04-05 21:53:59 -0500" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2010-04-05 21:53:56 -0500" MODIFIED_BY="Grade Profiler">Oral compared to systemic antibiotic (IM or IV) for patients submitted to transrectal prostate biopsy</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Oral compared to systemic antibiotic (IM or IV) for patients submitted to transrectal prostate biopsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients submitted to transrectal prostate biopsy<BR/>
<B>Settings:</B> low risk patients<BR/>
<B>Intervention:</B> Oral<BR/>
<B>Comparison: </B>systemic antibiotic (IM or IV)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>systemic antibiotic (IM or IV)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Oral</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Bacteriuria</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.34 </B>
<BR/>(0.06 to 1.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>354<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>30 per 1000</B>
<BR/>(5 to 168)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>94 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
<BR/>(6 to 181)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Fever</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.8 </B>
<BR/>(0.24 to 13.45)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>522<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(1 to 54)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>UTI</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.27 to 2.7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>508<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
<BR/>(5 to 51)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(6 to 59)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hospitalization</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.8 </B>
<BR/>(0.24 to 13.45)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>407<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(1 to 67)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(1 to 54)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> large heterogeneity<BR/>
<SUP>2</SUP> most of studies with unclear allocation concealment <BR/>
<SUP>3</SUP> studies with unclear allocation concealment and unclear blinding<BR/>
<SUP>4</SUP> studies with wide confidence interval</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-10-17 21:11:54 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-10-17 21:11:54 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-10-17 21:11:54 -0500" MODIFIED_BY="[Empty name]">Outcomes analysed in each included study</TITLE>
<TABLE COLS="9" ROWS="20">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Bacteriuria</P>
</TH>
<TH>
<P>Bacteremia</P>
</TH>
<TH>
<P>Fever</P>
</TH>
<TH>
<P>UTI</P>
</TH>
<TH>
<P>Sepsis</P>
</TH>
<TH>
<P>Mortality</P>
</TH>
<TH>
<P>Hospitalization</P>
</TH>
<TH>
<P>Adverse events</P>
</TH>
</TR>
<TR>
<TD>
<P>Aron 2000</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bates 1998</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Brewster 1995</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>Briffaux 2008</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Brown 1981</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cam 2008</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Cormio 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Crawford 1982</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>Fong 1991</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Freitas 1999</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Isen 1999</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>Kapoor 1998</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>Melekos 1990</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Petteffi 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ruebush 1979</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>Schaeffer 2007</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Shivde 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekdogan 2006</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yang 2001</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P>X</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-08-06 10:12:22 -0500" MODIFIED_BY="James Tacklind" NO="2">
<TITLE>Included studies in each category of comparison</TITLE>
<TABLE COLS="8" ROWS="11">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>
<B>ATB X Placebo</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>ATB X Enema and ATB X ATB + enema </B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Short X Long-course</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Multiple X Single-dose</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Quinolones X another</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Sulfonamide X another</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Piperacilin Tazobactan X another</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Oral versus systemic administration</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Ruebush 1979</P>
</TD>
<TD ALIGN="CENTER">
<P>Brown 1981</P>
</TD>
<TD ALIGN="CENTER">
<P>Aron 2000</P>
</TD>
<TD ALIGN="CENTER">
<P>Bates 1998</P>
</TD>
<TD ALIGN="CENTER">
<P>Isen 1999</P>
</TD>
<TD ALIGN="CENTER">
<P>Fong 1991</P>
</TD>
<TD ALIGN="CENTER">
<P>Brewster 1995</P>
</TD>
<TD ALIGN="CENTER">
<P>Fong 1991</P>
</TD>
</TR>
<TR>
<TD>
<P>Brown 1981</P>
</TD>
<TD ALIGN="CENTER">
<P>Melekos 1990</P>
</TD>
<TD ALIGN="CENTER">
<P>Yang 2001</P>
</TD>
<TD ALIGN="CENTER">
<P>Aron 2000</P>
</TD>
<TD ALIGN="CENTER">
<P>Cormio 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>Isen 1999</P>
</TD>
<TD ALIGN="CENTER">
<P>Cormio 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>Cormio 2002</P>
</TD>
</TR>
<TR>
<TD>
<P>Crawford 1982</P>
</TD>
<TD ALIGN="CENTER">
<P>Freitas 1999</P>
</TD>
<TD ALIGN="CENTER">
<P>Petteffi 2002</P>
</TD>
<TD ALIGN="CENTER">
<P>Yang 2001</P>
</TD>
<TD ALIGN="CENTER">
<P>Cam 2008</P>
</TD>
<TD ALIGN="CENTER">
<P>Shivde 2002</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Shivde 2002</P>
</TD>
</TR>
<TR>
<TD>
<P>Melekos 1990</P>
</TD>
<TD ALIGN="CENTER">
<P>Tekdogan 2006</P>
</TD>
<TD ALIGN="CENTER">
<P>Schaeffer 2007</P>
</TD>
<TD ALIGN="CENTER">
<P>Petteffi 2002</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Cam 2008</P>
</TD>
</TR>
<TR>
<TD>
<P>Kapoor 1998</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Briffaux 2008</P>
</TD>
<TD ALIGN="CENTER">
<P>Schaeffer 2007</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Isen 1999</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Cam 2008</P>
</TD>
<TD ALIGN="CENTER">
<P>Briffaux 2008</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Aron 2000</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>Cam 2008</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Yang 2001</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tekdogan 2006</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-10 09:52:21 -0600" MODIFIED_BY="James Tacklind">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-10 09:52:21 -0600" MODIFIED_BY="James Tacklind" NO="1">
<NAME>Antibiotics (classes) versus placebo</NAME>
<DICH_OUTCOME CHI2="3.017664740336313" CI_END="0.418434887839471" CI_START="0.1541320581887735" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2539571429999288" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.37837211246653973" LOG_CI_START="-0.8121070222388727" LOG_EFFECT_SIZE="-0.5952395673527062" METHOD="MH" MODIFIED="2010-10-25 15:21:14 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.8833633263101734" P_Q="0.0" P_Z="7.46745543970868E-8" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="458" TOTAL_2="412" WEIGHT="100.0" Z="5.37954445399325">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2173348693855888" CI_END="0.6394885343519523" CI_START="0.16916989544915656" DF="2" EFFECT_SIZE="0.32891063907580453" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.19416723775658254" LOG_CI_START="-0.7716769190957701" LOG_EFFECT_SIZE="-0.48292207842617624" MODIFIED="2009-04-20 09:29:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.54407567473" P_Z="0.0010458193943689578" STUDIES="3" TAU2="0.0" TOTAL_1="323" TOTAL_2="305" WEIGHT="48.090981075000215" Z="3.2779013465529125">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="0.8324416676224641" CI_START="0.04002771244843547" EFFECT_SIZE="0.18253968253968253" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.07964618943397245" LOG_CI_START="-1.3976392287659676" LOG_EFFECT_SIZE="-0.7386427090999701" MODIFIED="2009-04-20 09:28:54 -0500" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.7741956354743791" STUDY_ID="STD-Isen-1999a" TOTAL_1="42" TOTAL_2="23" VAR="0.5993788819875776" WEIGHT="11.75924763476707"/>
<DICH_DATA CI_END="0.7726914823450427" CI_START="0.14499332607871931" EFFECT_SIZE="0.334716459197787" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.111993875112206" LOG_CI_START="-0.8386519875159932" LOG_EFFECT_SIZE="-0.47532293131409953" MODIFIED="2009-04-20 09:29:17 -0500" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.426842572241653" STUDY_ID="STD-Kapoor-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.18219458147787077" WEIGHT="31.782024533924456"/>
<DICH_DATA CI_END="3.7781065604215764" CI_START="0.11763682080868876" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.57727420291097" LOG_CI_START="-0.9294567210223325" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-04-20 09:29:29 -0500" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="4.5497089063086875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7349695989890959" CI_END="0.5681069838572369" CI_START="0.05023439457259106" DF="1" EFFECT_SIZE="0.16893344957861087" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.2455698718175885" LOG_CI_START="-1.2989988275114954" LOG_EFFECT_SIZE="-0.772284349664542" MODIFIED="2009-09-10 20:39:34 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.39127710380134917" P_Z="0.0040562068787340765" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="57" WEIGHT="22.908323597612224" Z="2.8737571774251833">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="1.2261143967424541" CI_START="0.0043363329652629365" EFFECT_SIZE="0.07291666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.0885309918432923" LOG_CI_START="-2.362877377893915" LOG_EFFECT_SIZE="-1.1371731930253115" MODIFIED="2009-09-10 20:39:34 -0500" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.4399694110507713" STUDY_ID="STD-Ruebush-1979" TOTAL_1="31" TOTAL_2="34" VAR="2.073511904761905" WEIGHT="10.864976492677464"/>
<DICH_DATA CI_END="0.9299061119127887" CI_START="0.0702314364199314" EFFECT_SIZE="0.25555555555555554" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="-0.031560897829455724" LOG_CI_START="-1.1534684490140084" LOG_EFFECT_SIZE="-0.592514673421732" MODIFIED="2009-08-28 20:29:50 -0500" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.6590140490977507" STUDY_ID="STD-Isen-1999b" TOTAL_1="45" TOTAL_2="23" VAR="0.43429951690821256" WEIGHT="12.043347104934762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24955892986913242" CI_END="0.5367124732684159" CI_START="0.07218120977747379" DF="2" EFFECT_SIZE="0.196826206647322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.27025831153484436" LOG_CI_START="-1.1415758433172674" LOG_EFFECT_SIZE="-0.7059170774260559" MODIFIED="2010-03-10 15:00:59 -0600" MODIFIED_BY="James Tacklind" NO="3" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-08-06 13:31:00 -0500&quot; modified_by=&quot;James Tacklind&quot; class=&quot;inserted&quot;&gt;is this a mix? if so, untangle&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-03-10 15:00:59 -0600" NOTES_MODIFIED_BY="James Tacklind" P_CHI2="0.8826915502699345" P_Z="0.0014941572672866976" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="50" WEIGHT="29.000695327387554" Z="3.1758159278547256">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="0.9975682463642224" CI_START="0.01642393897331215" EFFECT_SIZE="0.128" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.0010573833549730185" LOG_CI_START="-1.78452267734929" LOG_EFFECT_SIZE="-0.8927900303521317" MODIFIED="2009-04-20 09:32:50 -0500" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="1.0476163419878481" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="16" VAR="1.0975" WEIGHT="9.247375825830666"/>
<DICH_DATA CI_END="1.521151188376642" CI_START="0.02750472359020187" EFFECT_SIZE="0.20454545454545456" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18217238105798386" LOG_CI_START="-1.5605927151517087" LOG_EFFECT_SIZE="-0.6892101670468626" MODIFIED="2009-04-20 09:32:25 -0500" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="1.0237088443399314" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="9" VAR="1.047979797979798" WEIGHT="6.6729063959194095"/>
<DICH_DATA CI_END="1.0029939969096775" CI_START="0.05817025720260045" EFFECT_SIZE="0.24154589371980675" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.0012983337015712495" LOG_CI_START="-1.2352990159433692" LOG_EFFECT_SIZE="-0.617000341120899" MODIFIED="2010-03-10 15:00:59 -0600" MODIFIED_BY="James Tacklind" ORDER="137" O_E="0.0" SE="0.7263834044370411" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="0.5276328502415459" WEIGHT="13.080413105637477"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.32571449711477" CI_END="0.9189980500345855" CI_START="0.48628232772182634" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6685001951702315" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="45" I2="39.94509418101327" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.03668541011564922" LOG_CI_START="-0.3131115131016811" LOG_EFFECT_SIZE="-0.17489846160866518" METHOD="MH" MODIFIED="2011-02-10 09:52:21 -0600" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.13917516559573573" P_Q="0.0" P_Z="0.013131223734029281" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="237" WEIGHT="100.00000000000001" Z="2.4801904161834303">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23369683116638318" CI_END="2.0061166576342155" CI_START="0.05139808900464995" DF="1" EFFECT_SIZE="0.3211083345582831" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.30235618406511194" LOG_CI_START="-1.2890530278950723" LOG_EFFECT_SIZE="-0.4933484219149802" MODIFIED="2009-08-24 20:52:54 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6287961530860746" P_Z="0.22428749411899374" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="150" WEIGHT="9.389971182374584" Z="1.2152061600699402">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="3.8936918501307134" CI_START="0.009271406518414679" EFFECT_SIZE="0.19" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5903615781333427" LOG_CI_START="-2.032854376227685" LOG_EFFECT_SIZE="-0.721246399047171" MODIFIED="2009-08-24 20:52:53 -0500" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="1.540890036720063" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="75" VAR="2.3743421052631577" WEIGHT="5.245022856537324"/>
<DICH_DATA CI_END="5.258458209947324" CI_START="0.04510478928417458" EFFECT_SIZE="0.487012987012987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7208584268409616" LOG_CI_START="-1.3457773417304877" LOG_EFFECT_SIZE="-0.312459457444763" MODIFIED="2009-08-24 20:52:54 -0500" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.2139520804709112" STUDY_ID="STD-Aron-2000b" TOTAL_1="77" TOTAL_2="75" VAR="1.4736796536796537" WEIGHT="4.144948325837259"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1732628368567721" CI_START="0.6115653541042336" DF="0" EFFECT_SIZE="0.8470695970695971" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.06939531459607089" LOG_CI_START="-0.2135571258554425" LOG_EFFECT_SIZE="-0.07208090562968582" MODIFIED="2010-02-03 19:00:21 -0600" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3179959622224824" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="37" WEIGHT="56.55064137068647" Z="0.9985846298535365">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="1.1732628368567721" CI_START="0.6115653541042336" EFFECT_SIZE="0.8470695970695971" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.06939531459607089" LOG_CI_START="-0.2135571258554425" LOG_EFFECT_SIZE="-0.07208090562968582" MODIFIED="2010-02-03 19:00:21 -0600" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.16620766415838842" STUDY_ID="STD-Ruebush-1979" TOTAL_1="42" TOTAL_2="37" VAR="0.027624987624987635" WEIGHT="56.55064137068647"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.41179520576814" CI_END="0.9772708491770586" CI_START="0.22391275603256158" DF="2" EFFECT_SIZE="0.46778564453125" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" I2="63.04368654105188" ID="CMP-001.02.03" LOG_CI_END="-0.009985055522513489" LOG_CI_START="-0.6499211644971217" LOG_EFFECT_SIZE="-0.32995311000981764" MODIFIED="2010-06-30 08:25:16 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.06681051505079949" P_Z="0.04326657534136875" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="50" WEIGHT="34.059387446938956" Z="2.0211274317445493">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="1.3049174179308483" CI_START="0.08207985926524346" EFFECT_SIZE="0.32727272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.11558302809439618" LOG_CI_START="-1.0857633968762719" LOG_EFFECT_SIZE="-0.48509018439093776" MODIFIED="2010-03-10 15:03:21 -0600" MODIFIED_BY="James Tacklind" ORDER="142" O_E="0.0" SE="0.705676836788482" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="9" VAR="0.4979797979797979" WEIGHT="11.25057402727256"/>
<DICH_DATA CI_END="4.450906212010521" CI_START="0.41475910461892496" EFFECT_SIZE="1.358695652173913" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6484484430725836" LOG_CI_START="-0.3822040717475814" LOG_EFFECT_SIZE="0.13312218566250114" MODIFIED="2010-06-30 08:25:16 -0500" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.6054103890175943" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="0.3665217391304348" WEIGHT="7.841309170523299"/>
<DICH_DATA CI_END="0.8055918751252933" CI_START="0.014123501153742639" EFFECT_SIZE="0.10666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.09388492255131672" LOG_CI_START="-1.8500576302481964" LOG_EFFECT_SIZE="-0.9719712763997564" MODIFIED="2010-03-10 15:03:24 -0600" MODIFIED_BY="James Tacklind" ORDER="144" O_E="0.0" SE="1.0315845416962521" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="16" VAR="1.0641666666666667" WEIGHT="14.967504249143095"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.644035662468972" CI_END="0.6436758089303496" CI_START="0.23109101457606854" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3856782282470533" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.1913328125200611" LOG_CI_START="-0.6362169406995849" LOG_EFFECT_SIZE="-0.413774876609823" METHOD="MH" MODIFIED="2010-03-10 14:27:50 -0600" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.6870351749759134" P_Q="0.0" P_Z="2.6653989947016804E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="423" TOTAL_2="397" WEIGHT="100.0" Z="3.645820583356492">
<NAME>Fever</NAME>
<GROUP_LABEL_1>antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0620051455246706" CI_END="1.0590278461948563" CI_START="0.22117373624561487" DF="4" EFFECT_SIZE="0.4839722569849048" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.024907379644570442" LOG_CI_START="-0.6552664455445721" LOG_EFFECT_SIZE="-0.31517953295000084" MODIFIED="2009-08-24 20:53:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7243556192202247" P_Z="0.06930603106790952" STUDIES="5" TAU2="0.0" TOTAL_1="326" TOTAL_2="314" WEIGHT="40.161271831993595" Z="1.816419598547109">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="1.89807666817588" CI_START="0.07597567656083698" EFFECT_SIZE="0.379746835443038" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2783137507115302" LOG_CI_START="-1.119325423853088" LOG_EFFECT_SIZE="-0.42050583657077895" MODIFIED="2009-08-24 20:53:39 -0500" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.8209801695647498" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="75" VAR="0.6740084388185654" WEIGHT="11.235304948675816"/>
<DICH_DATA CI_END="1.9466131460151044" CI_START="0.07797967254207672" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28927965195960037" LOG_CI_START="-1.108018592865239" LOG_EFFECT_SIZE="-0.4093694704528194" MODIFIED="2009-08-24 20:53:38 -0500" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.8207799057479743" STUDY_ID="STD-Aron-2000b" TOTAL_1="77" TOTAL_2="75" VAR="0.6736796536796537" WEIGHT="11.094957201981831"/>
<DICH_DATA CI_END="8.500739760948548" CI_START="0.26468284681954973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9294567210223326" LOG_CI_START="-0.5772742029109699" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-04-20 09:53:40 -0500" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="4.380346739483736"/>
<DICH_DATA CI_END="3.021334983454774" CI_START="0.034512946820572904" EFFECT_SIZE="0.3229166666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4801988793284544" LOG_CI_START="-1.4620179577390457" LOG_EFFECT_SIZE="-0.4909095392052957" MODIFIED="2009-08-24 20:53:37 -0500" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="1.1408677842218478" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="62" VAR="1.3015793010752688" WEIGHT="6.674814079213311"/>
<DICH_DATA CI_END="2.9309710934368343" CI_START="0.03345349242198305" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46701153525086136" LOG_CI_START="-1.4755585367774158" LOG_EFFECT_SIZE="-0.5042735007632773" MODIFIED="2009-08-24 20:53:36 -0500" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="1.1410752761863494" STUDY_ID="STD-Yang-2001b" TOTAL_1="66" TOTAL_2="62" VAR="1.3020527859237536" WEIGHT="6.775848862638904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.37517081163303" CI_START="0.2032103448789626" DF="0" EFFECT_SIZE="0.6947368421052632" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.3756948475954823" LOG_CI_START="-0.6920541870894403" LOG_EFFECT_SIZE="-0.15817966974697906" MODIFIED="2009-08-24 21:20:42 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5614356904025171" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="33" WEIGHT="11.722054654956477" Z="0.5807103461947934">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="2.37517081163303" CI_START="0.2032103448789626" EFFECT_SIZE="0.6947368421052632" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3756948475954823" LOG_CI_START="-0.6920541870894403" LOG_EFFECT_SIZE="-0.15817966974697906" MODIFIED="2009-04-20 09:54:45 -0500" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.6272010684168877" STUDY_ID="STD-Ruebush-1979" TOTAL_1="38" TOTAL_2="33" VAR="0.3933811802232855" WEIGHT="11.722054654956477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9238080167181582" CI_END="0.5383372133175237" CI_START="0.0968553429745464" DF="2" EFFECT_SIZE="0.22834367832683766" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-0.26894559792934936" LOG_CI_START="-1.0138764166551566" LOG_EFFECT_SIZE="-0.641411007292253" MODIFIED="2009-08-07 08:19:23 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.38216462652314587" P_Z="7.376406203578844E-4" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="50" WEIGHT="48.11667351304993" Z="3.375192546686945">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="2.0413995209160234" CI_START="0.006942460530483309" EFFECT_SIZE="0.11904761904761904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3099280085129301" LOG_CI_START="-2.1584865806366933" LOG_EFFECT_SIZE="-0.9242792860618817" MODIFIED="2009-04-20 09:55:01 -0500" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="1.4499589485157682" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="9" VAR="2.102380952380952" WEIGHT="8.362480139014405"/>
<DICH_DATA CI_END="0.9650910966843791" CI_START="0.1360233688716302" EFFECT_SIZE="0.36231884057971014" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.015431690884098168" LOG_CI_START="-0.8663864732463373" LOG_EFFECT_SIZE="-0.44090908206521773" MODIFIED="2009-04-20 09:55:12 -0500" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.49985505145368697" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="0.24985507246376806" WEIGHT="25.18699375203148"/>
<DICH_DATA CI_END="1.0070249036381052" CI_START="0.003508533000367982" EFFECT_SIZE="0.05944055944055944" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.0030402107511095047" LOG_CI_START="-2.454874434252648" LOG_EFFECT_SIZE="-1.225917111750769" MODIFIED="2009-04-20 09:55:25 -0500" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="1.4437912293489246" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="16" VAR="2.084533113944879" WEIGHT="14.567199622004052"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1193646032157667" CI_END="0.6167120854930029" CI_START="0.217035239622893" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36585277811342093" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.20991754077185673" LOG_CI_START="-0.6634697448094076" LOG_EFFECT_SIZE="-0.43669364279063205" METHOD="MH" MODIFIED="2010-03-10 14:31:26 -0600" MODIFIED_BY="James Tacklind" NO="4" P_CHI2="0.8911877603337155" P_Q="0.0" P_Z="1.6050648028349202E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="543" TOTAL_2="534" WEIGHT="100.0" Z="3.774224023289614">
<NAME>UTI</NAME>
<GROUP_LABEL_1>antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1193646032157667" CI_END="0.6167120854930029" CI_START="0.217035239622893" DF="4" EFFECT_SIZE="0.36585277811342093" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="48" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.20991754077185673" LOG_CI_START="-0.6634697448094076" LOG_EFFECT_SIZE="-0.43669364279063205" MODIFIED="2009-08-24 20:54:08 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8911877603337155" P_Z="1.6050648028349202E-4" STUDIES="5" TAU2="0.0" TOTAL_1="543" TOTAL_2="534" WEIGHT="100.0" Z="3.774224023289614">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="0.7870987374251757" CI_START="0.09347662845956595" EFFECT_SIZE="0.27124773960216997" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" LOG_CI_END="-0.10397078424933129" LOG_CI_START="-1.0292969602487028" LOG_EFFECT_SIZE="-0.5666338722490171" MODIFIED="2009-08-24 20:54:08 -0500" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.5435411762204744" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="75" VAR="0.2954370102471368" WEIGHT="29.51429716319469"/>
<DICH_DATA CI_END="1.0287461966075213" CI_START="0.16938668288051129" EFFECT_SIZE="0.4174397031539889" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.012308242586868723" LOG_CI_START="-0.7711207367376212" LOG_EFFECT_SIZE="-0.3794062470753762" MODIFIED="2009-08-24 20:54:07 -0500" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.4601900604911972" STUDY_ID="STD-Aron-2000b" TOTAL_1="77" TOTAL_2="75" VAR="0.21177489177489175" WEIGHT="29.14561423727204"/>
<DICH_DATA CI_END="1.3273129129400396" CI_START="0.19277341386416197" EFFECT_SIZE="0.5058365758754864" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.1229733195058732" LOG_CI_START="-0.7149528615547889" LOG_EFFECT_SIZE="-0.2959897710244578" MODIFIED="2009-04-20 09:57:47 -0500" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.492201986556524" STUDY_ID="STD-Kapoor-1998" TOTAL_1="257" TOTAL_2="260" VAR="0.2422627955701886" WEIGHT="24.514433733178677"/>
<DICH_DATA CI_END="2.106970476714601" CI_START="0.027838446624895475" EFFECT_SIZE="0.2421875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3236584502308972" LOG_CI_START="-1.5553550018580886" LOG_EFFECT_SIZE="-0.6158482758135957" MODIFIED="2009-08-24 20:54:06 -0500" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="1.103741803023667" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="62" VAR="1.2182459677419355" WEIGHT="8.349634399392832"/>
<DICH_DATA CI_END="2.043981900563597" CI_START="0.026983512339527668" EFFECT_SIZE="0.23484848484848486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3104770458070208" LOG_CI_START="-1.568901520550175" LOG_EFFECT_SIZE="-0.6292122373715772" MODIFIED="2009-08-24 20:54:05 -0500" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="1.1039562729521584" STUDY_ID="STD-Yang-2001b" TOTAL_1="66" TOTAL_2="62" VAR="1.2187194525904204" WEIGHT="8.476020466961767"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.602832723694392" CI_END="0.5514282370620681" CI_START="0.0309317767827477" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.130601129935801" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.2585109986831753" LOG_CI_START="-1.5095951325419237" LOG_EFFECT_SIZE="-0.8840530656125494" METHOD="MH" MODIFIED="2010-10-25 11:16:04 -0500" MODIFIED_BY="James Tacklind" NO="5" P_CHI2="0.7397697312080834" P_Q="0.0" P_Z="0.005606712162905906" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="306" WEIGHT="100.0" Z="2.769937084372699">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.38653528033822626" CI_END="0.8688523190589065" CI_START="0.02985330745002266" DF="1" EFFECT_SIZE="0.16105314467445433" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.06105403536750478" LOG_CI_START="-1.525007546352996" LOG_EFFECT_SIZE="-0.7930307908602504" MODIFIED="2009-04-20 10:01:01 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5341266008636727" P_Z="0.03371664752656463" STUDIES="2" TAU2="0.0" TOTAL_1="299" TOTAL_2="283" WEIGHT="64.80308295582763" Z="2.1234441900700642">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="1.4795601852878142" CI_START="0.004296915925198866" EFFECT_SIZE="0.07973421926910298" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.1701326360101773" LOG_CI_START="-2.366843143774652" LOG_EFFECT_SIZE="-1.0983552538822374" MODIFIED="2009-04-20 10:00:29 -0500" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.4902321312782552" STUDY_ID="STD-Isen-1999a" TOTAL_1="42" TOTAL_2="23" VAR="2.2207918050941307" WEIGHT="34.37466589972706"/>
<DICH_DATA CI_END="2.2475150311093746" CI_START="0.02846150503464473" EFFECT_SIZE="0.2529182879377432" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.351702604924078" LOG_CI_START="-1.545742138300956" LOG_EFFECT_SIZE="-0.5970197666884389" MODIFIED="2009-04-20 10:01:01 -0500" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.1145684346733442" STUDY_ID="STD-Kapoor-1998" TOTAL_1="257" TOTAL_2="260" VAR="1.2422627955701886" WEIGHT="30.42841705610057"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3844470208687727" CI_START="0.004012678813547621" DF="0" EFFECT_SIZE="0.07453416149068323" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.14127634109670306" LOG_CI_START="-2.396565601065153" LOG_EFFECT_SIZE="-1.1276446299842249" MODIFIED="2009-08-24 21:21:07 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08155223224233733" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="23" WEIGHT="35.19691704417236" Z="1.7417498114530887">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="1.3844470208687727" CI_START="0.004012678813547621" EFFECT_SIZE="0.07453416149068323" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.14127634109670306" LOG_CI_START="-2.396565601065153" LOG_EFFECT_SIZE="-1.1276446299842249" MODIFIED="2009-04-20 10:01:16 -0500" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="1.4907409193460937" STUDY_ID="STD-Isen-1999b" TOTAL_1="45" TOTAL_2="23" VAR="2.2223084886128364" WEIGHT="35.19691704417236"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3776777433635873" CI_END="11.557908714423803" CI_START="0.22644400096454217" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6177821522309714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="1.0628792600405061" LOG_CI_START="-0.6450391803133564" LOG_EFFECT_SIZE="0.20892003986357494" METHOD="MH" MODIFIED="2010-08-06 14:39:27 -0500" MODIFIED_BY="James Tacklind" NO="6" P_CHI2="0.5388490056099589" P_Q="0.0" P_Z="0.6315810478497039" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="62" WEIGHT="100.0" Z="0.4795027023614082">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotic</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.593638320208182" CI_START="0.057091198046071254" DF="0" EFFECT_SIZE="0.8809523809523809" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="1.1333357106629383" LOG_CI_START="-1.2434308433247494" LOG_EFFECT_SIZE="-0.05504756633090548" MODIFIED="2010-03-10 14:42:38 -0600" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="1.0" P_Z="0.9276608403547388" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="37" WEIGHT="68.89763779527559" Z="0.09078825790790167">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="13.593638320208182" CI_START="0.057091198046071254" EFFECT_SIZE="0.8809523809523809" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1333357106629383" LOG_CI_START="-1.2434308433247494" LOG_EFFECT_SIZE="-0.05504756633090548" MODIFIED="2009-04-20 10:10:40 -0500" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.3961244389965564" STUDY_ID="STD-Ruebush-1979" TOTAL_1="42" TOTAL_2="37" VAR="1.9491634491634493" WEIGHT="68.89763779527559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.00582420414608" CI_START="0.13896961332370927" DF="0" EFFECT_SIZE="3.2500000000000004" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="1.8808468728440408" LOG_CI_START="-0.857080150886292" LOG_EFFECT_SIZE="0.5118833609788744" MODIFIED="2010-03-10 14:42:38 -0600" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="1.0" P_Z="0.4636374323790845" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="25" WEIGHT="31.10236220472441" Z="0.7328704842081468">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="76.00582420414608" CI_START="0.13896961332370927" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8808468728440408" LOG_CI_START="-0.857080150886292" LOG_EFFECT_SIZE="0.5118833609788743" MODIFIED="2009-10-29 19:01:45 -0500" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="2.5865384615384617" WEIGHT="31.10236220472441"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1531393034782473" CI_END="0.4584863997756464" CI_START="0.16617654634887552" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2760247932027969" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.33867354241487996" LOG_CI_START="-0.7794302712259499" LOG_EFFECT_SIZE="-0.559051906820415" METHOD="MH" MODIFIED="2010-10-25 15:22:34 -0500" MODIFIED_BY="James Tacklind" NO="7" P_CHI2="0.9050892187568063" P_Q="0.0" P_Z="6.626512350770321E-7" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="427" TOTAL_2="378" WEIGHT="100.0" Z="4.972001701764766">
<NAME>Bacteriuria (with pre-biopsy enema)</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2173348693855888" CI_END="0.6394885343519523" CI_START="0.16916989544915656" DF="2" EFFECT_SIZE="0.32891063907580453" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="30" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.19416723775658254" LOG_CI_START="-0.7716769190957701" LOG_EFFECT_SIZE="-0.48292207842617624" MODIFIED="2010-04-04 22:36:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.54407567473" P_Z="0.0010458193943689578" STUDIES="3" TAU2="0.0" TOTAL_1="323" TOTAL_2="305" WEIGHT="53.952957190895326" Z="3.2779013465529125">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="0.8324416676224641" CI_START="0.04002771244843547" EFFECT_SIZE="0.18253968253968253" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="-0.07964618943397245" LOG_CI_START="-1.3976392287659676" LOG_EFFECT_SIZE="-0.7386427090999701" MODIFIED="2010-04-04 22:36:39 -0500" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.7741956354743791" STUDY_ID="STD-Isen-1999a" TOTAL_1="42" TOTAL_2="23" VAR="0.5993788819875776" WEIGHT="13.19262302522536"/>
<DICH_DATA CI_END="0.7726914823450427" CI_START="0.14499332607871931" EFFECT_SIZE="0.334716459197787" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.111993875112206" LOG_CI_START="-0.8386519875159932" LOG_EFFECT_SIZE="-0.47532293131409953" MODIFIED="2010-04-04 22:36:39 -0500" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.426842572241653" STUDY_ID="STD-Kapoor-1998" TOTAL_1="241" TOTAL_2="242" VAR="0.18219458147787077" WEIGHT="35.65604549519587"/>
<DICH_DATA CI_END="3.7781065604215764" CI_START="0.11763682080868876" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.57727420291097" LOG_CI_START="-0.9294567210223325" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-04-04 22:36:39 -0500" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="5.104288670474098"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9299061119127887" CI_START="0.0702314364199314" DF="0" EFFECT_SIZE="0.25555555555555554" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.031560897829455724" LOG_CI_START="-1.1534684490140084" LOG_EFFECT_SIZE="-0.592514673421732" MODIFIED="2010-04-05 21:29:02 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03843012949063412" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="23" WEIGHT="13.511352363019672" Z="2.0702372829061617">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="0.9299061119127887" CI_START="0.0702314364199314" EFFECT_SIZE="0.25555555555555554" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="-0.031560897829455724" LOG_CI_START="-1.1534684490140084" LOG_EFFECT_SIZE="-0.592514673421732" MODIFIED="2010-04-04 22:36:44 -0500" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.6590140490977507" STUDY_ID="STD-Isen-1999b" TOTAL_1="45" TOTAL_2="23" VAR="0.43429951690821256" WEIGHT="13.511352363019672"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24955892986913242" CI_END="0.5367124732684159" CI_START="0.07218120977747379" DF="2" EFFECT_SIZE="0.196826206647322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="-0.27025831153484436" LOG_CI_START="-1.1415758433172674" LOG_EFFECT_SIZE="-0.7059170774260559" MODIFIED="2010-10-25 11:17:18 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.8826915502699345" P_Z="0.0014941572672866976" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="50" WEIGHT="32.535690446085" Z="3.1758159278547256">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="1.521151188376642" CI_START="0.02750472359020187" EFFECT_SIZE="0.20454545454545456" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.18217238105798386" LOG_CI_START="-1.5605927151517087" LOG_EFFECT_SIZE="-0.6892101670468626" MODIFIED="2010-04-04 22:36:49 -0500" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="1.0237088443399314" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="9" VAR="1.047979797979798" WEIGHT="7.4862900500286775"/>
<DICH_DATA CI_END="1.0029939969096775" CI_START="0.05817025720260045" EFFECT_SIZE="0.24154589371980675" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.0012983337015712495" LOG_CI_START="-1.2352990159433692" LOG_EFFECT_SIZE="-0.617000341120899" MODIFIED="2010-04-04 22:36:49 -0500" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.7263834044370411" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="0.5276328502415459" WEIGHT="14.674829927613033"/>
<DICH_DATA CI_END="0.9975682463642224" CI_START="0.01642393897331215" EFFECT_SIZE="0.128" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.0010573833549730185" LOG_CI_START="-1.78452267734929" LOG_EFFECT_SIZE="-0.8927900303521317" MODIFIED="2010-04-04 22:36:49 -0500" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="1.0476163419878481" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="16" VAR="1.0975" WEIGHT="10.374570468443288"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.85138026544442" CI_END="0.8676257886266832" CI_START="0.2191862834690381" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4360867712405134" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" I2="31.64006066018007" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.06166754783832519" LOG_CI_START="-0.6591866271954088" LOG_EFFECT_SIZE="-0.36042708751686703" METHOD="MH" MODIFIED="2010-10-25 15:29:15 -0500" MODIFIED_BY="James Tacklind" NO="8" P_CHI2="0.21052569977029423" P_Q="0.0" P_Z="0.01805325615181039" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="215" TOTAL_2="200" WEIGHT="100.00000000000003" Z="2.3645240294111485">
<NAME>Bacteremia (with pre-biopsy enema)</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23369683116638318" CI_END="2.0061166576342155" CI_START="0.05139808900464995" DF="1" EFFECT_SIZE="0.3211083345582831" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.30235618406511194" LOG_CI_START="-1.2890530278950723" LOG_EFFECT_SIZE="-0.4933484219149802" MODIFIED="2010-04-04 22:42:32 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6287961530860746" P_Z="0.22428749411899374" STUDIES="2" TAU2="0.0" TOTAL_1="156" TOTAL_2="150" WEIGHT="21.61129986402043" Z="1.2152061600699402">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="3.8936918501307134" CI_START="0.009271406518414679" EFFECT_SIZE="0.19" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5903615781333427" LOG_CI_START="-2.032854376227685" LOG_EFFECT_SIZE="-0.721246399047171" MODIFIED="2010-04-04 22:42:32 -0500" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="1.540890036720063" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="75" VAR="2.3743421052631577" WEIGHT="12.071577169377868"/>
<DICH_DATA CI_END="5.258458209947324" CI_START="0.04510478928417458" EFFECT_SIZE="0.487012987012987" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7208584268409616" LOG_CI_START="-1.3457773417304877" LOG_EFFECT_SIZE="-0.312459457444763" MODIFIED="2010-04-04 22:42:32 -0500" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="1.2139520804709112" STUDY_ID="STD-Aron-2000b" TOTAL_1="77" TOTAL_2="75" VAR="1.4736796536796537" WEIGHT="9.539722694642562"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.411795205768141" CI_END="0.9772708491770588" CI_START="0.22391275603256158" DF="2" EFFECT_SIZE="0.46778564453125004" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" I2="63.04368654105188" ID="CMP-001.08.02" LOG_CI_END="-0.00998505552251344" LOG_CI_START="-0.6499211644971217" LOG_EFFECT_SIZE="-0.3299531100098176" MODIFIED="2010-04-05 21:29:25 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0668105150507996" P_Z="0.04326657534136879" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="50" WEIGHT="78.38870013597959" Z="2.021127431744549">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="1.3049174179308483" CI_START="0.08207985926524346" EFFECT_SIZE="0.32727272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.11558302809439618" LOG_CI_START="-1.0857633968762719" LOG_EFFECT_SIZE="-0.48509018439093776" MODIFIED="2010-04-04 22:42:42 -0500" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.705676836788482" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="9" VAR="0.4979797979797979" WEIGHT="25.893533028315524"/>
<DICH_DATA CI_END="4.450906212010521" CI_START="0.41475910461892496" EFFECT_SIZE="1.358695652173913" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6484484430725836" LOG_CI_START="-0.3822040717475814" LOG_EFFECT_SIZE="0.13312218566250114" MODIFIED="2010-04-04 22:42:42 -0500" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.6054103890175943" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="0.3665217391304348" WEIGHT="18.04700786821991"/>
<DICH_DATA CI_END="0.8055918751252933" CI_START="0.014123501153742639" EFFECT_SIZE="0.10666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.09388492255131672" LOG_CI_START="-1.8500576302481964" LOG_EFFECT_SIZE="-0.9719712763997564" MODIFIED="2010-04-04 22:42:42 -0500" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="1.0315845416962521" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="16" VAR="1.0641666666666667" WEIGHT="34.44815923944416"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.837183403106162" CI_END="0.6084040257521575" CI_START="0.19522632769240228" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.34463964325200236" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.21580792092383355" LOG_CI_START="-0.709461614945353" LOG_EFFECT_SIZE="-0.4626347679345933" METHOD="MH" MODIFIED="2010-08-06 14:40:26 -0500" MODIFIED_BY="James Tacklind" NO="9" P_CHI2="0.6798248081772036" P_Q="0.0" P_Z="2.3914041077110806E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="385" TOTAL_2="364" WEIGHT="100.00000000000001" Z="3.6736177370054146">
<NAME>Fever (with pre-biopsy enema)</NAME>
<GROUP_LABEL_1>antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0620051455246715" CI_END="1.0590278461948561" CI_START="0.22117373624561482" DF="4" EFFECT_SIZE="0.4839722569849047" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.024907379644570352" LOG_CI_START="-0.6552664455445723" LOG_EFFECT_SIZE="-0.31517953295000095" MODIFIED="2010-04-04 22:45:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7243556192202246" P_Z="0.0693060310679094" STUDIES="5" TAU2="0.0" TOTAL_1="326" TOTAL_2="314" WEIGHT="45.49411710367646" Z="1.8164195985471097">
<NAME>Quinolones</NAME>
<DICH_DATA CI_END="1.89807666817588" CI_START="0.07597567656083698" EFFECT_SIZE="0.379746835443038" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2783137507115302" LOG_CI_START="-1.119325423853088" LOG_EFFECT_SIZE="-0.42050583657077895" MODIFIED="2010-04-04 22:45:26 -0500" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.8209801695647498" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="75" VAR="0.6740084388185654" WEIGHT="12.727193530344934"/>
<DICH_DATA CI_END="1.9466131460151044" CI_START="0.07797967254207672" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28927965195960037" LOG_CI_START="-1.108018592865239" LOG_EFFECT_SIZE="-0.4093694704528194" MODIFIED="2010-04-04 22:45:26 -0500" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.8207799057479743" STUDY_ID="STD-Aron-2000b" TOTAL_1="77" TOTAL_2="75" VAR="0.6736796536796537" WEIGHT="12.568209600502183"/>
<DICH_DATA CI_END="8.500739760948548" CI_START="0.26468284681954973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9294567210223326" LOG_CI_START="-0.5772742029109699" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-04-04 22:45:26 -0500" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="4.961994439678784"/>
<DICH_DATA CI_END="3.021334983454774" CI_START="0.034512946820572904" EFFECT_SIZE="0.3229166666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4801988793284544" LOG_CI_START="-1.4620179577390457" LOG_EFFECT_SIZE="-0.4909095392052957" MODIFIED="2010-04-04 22:45:26 -0500" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="1.1408677842218478" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="62" VAR="1.3015793010752688" WEIGHT="7.561134384272432"/>
<DICH_DATA CI_END="2.9309710934368343" CI_START="0.03345349242198305" EFFECT_SIZE="0.31313131313131315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46701153525086136" LOG_CI_START="-1.4755585367774158" LOG_EFFECT_SIZE="-0.5042735007632773" MODIFIED="2010-04-04 22:45:26 -0500" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="1.1410752761863494" STUDY_ID="STD-Yang-2001b" TOTAL_1="66" TOTAL_2="62" VAR="1.3020527859237536" WEIGHT="7.675585148878119"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9238080167181586" CI_END="0.5383372133175237" CI_START="0.0968553429745464" DF="2" EFFECT_SIZE="0.22834367832683763" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-0.26894559792934936" LOG_CI_START="-1.0138764166551566" LOG_EFFECT_SIZE="-0.6414110072922531" MODIFIED="2010-04-05 21:29:56 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.38216462652314576" P_Z="7.376406203578852E-4" STUDIES="3" TAU2="0.0" TOTAL_1="59" TOTAL_2="50" WEIGHT="54.505882896323556" Z="3.3751925466869444">
<NAME>Other classes of antibiotics</NAME>
<DICH_DATA CI_END="2.0413995209160234" CI_START="0.006942460530483309" EFFECT_SIZE="0.11904761904761904" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3099280085129301" LOG_CI_START="-2.1584865806366933" LOG_EFFECT_SIZE="-0.9242792860618817" MODIFIED="2010-04-04 22:45:37 -0500" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="1.4499589485157682" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="9" VAR="2.102380952380952" WEIGHT="9.472898475750405"/>
<DICH_DATA CI_END="0.9650910966843791" CI_START="0.1360233688716302" EFFECT_SIZE="0.36231884057971014" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.015431690884098168" LOG_CI_START="-0.8663864732463373" LOG_EFFECT_SIZE="-0.44090908206521773" MODIFIED="2010-04-04 22:45:37 -0500" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.49985505145368697" STUDY_ID="STD-Crawford-1982" TOTAL_1="23" TOTAL_2="25" VAR="0.24985507246376806" WEIGHT="28.531468028153007"/>
<DICH_DATA CI_END="1.0070249036381052" CI_START="0.003508533000367982" EFFECT_SIZE="0.05944055944055944" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.0030402107511095047" LOG_CI_START="-2.454874434252648" LOG_EFFECT_SIZE="-1.225917111750769" MODIFIED="2010-04-04 22:45:37 -0500" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.4437912293489246" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="16" VAR="2.084533113944879" WEIGHT="16.501516392420143"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-04-13 10:02:16 -0500" MODIFIED_BY="James Tacklind" NO="2">
<NAME>Antibiotics versus enema</NAME>
<DICH_OUTCOME CHI2="0.8763427517090892" CI_END="4.794992116602851" CI_START="0.6118353155103984" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7128180039138945" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.680787897488185" LOG_CI_START="-0.21336545888346992" LOG_EFFECT_SIZE="0.23371121930235753" METHOD="MH" MODIFIED="2010-04-13 09:55:15 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.6452152219265127" P_Q="0.0" P_Z="0.30556168401337147" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="68" WEIGHT="100.0" Z="1.0245794400958845">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>enema</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enema</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-10-14 20:05:36 -0500" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Brown-1981" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="19.32485322896282"/>
<DICH_DATA CI_END="5.247074496563887" CI_START="0.1275799472718912" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7199172302393039" LOG_CI_START="-0.8942175816771043" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2008-10-14 20:05:34 -0500" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.9481507786158797" STUDY_ID="STD-Melekos-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.898989898989899" WEIGHT="42.514677103718206"/>
<DICH_DATA CI_END="12.44106446389317" CI_START="0.5284613690668037" EFFECT_SIZE="2.5641025641025643" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0948575404044387" LOG_CI_START="-0.2769867544574369" LOG_EFFECT_SIZE="0.40893539297350084" MODIFIED="2008-10-14 20:05:38 -0500" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.8058281295406449" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="39" TOTAL_2="40" VAR="0.6493589743589743" WEIGHT="38.160469667318985"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.542246596709908" CI_END="8.934392015400384" CI_START="0.40025507559033197" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.89104091745201" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="60.664712805824294" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.9510650041454582" LOG_CI_START="-0.3976631521334665" LOG_EFFECT_SIZE="0.27670092600599594" METHOD="MH" MODIFIED="2010-04-13 10:02:16 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.11083730873588571" P_Q="0.0" P_Z="0.42128126537083" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7639183584460819" TOTALS="YES" TOTAL_1="32" TOTAL_2="28" WEIGHT="100.0" Z="0.8042003823170409">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Enema</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enema</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.354084750922915" CI_START="1.114665287103816" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="1.156975506111812" LOG_CI_START="0.04714447654411281" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2008-10-14 20:06:02 -0500" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.6519202405202649" STUDY_ID="STD-Brown-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.42500000000000004" WEIGHT="52.79247450511801"/>
<DICH_DATA CI_END="3.5730551928239476" CI_START="0.18735268600041738" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5530397247817147" LOG_CI_START="-0.727340076219515" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="39" O_E="0.0" SE="0.7521014330903549" STUDY_ID="STD-Melekos-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.5656565656565656" WEIGHT="47.20752549488199"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.749930232359159" CI_END="5.052582679398952" CI_START="0.15608297937809226" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8880440068795762" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="65.71401233686021" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.7035134289489332" LOG_CI_START="-0.8066444535371968" LOG_EFFECT_SIZE="-0.051565512294131866" METHOD="MH" MODIFIED="2010-04-13 09:55:55 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.032807360624102055" P_Q="0.0" P_Z="0.8935219943469792" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.03623443207499" TOTALS="YES" TOTAL_1="101" TOTAL_2="96" WEIGHT="99.99999999999999" Z="0.13384898110715793">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Enema</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antibiotics</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours enema</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.49535692115668" CI_START="0.7043174704660874" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5501715475508746" LOG_CI_START="-0.15223153887883709" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-12-29 19:33:34 -0600" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.9999999999999999" STUDY_ID="STD-Brown-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.9999999999999999" WEIGHT="25.9169929575965"/>
<DICH_DATA CI_END="0.7263460168923435" CI_START="0.002732061424897258" EFFECT_SIZE="0.0445468509984639" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.13885644069424966" LOG_CI_START="-2.563509540644222" LOG_EFFECT_SIZE="-1.3511829906692359" MODIFIED="2009-12-29 19:34:14 -0600" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="1.424253233137028" STUDY_ID="STD-Freitas-1999" TOTAL_1="30" TOTAL_2="28" VAR="2.028497272101277" WEIGHT="19.359227649109098"/>
<DICH_DATA CI_END="5.247074496563887" CI_START="0.1275799472718912" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7199172302393039" LOG_CI_START="-0.8942175816771043" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2009-10-29 19:04:28 -0500" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.9481507786158797" STUDY_ID="STD-Melekos-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.898989898989899" WEIGHT="26.808876432674925"/>
<DICH_DATA CI_END="8.712520063738259" CI_START="0.27166237644334323" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9401437912278195" LOG_CI_START="-0.5659705045135307" LOG_EFFECT_SIZE="0.18708664335714445" MODIFIED="2009-10-29 19:04:29 -0500" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.884698992704472" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="39" TOTAL_2="40" VAR="0.7826923076923076" WEIGHT="27.91490296061947"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-10-25 15:27:45 -0500" MODIFIED_BY="James Tacklind" NO="3">
<NAME>Antibiotics versus antibiotics + enema</NAME>
<DICH_OUTCOME CHI2="0.014635889065998546" CI_END="1.287707205296599" CI_START="0.13440333456026898" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41601940138549764" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.10981712577267734" LOG_CI_START="-0.8715899562586855" LOG_EFFECT_SIZE="-0.38088641524300404" METHOD="MH" MODIFIED="2010-10-25 15:27:45 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.9927087665457351" P_Q="0.0" P_Z="0.12817620818038608" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="71" WEIGHT="100.0" Z="1.5213333381121847">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Antbiotic + enema</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ATB + enema</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ATB</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.280395630134262" CI_START="0.04826926950242054" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6314839120139702" LOG_CI_START="-1.3163292736583827" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="117" O_E="0.0" SE="1.1441551070947107" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="10" VAR="1.309090909090909" WEIGHT="22.56294954092963"/>
<DICH_DATA CI_END="4.527165596928454" CI_START="0.042764064148957066" EFFECT_SIZE="0.44" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6558263806266657" LOG_CI_START="-1.368921027654291" LOG_EFFECT_SIZE="-0.3565473235138126" ORDER="118" O_E="0.0" SE="1.1893466502855483" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="22" VAR="1.4145454545454546" WEIGHT="22.91208609088599"/>
<DICH_DATA CI_END="1.8922859049581513" CI_START="0.08037897423506087" EFFECT_SIZE="0.39" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27698675445743703" LOG_CI_START="-1.0948575404044385" LOG_EFFECT_SIZE="-0.4089353929735008" ORDER="119" O_E="0.0" SE="0.8058281295406449" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="40" TOTAL_2="39" VAR="0.6493589743589743" WEIGHT="54.52496436818438"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03910172791222161" CI_END="0.7493537582256081" CI_START="0.0804238421542211" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24549115741551397" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.12531311023751673" LOG_CI_START="-1.0946151828307467" LOG_EFFECT_SIZE="-0.6099641465341317" METHOD="MH" MODIFIED="2009-08-25 14:53:47 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.8432473533385603" P_Q="0.0" P_Z="0.013634958682693533" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="32" WEIGHT="100.0" Z="2.466739302164493">
<NAME>Bacteremia</NAME>
<GROUP_LABEL_1>Antbiotic + Enema</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ATB + enema</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ATB</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8267350704800446" CI_START="0.06247816792384428" EFFECT_SIZE="0.22727272727272727" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.08263363901078495" LOG_CI_START="-1.20427171396159" LOG_EFFECT_SIZE="-0.6434526764861874" ORDER="120" O_E="0.0" SE="0.6588557574241186" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="10" VAR="0.4340909090909091" WEIGHT="72.42164244440553"/>
<DICH_DATA CI_END="2.6195449292633275" CI_START="0.032847096258296286" EFFECT_SIZE="0.29333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41822585167260906" LOG_CI_START="-1.4835030168115966" LOG_EFFECT_SIZE="-0.5326385825694938" ORDER="121" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="22" VAR="1.2478787878787878" WEIGHT="27.57835755559447"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.863775976564715" CI_END="1.3371189622475879" CI_START="0.21009709105472812" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5300233998252671" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="38.31952757579719" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.12617004776260957" LOG_CI_START="-0.6775799606717514" LOG_EFFECT_SIZE="-0.27570495645457094" METHOD="MH" MODIFIED="2010-10-25 15:27:04 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.1820483782890887" P_Q="0.0" P_Z="0.17874587740004658" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="101" WEIGHT="100.0" Z="1.3446265115760132">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Antbiotic + enema</GROUP_LABEL_1>
<GROUP_LABEL_2>Antibiotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ATB + enema</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ATB</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3392981026763624" CI_START="0.005185137222674427" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.12687725359016136" LOG_CI_START="-2.285239745685411" LOG_EFFECT_SIZE="-1.0791812460476249" ORDER="122" O_E="0.0" SE="1.4168894655461863" STUDY_ID="STD-Brown-1981" TOTAL_1="11" TOTAL_2="10" VAR="2.0075757575757573" WEIGHT="48.04311635858001"/>
<DICH_DATA CI_END="94.01409916071538" CI_START="0.23466187020031795" EFFECT_SIZE="4.696969696969697" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.973192989009617" LOG_CI_START="-0.6295574724248089" LOG_EFFECT_SIZE="0.6718177582924041" MODIFIED="2008-10-02 20:42:21 -0500" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="1.5288685048691535" STUDY_ID="STD-Freitas-1999" TOTAL_1="32" TOTAL_2="30" VAR="2.3374389051808406" WEIGHT="4.316373735341172"/>
<DICH_DATA CI_END="3.4974693284776013" CI_START="0.008949835497643726" EFFECT_SIZE="0.17692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.54375391457735" LOG_CI_START="-2.0481849471558378" LOG_EFFECT_SIZE="-0.7522155162892439" ORDER="124" O_E="0.0" SE="1.5225177176863645" STUDY_ID="STD-Melekos-1990" TOTAL_1="25" TOTAL_2="22" VAR="2.318060200668896" WEIGHT="22.209170982089397"/>
<DICH_DATA CI_END="4.540354183755421" CI_START="0.20937243252986007" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6570897326039782" LOG_CI_START="-0.6790805012069047" LOG_EFFECT_SIZE="-0.010995384301463193" MODIFIED="2008-10-02 20:42:26 -0500" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.7848730094898416" STUDY_ID="STD-Tekdogan-2006" TOTAL_1="40" TOTAL_2="39" VAR="0.616025641025641" WEIGHT="25.43133892398942"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-10-25 15:26:01 -0500" MODIFIED_BY="James Tacklind" NO="4">
<NAME>Short-course versus long-course treatment</NAME>
<DICH_OUTCOME CHI2="3.043335683085189" CI_END="3.7314818615815915" CI_START="1.1743940105923116" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.093377641247577" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="16" I2="34.28263562524608" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.571881334892721" LOG_CI_START="0.06981382767643854" LOG_EFFECT_SIZE="0.3208475812845797" METHOD="MH" MODIFIED="2010-10-25 15:26:01 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.21834749367448325" P_Q="0.0" P_Z="0.012243739451571239" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="428" TOTAL_2="441" WEIGHT="100.0" Z="2.5050404370170316">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Short-course</GROUP_LABEL_1>
<GROUP_LABEL_2>Long-course</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours short-course</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours long-course</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2452860972487305" CI_START="0.35407066532690257" EFFECT_SIZE="1.0719424460431655" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5112529892656416" LOG_CI_START="-0.4509100529492835" LOG_EFFECT_SIZE="0.030171468158178956" MODIFIED="2010-03-11 10:14:40 -0600" MODIFIED_BY="James Tacklind" ORDER="127" O_E="0.0" SE="0.5651793337809191" STUDY_ID="STD-Briffaux-2009" TOTAL_1="139" TOTAL_2="149" VAR="0.3194276793330436" WEIGHT="37.00651094495643"/>
<DICH_DATA CI_END="11.386142358264419" CI_START="1.4405669175648903" EFFECT_SIZE="4.05" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0563766093914073" LOG_CI_START="0.1585334370379298" LOG_EFFECT_SIZE="0.6074550232146685" MODIFIED="2010-03-11 10:14:40 -0600" MODIFIED_BY="James Tacklind" ORDER="47" O_E="0.0" SE="0.5273975238358142" STUDY_ID="STD-Petteffi-2002" TOTAL_1="50" TOTAL_2="54" VAR="0.27814814814814814" WEIGHT="24.575436156030833"/>
<DICH_DATA CI_END="4.856587411519463" CI_START="0.6862933203558172" EFFECT_SIZE="1.8256624825662482" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6863312098120414" LOG_CI_START="-0.16349022804613011" LOG_EFFECT_SIZE="0.26142049088295566" MODIFIED="2010-03-11 10:14:41 -0600" MODIFIED_BY="James Tacklind" ORDER="48" O_E="0.0" SE="0.49918931928185184" STUDY_ID="STD-Schaeffer-2007" TOTAL_1="239" TOTAL_2="238" VAR="0.2491899764850786" WEIGHT="38.418052899012736"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.795306228113099" CI_END="8.164246225272734" CI_START="0.988139744872633" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8403197323749234" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.911916094116635" LOG_CI_START="-0.005181632198434278" LOG_EFFECT_SIZE="0.45336723095910036" METHOD="MH" MODIFIED="2010-10-25 15:25:21 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.42427327394066017" P_Q="0.0" P_Z="0.05264564290620442" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="324" TOTAL_2="328" WEIGHT="99.99999999999999" Z="1.9378162630952076">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Short-course</GROUP_LABEL_1>
<GROUP_LABEL_2>Long-course</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours short-course</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours long-course</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.74651753945392" CI_START="0.1408145767028583" EFFECT_SIZE="0.9746835443037974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8290796537680516" LOG_CI_START="-0.8513523860039707" LOG_EFFECT_SIZE="-0.011136366117959567" MODIFIED="2009-10-29 19:09:54 -0500" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.9870940984348381" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="77" VAR="0.9743547591648858" WEIGHT="45.21738319384163"/>
<DICH_DATA CI_END="73.52932307939714" CI_START="0.1242759846333404" EFFECT_SIZE="3.0229007633587788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8664605678181196" LOG_CI_START="-0.9056127872786239" LOG_EFFECT_SIZE="0.4804238902697481" MODIFIED="2009-07-03 20:53:36 -0500" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.6283296107682403" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="131" VAR="2.6514573213046493" WEIGHT="11.118814590043648"/>
<DICH_DATA CI_END="65.36100034119298" CI_START="1.0977626516937353" EFFECT_SIZE="8.470588235294118" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8153186903930183" LOG_CI_START="0.040508451040933265" LOG_EFFECT_SIZE="0.9279135707169758" MODIFIED="2009-07-03 20:53:43 -0500" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="1.0425323200477894" STUDY_ID="STD-Petteffi-2002" TOTAL_1="51" TOTAL_2="54" VAR="1.0868736383442266" WEIGHT="21.684719752272695"/>
<DICH_DATA CI_END="16.137890916149782" CI_START="0.06589935252541208" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2078467755329105" LOG_CI_START="-1.1811188524169476" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-07-03 20:53:50 -0500" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.4032902354283254" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="66" VAR="1.9692234848484849" WEIGHT="21.97908246384201"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1059900969508236" CI_END="2.675069125747603" CI_START="0.7283621043143416" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3958577927625184" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.4273350089900909" LOG_CI_START="-0.13765265803815915" LOG_EFFECT_SIZE="0.14484117547596584" METHOD="MH" MODIFIED="2010-10-25 15:20:40 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.540247631777999" P_Q="0.0" P_Z="0.3149357545360407" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="651" TOTAL_2="661" WEIGHT="100.0" Z="1.0049192362181056">
<NAME>UTI</NAME>
<GROUP_LABEL_1>Short-course</GROUP_LABEL_1>
<GROUP_LABEL_2>Long-course</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours short-course</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours long-course</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2133149703875974" CI_START="0.19076624364548558" EFFECT_SIZE="0.6497890295358649" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3450432215041893" LOG_CI_START="-0.719498471851471" LOG_EFFECT_SIZE="-0.18722762517364083" MODIFIED="2009-07-03 20:54:25 -0500" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.6253170602434834" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="77" VAR="0.39102142583155236" WEIGHT="40.43293693192739"/>
<DICH_DATA CI_END="16.973058014678912" CI_START="0.06769909150344361" EFFECT_SIZE="1.0719424460431655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2297600956620651" LOG_CI_START="-1.1694171593457072" LOG_EFFECT_SIZE="0.030171468158178956" MODIFIED="2009-07-03 20:54:34 -0500" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="1.4092885957105132" STUDY_ID="STD-Briffaux-2009" TOTAL_1="139" TOTAL_2="149" VAR="1.9860943459997102" WEIGHT="6.422496223276441"/>
<DICH_DATA CI_END="7.046631950613566" CI_START="0.14410342332322773" EFFECT_SIZE="1.0076923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8479815886546636" LOG_CI_START="-0.8413257019568084" LOG_EFFECT_SIZE="0.0033279433489274797" MODIFIED="2009-07-03 20:54:40 -0500" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.9923074647111312" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="131" VAR="0.9846741045214328" WEIGHT="13.256057697261221"/>
<DICH_DATA CI_END="7.149077703294379" CI_START="0.937680297490834" EFFECT_SIZE="2.589121338912134" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8542500174366012" LOG_CI_START="-0.027945209278216702" LOG_EFFECT_SIZE="0.41315240407919224" MODIFIED="2009-07-03 20:54:45 -0500" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.5182058431090854" STUDY_ID="STD-Schaeffer-2007" TOTAL_1="239" TOTAL_2="238" VAR="0.268537295832398" WEIGHT="33.33734974590622"/>
<DICH_DATA CI_END="16.137890916149782" CI_START="0.06589935252541208" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2078467755329105" LOG_CI_START="-1.1811188524169476" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-07-03 20:54:55 -0500" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="1.4032902354283254" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="66" VAR="1.9692234848484849" WEIGHT="6.551159401628742"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06268332742980047" CI_END="36.45772217722928" CI_START="0.47051619351753216" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.1417325677969155" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="1.561789531110984" LOG_CI_START="-0.32742542508628" LOG_EFFECT_SIZE="0.6171820530123519" METHOD="MH" MODIFIED="2010-10-25 15:19:46 -0500" MODIFIED_BY="James Tacklind" NO="4" P_CHI2="0.8023040249331348" P_Q="0.0" P_Z="0.20033782386875942" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="185" WEIGHT="100.0" Z="1.28058968815658">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Short-course</GROUP_LABEL_1>
<GROUP_LABEL_2>Long-course</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours short-course</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours long-course</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.52932307939714" CI_START="0.1242759846333404" EFFECT_SIZE="3.0229007633587788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8664605678181196" LOG_CI_START="-0.9056127872786239" LOG_EFFECT_SIZE="0.4804238902697481" MODIFIED="2009-07-03 20:55:24 -0500" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.6283296107682403" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="131" VAR="2.6514573213046493" WEIGHT="50.61567905246813"/>
<DICH_DATA CI_END="107.56886839299642" CI_START="0.25999925314458266" EFFECT_SIZE="5.288461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0316865999418487" LOG_CI_START="-0.5850278995509219" LOG_EFFECT_SIZE="0.7233293501954635" MODIFIED="2009-07-03 20:55:27 -0500" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.5370710499477285" STUDY_ID="STD-Petteffi-2002" TOTAL_1="51" TOTAL_2="54" VAR="2.3625874125874127" WEIGHT="49.38432094753187"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-11-06 20:04:28 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Single versus multiple dose</NAME>
<DICH_OUTCOME CHI2="3.220475168599516" CI_END="3.329544221146995" CI_START="1.1798876445771775" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.98204139427124" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="20" I2="6.846044669097506" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.5223847873236491" LOG_CI_START="0.07184065335413305" LOG_EFFECT_SIZE="0.2971127203388911" METHOD="MH" MODIFIED="2010-11-06 20:04:00 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35886531479132033" P_Q="0.0" P_Z="0.00973765676181212" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="465" TOTAL_2="479" WEIGHT="100.0" Z="2.5850086031853587">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours multiple dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.020492959074188" CI_START="0.47271556327141756" EFFECT_SIZE="1.5405405405405406" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7007463623431722" LOG_CI_START="-0.3254000991321794" LOG_EFFECT_SIZE="0.1876731316054964" MODIFIED="2009-07-03 21:04:43 -0500" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.602763510977527" STUDY_ID="STD-Bates-1998" TOTAL_1="37" TOTAL_2="38" VAR="0.36332385016595536" WEIGHT="20.139069326922282"/>
<DICH_DATA CI_END="3.2452860972487305" CI_START="0.35407066532690257" EFFECT_SIZE="1.0719424460431655" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5112529892656416" LOG_CI_START="-0.4509100529492835" LOG_EFFECT_SIZE="0.030171468158178956" MODIFIED="2009-07-03 21:04:49 -0500" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.5651793337809191" STUDY_ID="STD-Briffaux-2009" TOTAL_1="139" TOTAL_2="149" VAR="0.3194276793330436" WEIGHT="29.553744050276574"/>
<DICH_DATA CI_END="11.386142358264419" CI_START="1.4405669175648903" EFFECT_SIZE="4.05" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.0563766093914073" LOG_CI_START="0.1585334370379298" LOG_EFFECT_SIZE="0.6074550232146685" MODIFIED="2010-11-06 20:04:00 -0500" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.5273975238358142" STUDY_ID="STD-Petteffi-2002" TOTAL_1="50" TOTAL_2="54" VAR="0.27814814814814814" WEIGHT="19.62617203117426"/>
<DICH_DATA CI_END="4.856587411519463" CI_START="0.6862933203558172" EFFECT_SIZE="1.8256624825662482" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6863312098120414" LOG_CI_START="-0.16349022804613011" LOG_EFFECT_SIZE="0.26142049088295566" MODIFIED="2009-07-03 21:05:00 -0500" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.49918931928185184" STUDY_ID="STD-Schaeffer-2007" TOTAL_1="239" TOTAL_2="238" VAR="0.2491899764850786" WEIGHT="30.681014591626884"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.795306228113099" CI_END="8.164246225272734" CI_START="0.988139744872633" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8403197323749234" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.911916094116635" LOG_CI_START="-0.005181632198434278" LOG_EFFECT_SIZE="0.45336723095910036" METHOD="MH" MODIFIED="2010-11-06 20:04:10 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.42427327394066017" P_Q="0.0" P_Z="0.05264564290620442" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="324" TOTAL_2="328" WEIGHT="99.99999999999999" Z="1.9378162630952076">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours multiple dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.74651753945392" CI_START="0.1408145767028583" EFFECT_SIZE="0.9746835443037974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8290796537680516" LOG_CI_START="-0.8513523860039707" LOG_EFFECT_SIZE="-0.011136366117959567" MODIFIED="2009-07-03 21:08:11 -0500" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.9870940984348381" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="77" VAR="0.9743547591648858" WEIGHT="45.21738319384163"/>
<DICH_DATA CI_END="73.52932307939714" CI_START="0.1242759846333404" EFFECT_SIZE="3.0229007633587788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8664605678181196" LOG_CI_START="-0.9056127872786239" LOG_EFFECT_SIZE="0.4804238902697481" MODIFIED="2009-07-03 21:08:16 -0500" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="1.6283296107682403" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="131" VAR="2.6514573213046493" WEIGHT="11.118814590043648"/>
<DICH_DATA CI_END="65.36100034119298" CI_START="1.0977626516937353" EFFECT_SIZE="8.470588235294118" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8153186903930183" LOG_CI_START="0.040508451040933265" LOG_EFFECT_SIZE="0.9279135707169758" MODIFIED="2010-11-06 20:04:10 -0500" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="1.0425323200477894" STUDY_ID="STD-Petteffi-2002" TOTAL_1="51" TOTAL_2="54" VAR="1.0868736383442266" WEIGHT="21.684719752272695"/>
<DICH_DATA CI_END="16.137890916149782" CI_START="0.06589935252541208" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2078467755329105" LOG_CI_START="-1.1811188524169476" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-07-03 21:08:32 -0500" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="1.4032902354283254" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="66" VAR="1.9692234848484849" WEIGHT="21.97908246384201"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.105990096950824" CI_END="2.675069125747603" CI_START="0.7283621043143413" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3958577927625182" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.4273350089900909" LOG_CI_START="-0.13765265803815926" LOG_EFFECT_SIZE="0.14484117547596576" METHOD="MH" MODIFIED="2010-03-10 10:54:55 -0600" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.5402476317779987" P_Q="0.0" P_Z="0.31493575453604106" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="651" TOTAL_2="661" WEIGHT="100.00000000000001" Z="1.004919236218105">
<NAME>UTI</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours multiple dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2133149703875974" CI_START="0.19076624364548558" EFFECT_SIZE="0.6497890295358649" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3450432215041893" LOG_CI_START="-0.719498471851471" LOG_EFFECT_SIZE="-0.18722762517364083" MODIFIED="2009-07-03 21:10:24 -0500" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.6253170602434834" STUDY_ID="STD-Aron-2000a" TOTAL_1="79" TOTAL_2="77" VAR="0.39102142583155236" WEIGHT="40.43293693192739"/>
<DICH_DATA CI_END="16.973058014678912" CI_START="0.06769909150344361" EFFECT_SIZE="1.0719424460431655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2297600956620651" LOG_CI_START="-1.1694171593457072" LOG_EFFECT_SIZE="0.030171468158178956" MODIFIED="2009-07-03 21:10:30 -0500" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="1.4092885957105132" STUDY_ID="STD-Briffaux-2009" TOTAL_1="139" TOTAL_2="149" VAR="1.9860943459997102" WEIGHT="6.422496223276441"/>
<DICH_DATA CI_END="7.046631950613566" CI_START="0.14410342332322773" EFFECT_SIZE="1.0076923076923077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8479815886546636" LOG_CI_START="-0.8413257019568084" LOG_EFFECT_SIZE="0.0033279433489274797" MODIFIED="2009-07-03 21:10:34 -0500" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.9923074647111312" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="131" VAR="0.9846741045214328" WEIGHT="13.256057697261221"/>
<DICH_DATA CI_END="7.149077703294379" CI_START="0.937680297490834" EFFECT_SIZE="2.589121338912134" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8542500174366012" LOG_CI_START="-0.027945209278216702" LOG_EFFECT_SIZE="0.41315240407919224" MODIFIED="2009-07-03 21:10:40 -0500" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.5182058431090854" STUDY_ID="STD-Schaeffer-2007" TOTAL_1="239" TOTAL_2="238" VAR="0.268537295832398" WEIGHT="33.33734974590622"/>
<DICH_DATA CI_END="16.137890916149782" CI_START="0.06589935252541208" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2078467755329105" LOG_CI_START="-1.1811188524169476" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-07-03 21:10:44 -0500" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="1.4032902354283254" STUDY_ID="STD-Yang-2001a" TOTAL_1="64" TOTAL_2="66" VAR="1.9692234848484849" WEIGHT="6.551159401628742"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2379417969629616" CI_END="15.059061461589774" CI_START="0.6367233938520152" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0965233281939812" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="1.1777979058119585" LOG_CI_START="-0.19604919343096364" LOG_EFFECT_SIZE="0.49087435619049746" METHOD="MH" MODIFIED="2010-11-06 20:04:28 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8878336412499541" P_Q="0.0" P_Z="0.16133766924144466" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="218" TOTAL_2="223" WEIGHT="100.0" Z="1.4005868041615954">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Multiple dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours multiple dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.69761919734676" CI_START="0.19445165935494998" EFFECT_SIZE="2.054054054054054" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.33641208287251" LOG_CI_START="-0.7111883464449171" LOG_EFFECT_SIZE="0.31261186821379633" MODIFIED="2009-07-03 21:12:00 -0500" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.2027706279666497" STUDY_ID="STD-Bates-1998" TOTAL_1="37" TOTAL_2="38" VAR="1.4466571834992887" WEIGHT="50.06562230355322"/>
<DICH_DATA CI_END="73.52932307939714" CI_START="0.1242759846333404" EFFECT_SIZE="3.0229007633587788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8664605678181196" LOG_CI_START="-0.9056127872786239" LOG_EFFECT_SIZE="0.4804238902697481" MODIFIED="2009-07-03 21:12:04 -0500" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="1.6283296107682403" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="131" VAR="2.6514573213046493" WEIGHT="25.274624351680732"/>
<DICH_DATA CI_END="107.56886839299642" CI_START="0.25999925314458266" EFFECT_SIZE="5.288461538461538" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0316865999418487" LOG_CI_START="-0.5850278995509219" LOG_EFFECT_SIZE="0.7233293501954635" MODIFIED="2010-11-06 20:04:28 -0500" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.5370710499477285" STUDY_ID="STD-Petteffi-2002" TOTAL_1="51" TOTAL_2="54" VAR="2.3625874125874127" WEIGHT="24.659753344766045"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-10-25 15:18:06 -0500" MODIFIED_BY="James Tacklind" NO="6">
<NAME>Quinolones versus other classes of antibiotics</NAME>
<DICH_OUTCOME CHI2="0.4317882352868033" CI_END="3.1028329588004846" CI_START="0.2757732552994454" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9250288350634371" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.4917583959438502" LOG_CI_START="-0.5594478543279437" LOG_EFFECT_SIZE="-0.03384472919204679" METHOD="MH" MODIFIED="2010-10-25 15:18:06 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.5111128113860591" P_Q="0.0" P_Z="0.8995685875543715" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="108" WEIGHT="100.0" Z="0.12620634678641238">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Quinolones</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quinolones</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.968917075367087" CI_START="0.24595562752919123" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.9013993075759273" LOG_CI_START="-0.6091432362194514" LOG_EFFECT_SIZE="0.14612803567823798" MODIFIED="2009-08-24 21:22:07 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7045326466884088" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="42" WEIGHT="39.792387543252595" Z="0.3792090308708679">
<NAME>Sulfonamides</NAME>
<DICH_DATA CI_END="7.968917075367087" CI_START="0.24595562752919123" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9013993075759273" LOG_CI_START="-0.6091432362194514" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="78" O_E="0.0" SE="0.8873001675315897" STUDY_ID="STD-Isen-1999a" TOTAL_1="45" TOTAL_2="42" VAR="0.7873015873015872" WEIGHT="39.792387543252595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5440348440040363" CI_START="0.10537616207563211" DF="0" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.549497983103357" LOG_CI_START="-0.9772576229935189" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2008-09-29 20:55:01 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5829134623748986" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="66" WEIGHT="60.2076124567474" Z="0.5491340492718929">
<NAME>Piperacillin Tazobactam</NAME>
<DICH_DATA CI_END="3.5440348440040363" CI_START="0.10537616207563211" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.549497983103357" LOG_CI_START="-0.9772576229935189" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="79" O_E="0.0" SE="0.8968238005834419" STUDY_ID="STD-Cormio-2002" TOTAL_1="72" TOTAL_2="66" VAR="0.8042929292929293" WEIGHT="60.2076124567474"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2714823111027395" CI_END="4.162001491489297" CI_START="0.07435492484981274" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5562960615755743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.6193022315088267" LOG_CI_START="-1.1286902609784206" LOG_EFFECT_SIZE="-0.25469401473479697" METHOD="MH" MODIFIED="2010-10-25 15:17:29 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.6023392070229088" P_Q="0.0" P_Z="0.5678916580012527" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="196" WEIGHT="100.0" Z="0.5711593134451152">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Quinolones</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quinolones</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.381705168253586" CI_START="0.01267957452453039" DF="0" EFFECT_SIZE="0.3059360730593607" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.8681566951054236" LOG_CI_START="-1.8968953193840075" LOG_EFFECT_SIZE="-0.5143693121392919" MODIFIED="2010-03-10 10:55:02 -0600" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="1.0" P_Z="0.4658760798917161" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="66" WEIGHT="60.21710909629872" Z="0.7292053250808798">
<NAME>Piperacillin Tazobactam</NAME>
<DICH_DATA CI_END="7.381705168253586" CI_START="0.01267957452453039" EFFECT_SIZE="0.3059360730593607" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8681566951054236" LOG_CI_START="-1.8968953193840075" LOG_EFFECT_SIZE="-0.5143693121392919" ORDER="84" O_E="0.0" SE="1.6242052405393081" STUDY_ID="STD-Cormio-2002" TOTAL_1="72" TOTAL_2="66" VAR="2.638042663395352" WEIGHT="60.21710909629872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.79860964994522" CI_START="0.05910662875786482" DF="0" EFFECT_SIZE="0.935251798561151" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="1.1702209147381502" LOG_CI_START="-1.2283638106326669" LOG_EFFECT_SIZE="-0.029071447947258328" MODIFIED="2010-03-10 10:55:02 -0600" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="1.0" P_Z="0.9621063545802746" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="130" WEIGHT="39.782890903701286" Z="0.047510509303563056">
<NAME>Ceftriaxone</NAME>
<DICH_DATA CI_END="14.79860964994522" CI_START="0.05910662875786482" EFFECT_SIZE="0.935251798561151" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1702209147381502" LOG_CI_START="-1.2283638106326669" LOG_EFFECT_SIZE="-0.029071447947258328" MODIFIED="2008-11-06 19:30:59 -0600" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.4089405408686968" STUDY_ID="STD-Cam-2008" TOTAL_1="139" TOTAL_2="130" VAR="1.9851134477033758" WEIGHT="39.782890903701286"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3295002143636139" CI_END="2.8820346077799956" CI_START="0.18125223356143003" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7227552904416986" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="24.783765418295502" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.4596991915638976" LOG_CI_START="-0.7417166329366804" LOG_EFFECT_SIZE="-0.1410087206863914" METHOD="MH" MODIFIED="2010-10-25 11:23:02 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.2488942936862507" P_Q="0.0" P_Z="0.6454608105671688" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="196" WEIGHT="100.0" Z="0.46007719960952176">
<NAME>UTI</NAME>
<GROUP_LABEL_1>other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Quinolones</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quinolones</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7546581922792295" CI_START="0.008974153001975271" DF="0" EFFECT_SIZE="0.18356164383561643" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.5745704068625042" LOG_CI_START="-2.0470065303738005" LOG_EFFECT_SIZE="-0.7362180617556483" MODIFIED="2010-03-10 10:55:05 -0600" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="1.0" P_Z="0.2709688047148574" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="66" WEIGHT="55.77900866354211" Z="1.1008342843678975">
<NAME>Piperacillin Tazobactam</NAME>
<DICH_DATA CI_END="3.7546581922792295" CI_START="0.008974153001975271" EFFECT_SIZE="0.18356164383561643" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5745704068625042" LOG_CI_START="-2.0470065303738005" LOG_EFFECT_SIZE="-0.7362180617556483" ORDER="87" O_E="0.0" SE="1.5399272699477353" STUDY_ID="STD-Cormio-2002" TOTAL_1="72" TOTAL_2="66" VAR="2.3713759967286854" WEIGHT="55.77900866354211"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.26200087381299" CI_START="0.23820692652546543" DF="0" EFFECT_SIZE="1.4028776978417266" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="0.917085236572804" LOG_CI_START="-0.6230456143559583" LOG_EFFECT_SIZE="0.1470198111084229" MODIFIED="2010-03-10 10:55:05 -0600" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="1.0" P_Z="0.7082603043291725" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="130" WEIGHT="44.220991336457885" Z="0.3741935753220218">
<NAME>Ceftriaxone</NAME>
<DICH_DATA CI_END="8.26200087381299" CI_START="0.23820692652546543" EFFECT_SIZE="1.4028776978417266" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.917085236572804" LOG_CI_START="-0.6230456143559583" LOG_EFFECT_SIZE="0.1470198111084229" MODIFIED="2008-11-06 19:32:09 -0600" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.9046804856062217" STUDY_ID="STD-Cam-2008" TOTAL_1="139" TOTAL_2="130" VAR="0.8184467810367091" WEIGHT="44.220991336457885"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2714823111027395" CI_END="4.162001491489297" CI_START="0.07435492484981274" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5562960615755743" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.6193022315088267" LOG_CI_START="-1.1286902609784206" LOG_EFFECT_SIZE="-0.25469401473479697" METHOD="MH" MODIFIED="2010-10-25 15:16:28 -0500" MODIFIED_BY="James Tacklind" NO="4" P_CHI2="0.6023392070229088" P_Q="0.0" P_Z="0.5678916580012527" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="196" WEIGHT="100.0" Z="0.5711593134451152">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Quinolones</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quinolones</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.79860964994522" CI_START="0.05910662875786482" DF="0" EFFECT_SIZE="0.935251798561151" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="1.1702209147381502" LOG_CI_START="-1.2283638106326669" LOG_EFFECT_SIZE="-0.029071447947258328" MODIFIED="2010-02-03 18:08:17 -0600" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9621063545802746" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="130" WEIGHT="39.782890903701286" Z="0.047510509303563056">
<NAME>Ceftriaxone</NAME>
<DICH_DATA CI_END="14.79860964994522" CI_START="0.05910662875786482" EFFECT_SIZE="0.935251798561151" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1702209147381502" LOG_CI_START="-1.2283638106326669" LOG_EFFECT_SIZE="-0.029071447947258328" ORDER="161" O_E="0.0" SE="1.4089405408686968" STUDY_ID="STD-Cam-2008" TOTAL_1="139" TOTAL_2="130" VAR="1.9851134477033758" WEIGHT="39.782890903701286"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.381705168253586" CI_START="0.01267957452453039" DF="0" EFFECT_SIZE="0.3059360730593607" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="0.8681566951054236" LOG_CI_START="-1.8968953193840075" LOG_EFFECT_SIZE="-0.5143693121392919" MODIFIED="2010-02-03 18:08:17 -0600" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4658760798917161" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="66" WEIGHT="60.21710909629872" Z="0.7292053250808798">
<NAME>Piperacillin Tazobactam</NAME>
<DICH_DATA CI_END="7.381705168253586" CI_START="0.01267957452453039" EFFECT_SIZE="0.3059360730593607" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8681566951054236" LOG_CI_START="-1.8968953193840075" LOG_EFFECT_SIZE="-0.5143693121392919" ORDER="92" O_E="0.0" SE="1.6242052405393081" STUDY_ID="STD-Cormio-2002" TOTAL_1="72" TOTAL_2="66" VAR="2.638042663395352" WEIGHT="60.21710909629872"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-10-25 11:23:44 -0500" MODIFIED_BY="James Tacklind" NO="7">
<NAME>Sulfonamides versus other antibiotics</NAME>
<DICH_OUTCOME CHI2="4.246427864627679" CI_END="16.130955019837113" CI_START="0.5968101700045811" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1027597405737426" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="52.90159014215688" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="1.2076600801953699" LOG_CI_START="-0.224163784832911" LOG_EFFECT_SIZE="0.49174814768122943" METHOD="MH" MODIFIED="2010-10-25 11:23:44 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.11964653463531871" P_Q="0.0" P_Z="0.17821640213405004" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.1226037017523267" TOTALS="YES" TOTAL_1="142" TOTAL_2="161" WEIGHT="100.0" Z="1.3462670688205867">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Other Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulfa</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulfa</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="48.51017267489086" CI_START="0.7052430710446727" DF="0" EFFECT_SIZE="5.849056603773585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="1.6858328205262656" LOG_CI_START="-0.1516611720592981" LOG_EFFECT_SIZE="0.7670858242334836" NO="1" P_CHI2="1.0" P_Z="0.10175066249966909" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="62" WEIGHT="30.922388285169628" Z="1.6364250382482177">
<NAME>Gentamicin</NAME>
<DICH_DATA CI_END="48.51017267489086" CI_START="0.7052430710446727" EFFECT_SIZE="5.849056603773585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6858328205262656" LOG_CI_START="-0.1516611720592981" LOG_EFFECT_SIZE="0.7670858242334836" ORDER="101" O_E="0.0" SE="1.0793530669867175" STUDY_ID="STD-Shivde-2002" TOTAL_1="53" TOTAL_2="62" VAR="1.1650030432136336" WEIGHT="30.922388285169628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.81243026096662" CI_START="1.1930599807821107" DF="0" EFFECT_SIZE="9.191489361702128" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="1.8501094994963723" LOG_CI_START="0.07666227826201703" LOG_EFFECT_SIZE="0.9633858888791946" MODIFIED="2010-08-06 14:44:41 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="1.0" P_Z="0.0332200255261873" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="54" WEIGHT="32.04003481663185" Z="2.12941397162426">
<NAME>Netilmicin-metronidazole</NAME>
<DICH_DATA CI_END="70.81243026096662" CI_START="1.1930599807821107" EFFECT_SIZE="9.191489361702128" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8501094994963723" LOG_CI_START="0.07666227826201703" LOG_EFFECT_SIZE="0.9633858888791946" MODIFIED="2009-10-29 19:16:20 -0500" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="1.0417316764583866" STUDY_ID="STD-Fong-1991" TOTAL_1="47" TOTAL_2="54" VAR="1.0852048857368006" WEIGHT="32.04003481663185"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.065774018044433" CI_START="0.12548756506591394" DF="0" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="0.6091432362194513" LOG_CI_START="-0.9013993075759275" LOG_EFFECT_SIZE="-0.146128035678238" NO="3" P_CHI2="1.0" P_Z="0.7045326466884088" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="45" WEIGHT="37.03757689819853" Z="0.37920903087086794">
<NAME>Quinolone</NAME>
<DICH_DATA CI_END="4.065774018044433" CI_START="0.12548756506591394" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6091432362194513" LOG_CI_START="-0.9013993075759275" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="103" O_E="0.0" SE="0.8873001675315897" STUDY_ID="STD-Isen-1999a" TOTAL_1="42" TOTAL_2="45" VAR="0.7873015873015872" WEIGHT="37.03757689819853"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-10-25 15:15:01 -0500" MODIFIED_BY="James Tacklind" NO="8">
<NAME>Piperacillin tazobactam versus other antibiotics</NAME>
<DICH_OUTCOME CHI2="0.5244493261279928" CI_END="3.4633541293546184" CI_START="0.30913341069772593" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.034716615533667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.5394969006056114" LOG_CI_START="-0.5098540544723916" LOG_EFFECT_SIZE="0.014821423066609912" METHOD="MH" MODIFIED="2010-10-25 15:13:17 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.46894994346219343" P_Q="0.0" P_Z="0.9558464679392078" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="126" WEIGHT="100.0" Z="0.055366520170608224">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Piper/tazob</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours piper/tazob</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.76420949101247" CI_START="0.11381666006874651" DF="0" EFFECT_SIZE="0.6545454545454545" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.575673785387255" LOG_CI_START="-0.9437941628411682" LOG_EFFECT_SIZE="-0.1840601887269566" NO="1" P_CHI2="1.0" P_Z="0.6349017152988059" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="61.278863232682056" Z="0.4748390267963034">
<NAME>Cefuroxime</NAME>
<DICH_DATA CI_END="3.76420949101247" CI_START="0.11381666006874651" EFFECT_SIZE="0.6545454545454545" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.575673785387255" LOG_CI_START="-0.9437941628411682" LOG_EFFECT_SIZE="-0.1840601887269566" ORDER="106" O_E="0.0" SE="0.8925429942770245" STUDY_ID="STD-Brewster-1995" TOTAL_1="55" TOTAL_2="54" VAR="0.7966329966329966" WEIGHT="61.278863232682056"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.489812309564526" CI_START="0.28216426869838673" DF="0" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.9772576229935189" LOG_CI_START="-0.549497983103357" LOG_EFFECT_SIZE="0.21387981994508104" NO="2" P_CHI2="1.0" P_Z="0.5829134623748986" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="72" WEIGHT="38.72113676731794" Z="0.549134049271893">
<NAME>Ciprofloxacin</NAME>
<DICH_DATA CI_END="9.489812309564526" CI_START="0.28216426869838673" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9772576229935189" LOG_CI_START="-0.549497983103357" LOG_EFFECT_SIZE="0.21387981994508104" ORDER="107" O_E="0.0" SE="0.8968238005834419" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="0.8042929292929293" WEIGHT="38.72113676731794"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7828954212154446" CI_END="3.154460977482377" CI_START="0.32337547600292826" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0099877821667083" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="43.91146064426623" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.49892515929980963" LOG_CI_START="-0.49029291900120464" LOG_EFFECT_SIZE="0.004316120149302485" METHOD="MH" MODIFIED="2010-10-25 12:02:50 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.1817943195991023" P_Q="0.0" P_Z="0.9863542171385495" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="126" WEIGHT="100.00000000000001" Z="0.0171032863857677">
<NAME>UTI</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Piper/tazob</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours piper/tazob</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3444593869690578" CI_START="0.14802052068054608" DF="0" EFFECT_SIZE="0.5890909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.37004271386394805" LOG_CI_START="-0.8296780724392113" LOG_EFFECT_SIZE="-0.22981767928763167" MODIFIED="2009-08-28 21:19:14 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4527136438407765" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="91.33720033688007" Z="0.7508986750197288">
<NAME>Cefuroxime</NAME>
<DICH_DATA CI_END="2.344459386969058" CI_START="0.14802052068054602" EFFECT_SIZE="0.5890909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3700427138639481" LOG_CI_START="-0.8296780724392114" LOG_EFFECT_SIZE="-0.22981767928763167" MODIFIED="2009-08-28 21:19:14 -0500" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.7047219285881465" STUDY_ID="STD-Brewster-1995" TOTAL_1="55" TOTAL_2="54" VAR="0.49663299663299665" WEIGHT="91.33720033688007"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="111.43112890764101" CI_START="0.2663358284001238" DF="0" EFFECT_SIZE="5.447761194029851" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="2.0470065303738005" LOG_CI_START="-0.5745704068625042" LOG_EFFECT_SIZE="0.7362180617556483" NO="2" P_CHI2="1.0" P_Z="0.2709688047148574" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="72" WEIGHT="8.662799663119937" Z="1.1008342843678975">
<NAME>Ciprofloxacin</NAME>
<DICH_DATA CI_END="111.43112890764101" CI_START="0.2663358284001238" EFFECT_SIZE="5.447761194029851" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0470065303738005" LOG_CI_START="-0.5745704068625042" LOG_EFFECT_SIZE="0.7362180617556483" ORDER="111" O_E="0.0" SE="1.5399272699477353" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="2.3713759967286854" WEIGHT="8.662799663119937"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0020444255374300925" CI_END="29.403551490999867" CI_START="0.3275258955537359" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1032925312561366" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="1.468399789588739" LOG_CI_START="-0.4847543571943592" LOG_EFFECT_SIZE="0.49182271619718987" METHOD="MH" MODIFIED="2010-10-25 15:15:01 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.9639356898871965" P_Q="0.0" P_Z="0.32360588757012976" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="126" WEIGHT="100.0" Z="0.9870749957066299">
<NAME>Sepsis</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Piper/tazob</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours piper/tazob</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.77462369492882" CI_START="0.12266319301041603" DF="0" EFFECT_SIZE="2.9464285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.03.01" LOG_CI_END="1.8498775689216282" LOG_CI_START="-0.9112857345062162" LOG_EFFECT_SIZE="0.4692959172077059" NO="1" P_CHI2="1.0" P_Z="0.5052556880171475" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="51.318976238790334" Z="0.6662431698095552">
<NAME>Cefuroxime</NAME>
<DICH_DATA CI_END="70.77462369492876" CI_START="0.12266319301041609" EFFECT_SIZE="2.9464285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8498775689216278" LOG_CI_START="-0.911285734506216" LOG_EFFECT_SIZE="0.4692959172077059" ORDER="112" O_E="0.0" SE="1.6219209924123017" STUDY_ID="STD-Brewster-1995" TOTAL_1="55" TOTAL_2="54" VAR="2.6306277056277056" WEIGHT="51.318976238790334"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="78.86699968247055" CI_START="0.1354700543040771" DF="0" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.03.02" LOG_CI_END="1.8968953193840075" LOG_CI_START="-0.8681566951054236" LOG_EFFECT_SIZE="0.5143693121392918" NO="2" P_CHI2="1.0" P_Z="0.4658760798917161" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="72" WEIGHT="48.681023761209666" Z="0.7292053250808798">
<NAME>Ciprofloxacin</NAME>
<DICH_DATA CI_END="78.86699968247055" CI_START="0.1354700543040771" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8968953193840075" LOG_CI_START="-0.8681566951054236" LOG_EFFECT_SIZE="0.5143693121392918" ORDER="113" O_E="0.0" SE="1.6242052405393081" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="2.638042663395352" WEIGHT="48.681023761209666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0020444255374300925" CI_END="29.403551490999867" CI_START="0.3275258955537359" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1032925312561366" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="1.468399789588739" LOG_CI_START="-0.4847543571943592" LOG_EFFECT_SIZE="0.49182271619718987" METHOD="MH" MODIFIED="2010-10-25 15:14:30 -0500" MODIFIED_BY="James Tacklind" NO="4" P_CHI2="0.9639356898871965" P_Q="0.0" P_Z="0.32360588757012976" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="126" WEIGHT="100.0" Z="0.9870749957066299">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Other ATB</GROUP_LABEL_1>
<GROUP_LABEL_2>Piper/tazo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other ATB</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours piper/tazob</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="70.77462369492882" CI_START="0.12266319301041603" DF="0" EFFECT_SIZE="2.9464285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.04.01" LOG_CI_END="1.8498775689216282" LOG_CI_START="-0.9112857345062162" LOG_EFFECT_SIZE="0.4692959172077059" NO="1" P_CHI2="1.0" P_Z="0.5052556880171475" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="54" WEIGHT="51.318976238790334" Z="0.6662431698095552">
<NAME>Cefuroxime</NAME>
<DICH_DATA CI_END="70.77462369492876" CI_START="0.12266319301041609" EFFECT_SIZE="2.9464285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8498775689216278" LOG_CI_START="-0.911285734506216" LOG_EFFECT_SIZE="0.4692959172077059" ORDER="114" O_E="0.0" SE="1.6219209924123017" STUDY_ID="STD-Brewster-1995" TOTAL_1="55" TOTAL_2="54" VAR="2.6306277056277056" WEIGHT="51.318976238790334"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="78.86699968247055" CI_START="0.1354700543040771" DF="0" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="1.8968953193840075" LOG_CI_START="-0.8681566951054236" LOG_EFFECT_SIZE="0.5143693121392918" NO="2" P_CHI2="1.0" P_Z="0.4658760798917161" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="72" WEIGHT="48.681023761209666" Z="0.7292053250808798">
<NAME>Ciprofloxacin</NAME>
<DICH_DATA CI_END="78.86699968247055" CI_START="0.1354700543040771" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8968953193840075" LOG_CI_START="-0.8681566951054236" LOG_EFFECT_SIZE="0.5143693121392918" ORDER="115" O_E="0.0" SE="1.6242052405393081" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="2.638042663395352" WEIGHT="48.681023761209666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-08-26 20:15:39 -0500" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Oral versus systemic antibiotic administration (IM or IV)</NAME>
<DICH_OUTCOME CHI2="4.740129610860295" CI_END="1.9329570924013249" CI_START="0.05858524278999134" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.33651561711303585" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="57.807060899395616" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.286222213707726" LOG_CI_START="-1.2322117659272183" LOG_EFFECT_SIZE="-0.47299477610974605" METHOD="MH" MODIFIED="2010-08-26 20:15:39 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09347489265236686" P_Q="0.0" P_Z="0.22206171610441916" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.378852802238813" TOTALS="YES" TOTAL_1="182" TOTAL_2="172" WEIGHT="100.0" Z="1.2210642523602733">
<NAME>Bacteriuria</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.489812309564526" CI_START="0.28216426869838673" EFFECT_SIZE="1.6363636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9772576229935189" LOG_CI_START="-0.549497983103357" LOG_EFFECT_SIZE="0.21387981994508104" MODIFIED="2010-08-26 20:15:33 -0500" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.8968238005834419" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="0.8042929292929293" WEIGHT="36.44049809817393"/>
<DICH_DATA CI_END="0.8381808258663154" CI_START="0.014121814437305397" EFFECT_SIZE="0.1087962962962963" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.07666227826201708" LOG_CI_START="-1.8501094994963723" LOG_EFFECT_SIZE="-0.9633858888791946" MODIFIED="2010-08-26 20:15:39 -0500" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="1.0417316764583866" STUDY_ID="STD-Fong-1991" TOTAL_1="54" TOTAL_2="47" VAR="1.0852048857368006" WEIGHT="32.28614259566245"/>
<DICH_DATA CI_END="1.4179508329216275" CI_START="0.02061423295072305" EFFECT_SIZE="0.17096774193548386" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15166117205929813" LOG_CI_START="-1.6858328205262654" LOG_EFFECT_SIZE="-0.7670858242334837" MODIFIED="2010-08-26 20:15:21 -0500" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="1.0793530669867175" STUDY_ID="STD-Shivde-2002" TOTAL_1="62" TOTAL_2="53" VAR="1.1650030432136336" WEIGHT="31.27335930616362"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27148231110273957" CI_END="13.44900828048539" CI_START="0.24026901529104647" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7976039542105358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="1.1286902609784208" LOG_CI_START="-0.6193022315088266" LOG_EFFECT_SIZE="0.254694014734797" METHOD="MH" MODIFIED="2009-08-25 15:02:37 -0500" MODIFIED_BY="James Tacklind" NO="2" P_CHI2="0.6023392070229088" P_Q="0.0" P_Z="0.5678916580012527" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="258" TOTAL_2="264" WEIGHT="100.0" Z="0.5711593134451153">
<NAME>Fever</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.918576156603052" CI_START="0.06757391563495303" EFFECT_SIZE="1.0692307692307692" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2283638106326669" LOG_CI_START="-1.1702209147381502" LOG_EFFECT_SIZE="0.0290714479472583" MODIFIED="2008-11-04 19:19:27 -0600" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="1.4089405408686968" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="139" VAR="1.9851134477033758" WEIGHT="66.88348676111202"/>
<DICH_DATA CI_END="78.86699968247055" CI_START="0.1354700543040771" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8968953193840075" LOG_CI_START="-0.8681566951054236" LOG_EFFECT_SIZE="0.5143693121392918" MODIFIED="2008-11-04 19:29:36 -0600" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="1.6242052405393081" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="2.638042663395352" WEIGHT="33.11651323888797"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-04 19:23:02 -0600" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="0.0" STUDY_ID="STD-Shivde-2002" TOTAL_1="62" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5545921598201344" CI_END="2.6983195321603892" CI_START="0.26767482989920705" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8498660022525552" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="21.709616452403996" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.4310933770768648" LOG_CI_START="-0.5723924646360493" LOG_EFFECT_SIZE="-0.07064954377959229" METHOD="MH" MODIFIED="2009-08-25 15:02:45 -0500" MODIFIED_BY="James Tacklind" NO="3" P_CHI2="0.278790223681743" P_Q="0.0" P_Z="0.7825641167288292" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="250" TOTAL_2="258" WEIGHT="100.0" Z="0.2759791031945652">
<NAME>UTI</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.198030739853802" CI_START="0.12103605594736408" EFFECT_SIZE="0.7128205128205128" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6230456143559583" LOG_CI_START="-0.917085236572804" LOG_EFFECT_SIZE="-0.1470198111084229" MODIFIED="2008-11-04 19:19:54 -0600" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.9046804856062217" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="139" VAR="0.8184467810367091" WEIGHT="47.94277556855321"/>
<DICH_DATA CI_END="111.43112890764101" CI_START="0.2663358284001238" EFFECT_SIZE="5.447761194029851" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0470065303738005" LOG_CI_START="-0.5745704068625042" LOG_EFFECT_SIZE="0.7362180617556483" MODIFIED="2008-11-04 19:30:11 -0600" MODIFIED_BY="[Empty name]" ORDER="486" O_E="0.0" SE="1.5399272699477353" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="2.3713759967286854" WEIGHT="7.912753150842807"/>
<DICH_DATA CI_END="3.5466798113836115" CI_START="0.008590038380316625" EFFECT_SIZE="0.17454545454545456" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5498219828260558" LOG_CI_START="-2.0660048957354067" LOG_EFFECT_SIZE="-0.7580914564546755" MODIFIED="2008-11-04 19:28:40 -0600" MODIFIED_BY="[Empty name]" ORDER="487" O_E="0.0" SE="1.5365496570188835" STUDY_ID="STD-Fong-1991" TOTAL_1="54" TOTAL_2="47" VAR="2.3609848484848484" WEIGHT="44.14447128060398"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.27148231110273957" CI_END="13.44900828048539" CI_START="0.24026901529104647" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7976039542105358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-009.04" LOG_CI_END="1.1286902609784208" LOG_CI_START="-0.6193022315088266" LOG_EFFECT_SIZE="0.254694014734797" METHOD="MH" MODIFIED="2009-09-02 20:24:14 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6023392070229088" P_Q="0.0" P_Z="0.5678916580012527" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="196" TOTAL_2="211" WEIGHT="100.0" Z="0.5711593134451153">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Systemic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours systemic</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.918576156603052" CI_START="0.06757391563495303" EFFECT_SIZE="1.0692307692307692" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2283638106326669" LOG_CI_START="-1.1702209147381502" LOG_EFFECT_SIZE="0.0290714479472583" MODIFIED="2009-09-02 20:24:04 -0500" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="1.4089405408686968" STUDY_ID="STD-Cam-2008" TOTAL_1="130" TOTAL_2="139" VAR="1.9851134477033758" WEIGHT="66.88348676111202"/>
<DICH_DATA CI_END="78.86699968247055" CI_START="0.1354700543040771" EFFECT_SIZE="3.2686567164179103" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8968953193840075" LOG_CI_START="-0.8681566951054236" LOG_EFFECT_SIZE="0.5143693121392918" MODIFIED="2009-09-02 20:24:14 -0500" MODIFIED_BY="[Empty name]" ORDER="489" O_E="0.0" SE="1.6242052405393081" STUDY_ID="STD-Cormio-2002" TOTAL_1="66" TOTAL_2="72" VAR="2.638042663395352" WEIGHT="33.11651323888797"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-02-10 09:52:22 -0600" MODIFIED_BY="James Tacklind">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-10-25 15:21:15 -0500" MODIFIED_BY="James Tacklind" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAAIQCAMAAABDmN0tAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAurElEQVR42u19S88lt5keu3UabyvwJG1/rXa3pNiOM/Yms4qzSIAg
8CY7GlnMLr8iyGq2ARJkl+yynPwCA1lwEWQzq8ll4awGCOBgrJFHUstqtSyP7VET3RnnnCpW8c4i
65B1O8+j/nTqwluxHr71kvUUeY8YAOwN91EFAGgLAKAtAIRw2lRpOGPC2BPnA4L3h7g+0x+fkTa7
JB+LOiPJKy/VKY651Z+77oKPXNbTdlsUt6pDRI4X4ByJc7GZ6+uLI6aLOvuCj1vW07aIKvhoYvml
5fYNl6uW3tXJeFzV0JyKsqOOKfC56V13zUaWjqEKXvCq92cjZd2mb3vhrhivm/e1cKkn43i/N/wU
Jm9GHVPgc9O7ng36Cv1yOhe8umXZQlm36SSIxJ53JvbwSiXPQ2mLpRlgNEzhe4yCrc/SrZZ19yMJ
nWeVWfecR55vq7BjbG3GJXD7HGcbccW3VtYt0ZYP/4prlGeGjNTweGLxJsetSxDOuc2wdnNl3Za1
DdOHJ+wn49fVlzId3c9aT2R9CdvxCjZe1g07CWO9DEO3oq80dVzvFRNX9DR1UxBz07vyEsNZdh2c
oZwsGmzh27GRst6DlAbYH/ByFwBtAQC0BQDQFgBtAQC0BYB8mJoENeLGuKPsiY+/DTGmQ07BlW1a
50RGDB4uRmm6mamKQRs8Hva1qFbyQ2hLaibMWgzWnvvmfwzbD5Wap6qMk+6kmCZtuVJO8oKLrChh
FWlGB8JzR4RbI93cVKez4YXXLiaruq9pMTDCP9Ua2ynmKXDbRsmkMNrboHxlrphSaD2sDtrrZfWb
FaZVtGKyHei4o+42od/UOs94oPJ0J1IdGjcPXCIbsnLu0YRBUJEtJbGIm7Ux9e5QRdLuopiWb6te
z1mPfe4UR5VWGDGshyfXkbqwtu6SZ73JthSwQpEiEtMQ4SoZbY10c1K1VMBWbdly4RlPamHVo32S
b0fMuF4x79uPAD8zkRD4eDHE1IM5cSfPF8rdnIRTSVPPMM7rpytKdI0ifpX2E9a+rWrPe5MfqnMx
yOTaMGMfxTz5DkLRNZbGyHQO3SsVWcq4YMO/Ot2wOZnpxVquld/cx+89vfDc7P52/eaSXsgVN2WT
xTyFnnulxG3T5r18+DS/GqQbSlX00rFBOVY0WsLTvUQeSVEsJqzcQzHvO56tZ0NSwxZGDG7ZHZ6o
jMlWIAKluVYG1ypdtyIybpmpKfaqfHSjOR+SU1vc9le4sJ941bmy7WLet524Qc8qhuZkWyLHqzFi
CP30EHZh/QBx3zaYjSoPj7mMZqF5pXQnUw3ViV1b3nNI5LYQt9KGY8K5Ah68Kdc/6HZQzDy9bVF+
XMQibOkjkxZPV1F8iTn9gg1M7bC5Yp6ySFt0L8QGpqNYBeUXDtY2tbYAAADHwR+ukusJ1ha4CqsQ
CMJFYIcAbYEd4uSMGYj4lt1P9kZ6+E2OHgDrW1ue2nLEUgIkBTZhbadY272LF5Z21pkR1tSzsmsm
oAWAbGsrklsBODPCBmeK3cS0rMBxaVvM2uhZ4Xq9sLbAbkYShq8lOIwt0HAkYYqGxTMbMpYnlQWA
66ytNo3O9zY8oWpP2FuOkTFgPSdh0J26GlxbcGrrWRefMBa4DZQqwPC0BzZAiNIuGVgLHH0kAQBA
WwAAbQHQFgBAWwAAbQHQFgDWhqlJkKlXD/1J2X/yZv8sgoy85JwyTYRPX6mqsbHixtA0UZtmglbN
9pH1WX2YAnHN0klGt0nbiWpWdXf+s3+WYe10XjIzXEm66SuV1o8ZWtIEa3WC0j1gZjduyVBcq3Qk
m1X+G1aouVqctpZ1OVf+2NblVYbwalDlcJlxKBVCVYq8ijDyerpVrPywSOq/RM+IbdDWsS5qc+I5
uqDRbXD/5z9cU5yWdduZbGhL82i4rbf6p2RFEpt4MEq2nHuby4SyJjS2zCmnPiNV6p87l2eULGwO
NOeRNUa6Kb82QFvSTkKknroQ1g+TW7iQufaecoNlZDA8dyinOZQ8siSlI1Hbx91p67RlRsVPPxd1
H1euz0s5dF5oA82h9kNdbsIP2w7uB10AFrGhMtyD3gJriYg1Y+3az5Ph4lKjPHASop6Wfdpy5Vqz
NnO8QhaOa0z4lCo5yhs11r5mt02T2eo2ZuWgz9oZq+6xe5YkuzXfFvPbbg0To8j1vfvrsI+vG4D2
vF002iGcBGB10KxTN+YmwNoCoC0AgLYAAN8WuA5vNsMZX28rc8Udqvu6jP5WxnsdjiQ1W7qgx1in
U5UxfYadxBy9rVt3tt52TCakt1WV0v/ctt42l7Vj4GX0t3GhhCNJzR0HGkVuLCPV8JV5SczR2/p1
R74aN6K3tSwG3dII2CnEWltt60pw+1eoy1dShAjkBJL57SARnhJ7mUkUlYNi1yyzKqXlqwZdgrfc
A7QR2o5iFNNwuBLcdco7KaWhOSrK6Ve2clYSlXhEE8VYgLXG9b1Zmawx2tqcpJybZApv13o3PvOu
TX3kQ5OBHX9ynt5W3qhmthptB48s+6FnC29X/cyhTcYTqTo613l6W5rWzEK0mKLtRVNERQJaWuyx
MakwkTO+a8gaKpmj4l1Ib7uEj5Dqv6+G+779HO2tzKnNIuvckNBpSepc1iZVvLISIafTKr64WxtJ
uNjbQUDbjySkRJ1B/e3SrJ03XDwRzT4dDuyJYefobUN156lx7aYUOXtLuDdX3Qms5Q1t635Bbwtc
43tAb7tYPwsoqnbobWFtAdAWAEBbAABtgQN3yaTt2uvxlJxphEK626rDuCvNb5uXqtTa2W5ItVxv
q/XEQb2tPULs6G1ve37bK4awg7rbqhKFlea3zUvVUfLN0duSaTdSs98G9LbN57cN4s2a73pPaUtA
Wp80qpHJn/42eouqGYBWlqRqutdNnxcWHfifdVCNLAseRhG81Z/78ZJ3K0VbyxLI/psPQ37LmD/9
bfSaF3xutVGu56Sqw1gNPp8Z8Y+DqFFDqdCs3/Tn1nlLdpquE/vGmS/PKV2Bsu78lY1uUc22NcoM
CvS2mbVkhgnLfDfEnLWchPTzIfNF4qJVKefPCS6v02UY888Zv9ltlq4usrw9Yc0pXpHxeg8IcttX
W+78ttV9u8lUA2HKPZaiTy2Wq/WN4v60OZUZpnh91s6UpMrrU9Vh5CJXLxkQWrthdJW09taeytab
0daeBraF/DZXVVuaaV74hvPbhpL2FLXq6iN6W8xvu17PCJiuX+ht5/UHl1wYB7yt6u7chG8bd+PA
2sZI1DDNjFcNr+4eP9ghbYGbxk9+9MnHb78H2gI7wqu3/+jsx7742TuvttUl65ZVFXpPuD43D53k
faQ+Mr9sj8H6U+ewLf12I3/90yDVcLLczZR3V2zWQjRx5pe6j+knZx0Zt/kYS4zbzfCtv/qF2nry
J/9w7S7ZfesOCOEtCcyDm/rIJZa6recNq+r0qchCw3VY22Vi/1ROdbi4MAGtTG2KJRMPZaOauZ2c
MDM3K1Vtccbar4n79Jdn1t51m5/9g2drW1t3JEEMbVf0VcS1ReWmcdXBbfNrtL/uUL8t2tFWhH5q
pepfXIaRLrBCU6XmqRJwttwCzn/2zz5kdy/Zy/Pf5fcvnv3eh9vxbbnNLt4/6Yb232+aFpnbkXnW
/axvb617ynmde+mmGrwAn5tiXjaxUk+Y7a5UCzym3/snzxk7M3b8e/7Ff98KbYVLXBGsxxg7ezrz
SQLXt7f6iWvs1Uo1tBeqE2FWWX4tqIQj6Yu0ua91rZP4G+/I53+4GWsrRIZZdGtQ8Vh5X2dbfG78
q3jpvF22IpIyF667yZavhSX6RM8/etr5tePfk+8/39AAmBDl5BBCsA2Ar9FYOGdL2Lv0tS1RiL/z
y2+/vFM+wvn37T9d17W1RhK444ny3Dtnug668fdOA1+AOfrO1sqO84TPb7dYEQqVYwLP4YfC88ki
uAf0jjeA0waffm+gyssnf//FH7DN0FZ07pjQQ45C7Q3O27hpul6XA8Ly75gxlsNrd/HjjiXvS1+n
S6av2PjJ8G2zeqE6fDD9dG5e5KXw88/U+7H3//qj1Z+t161wnlttnG3Ckdg+khWVNuEL1PF7v37B
7h59tLhrPeXblhul2gFB3NmsbY+Pv/qXz+RHW6ile1B0AVsfyKhtbQGAgbYAANoCoC0AgLYAANoC
N4Ua89s2/tK50VKHLSbhBZan7UZnkmq00mSLSXiBNZ0EKaWaCKXbcg4zfeIcJhhyB7YWJvYo1ta2
Q+SaInPHmuCWmhotAsuAsi5ZgCuXiVspHGBvzJJwDo5kbX2/0t+RPpt3R1uCU3tM2trz2FLKsqJn
A2zFSWCByW3JXMwoan134CLg3h/L2g4P/HFyW98PcHyCfnWhfRnbFpPwAuvQlpz/0/DP7dO7QVre
+kZjCRiiOLCTAACgLQCAtgBoCwCgLQCAtgCgYQ6ASWfJ4uLXXoEFO8cxYBUgtNaOVuuEJbD9yzoK
pasT9UeyjHWbmV4vzChgsDR6KXe899sHba9GcLVoW3rjL3uq9xMS2NC+IWmkdBCLvma48CKsail3
Amt35iS4iltTUitlL7o1FLdmMB1+oBIN0ZRSN8rI4AsAK71EA0k/BKItBdQ8jrX1Fbd68/KPOYpb
bdloWCPZ1d0Mj2dpCnRomoF9djTEDTzUyecjsYinMphbwytxSpNkO7BJ2sq8x7+53q5/ayn4dKWU
RfWoYiUwZkdRVsl0G4i6qRS/iE5ZjFe/e6AtDRSQ00yWLI/wi4ByzhZZTwr3MIEtd8lomhCUz5vA
vQ8/lic+HJPTJJSp0siiWJKgbdzfSEJiHEyG3UqtajSWjI88nynbRTAsOU07npRIlspiAXujraW4
HR3AUaDabVmDq8aeTb18OWvX9+pCDz+kncyAfRwSjg5TqawvHTCrEOmvNcewfTwQepuYNb+tpGtO
18lkdm6YGaEq1pnftvh1g2QZY1aLdscktWgNwC5923md9oqeIlUPqEODujsHpDQAaAsAoC0AgLbA
AbtkMtjDGcZhi7ox3mtR6Q2CmiJbFlO9spAGN0tfa8bBkNeRaZu6uVfe9dTb/bRW1tfgTutrnTg9
ycHbozsJ0tDQKnGtI71lkdlu/Xluh0QcxW4vzY02igxNREmTAQ5sbR2zpUW3va0yFLYsMdutoyg0
lbumPtdUvaa8hQkWZsQZ302DvoembdDqhY/Z2lrKNo5B5azrDJun3UnHGN4bgLYsaPbyJ3WTwU1/
X+Y/xR1n2PsmDQBtI4/VbL/QkVdF7SplkJ+KfFMJFoO2eV1/ZnsJLrlkknfuR+2mTjcYRVJegwFu
nLbOzK/S1tsyf88W5VryWCuSodjt0lXfNQZGYbVWVglrdTr5+lpfZgscBfd2dzdn8g+0bYN19Lb7
e7k77xMvsPZQ2KEmgRaLBIC2AADaAqAtAIC2AADaAgBoC4C2AADaAgBoC4C2AADaAgBoC4C2AADa
AgBoC4C2qAIAtAUA0BYAQrC/3OVMOFv8/Ke3xtPdeW7sR6CS4UygqoFGtOXeVsfO7uPMjnnc/E4z
h4tgK9Catj5rXdqJwcx2G5ePjXtrfD4wHNN75p+22xxkBur6tiJpJTl3KdxRsqdux2AujD3F6Z7E
bAg5RgCAOrQNs1YZS+ET12O8GEIIOw3huLuwtkDjkYTRgxXC8iPSgVnMWosk+QFgxkhCmojiKtaq
c70zgYoH6lpbbQw5N0fEAh22XHAjQYyFAUs4CZzzwW+9UE5YtlJYPBQhB0BFUCEFiAtcj3uYHAu4
BphxEQBAWwC0BQDQFgBAWwC0BQDQFgBAWwCwNQklyzD6C+KpZcFUErL2Kh8yYxFJihY3FSuZ8Jht
ohZ00Yal3KZX0HTj6HJcIgdSDK42aJ6Vt7SsiiWlmXHbR7arVXFVLUqqvKbSZILjMutl6RJLRhmz
lZNXzpi1hPsEa904Rh4UTDG0zqazFn3F6n7DplVWm6FtgAKjAQgf7ALLDOvcHOMiqnJOi5hINRax
JlOy601nSxmF9JtZDt7KDv1jtsbqWaccA2YuwOsdJLYF1mbxbD5bggylChycEYMWqJw32aHX0SSc
Mhw9Ch2gqcYsl76UNs5dYaqXq+4XHl7G15TU7tJ35Nvay5GHWmykb2QvEu0uGb2MoW1h6Cl7tXd9
1WqF7eWeO9XzOu2JtsxZQJwiT5pgHZH1rNtN68+73zIvIM13e+fx7laXEr4/4b1Lq+eaePav7CE0
ynHo3BPlNES5TpuTt0fbEwuYW/WwG/wB6lwn52DaeaDa47aTCVbPMTtVFaavt3EQkZL+ZiBO6qw+
YFFW9sM6bS5908DXDTvyWqbHgpcHvm4ArnE1bspVOIEmG8Pclx839diEtQVAWwAAbQEAtAWO2CWT
09oQW/4pGaOlBl4yxiZHhSHVSzeodw1XCrtGb2sIewN6W1ssEo57u3rbdDUzV/4pabnBwoy85Jwe
9US66SutqLc1cqCkGjcat7UGZFMS3FPKukiKimqdSM3JSwU0rJh2UtGqKoVqXdjclwlthG8u8iW4
y9PWaftRUa0baQOSDkWi4hed89tcZb1t5fRqm4k3bENjw6fS9i/9n2UuJpNepY7LZJvLUbTaKZTq
beUVQke51ONu074tyeTnVVpOY/ws1v4zuozlt4+q5O6nWUrDObwbb8ASj7vThmk7GCvK8vU21cRl
mydpTpqSIh5Lwxy2dwOWxP2oJy5ZloewkKM+mYeSxMomrJXVu4FVYsvl6n8XTsKEqNYJRUuMJGR2
tUq1pxPhcxStKsxMvW0oh5gaV3WPI2rcWwL0tlsD9LblTgKwCSd9wWiH8G2B1UEz3ytQK2P74Nmj
R09fbauS3oJOHEjg1R8/uP/Jb3/7q3/zzW/8Ohjg+z+FtQU21vN558kHzz/vNj/52e89/dUmu2Rq
/bFxT7g+Nw+dNFYu7xaFNhYu0wueN/fbx7V+edUF1MerYsFkvVXbhyt2lm8LRxtrUqfPh7U2hZs+
E15kq3C8+sLxD77++lPn0NO3f/Zwa12yyxrO/vqkPLipj+glyy+x3UWmh/SaL7MrRL8ANa+9gPol
3SFx//KdVduHLTHRFnQhuVl4xqxV49269SKbhavMnlfPvvHDv/z0Tu0Nv68/eOfxt7dgbV3XVgzt
v2/7l0Y8WFRuGlcd3Da/RvvrDglmmITWBtctXZUkvetj7tWHKS3yMkilnz43UbhrOPv78vFL9j8Y
e3n38szZl8bv2WP45tsfPNzUSIKz9Cjvn3RD++83TYvM7cg85/40J2/dBdR54/XYxTWlaFO4bz39
0Z9/dKbp+V/w7xd/8aPHP9kObYVLXBGs5lhV9XTmC9zqpE2q7CSo5KL2TJ1wzmfXQqa9jFzUVOFm
4v/9r4kA//N3/2hD1laIDLPo1pHisfK9zraYi+MsBS1EXm0MlTJWRtVaiJRCNKrmn7/47LvP7jp/
Nvj3zndevfzdpnxbUcxa3dNdGU3XTY8l7tnamZVxVeHrX/nZdX3wna8uvizr/Vvj9z36+K/Wv9v3
g55tQfefc9t14FafmPEtUPoKz7bA1p4D86FLmNMhm0qcO1tW+CGzVnj9/Mu7R4+7zZfq0Pn36Xd+
9/nHW7gx9+3H/eUOjEOOQu31rDQ2Tc/sckCwIYjV/zKPLeQ3WMVYIDnee7DqZ6iMiV7oRKr6tK53
0547Z5vhw69+/fA9Y//x+9/75fOH27An1ynAcquNH8fdXdHVSZvwNnX86ruvfiAuY1/P3v7sdXmh
luiStRq+Wc7YHoK4c1nbBA8/+eI/PvrmvX/3vS8+fr2hWoLeFriumUFvCwCgLQDaAgBoCwCgLQDa
AsDGYWgSnIk27dWhU1jkS+f6cwG4k9MCu6QtbXktzPpz6cpG6QIrOQlSSjXXSrflHGb6xDlMMGQD
UIt2wGBp929tbcNG7iTa5o41/y0tPLH4RtsBsC5tk7eWrOndaUEitJpoTILBB6OtPUGPjJ1gi8ye
1moOV4JvezDaSmvmTUpZVvRsgJW7ZFF7240WSZqwxI0e5ftKF1ja2o4T4ZM1y73pBzg+Qb+6UFNj
2yoDwrjt/mlLzv9p+Gc4BhQKsp0VnkpTBGeP6CQAAGgLAKAtANoCAGgLAKAtAGiYA2B6tXdzvwCB
BTvHMWAV4DIMHA6iF/B1h1L7l3Xk5TVuhVf+1cmYy7ZLc5mveGkk3vvthbZXg0JEZpb0xl+oUQdR
1AqpyTwCSesUsXAU3RBHlZqpBIqXpvsH1u7MSXAVt6akVspedGsobs1gOvxAJRqiKaXu1ILP5BTF
SI/NehAEWpNOHdQ8jLX1Fbd6s1tv01HcastGwxrJru5m8B+kKdChUMa+3zEIIYxIFIkSSdcisST9
4VGqNGD0Tmgr8wyWuXo3hWgRuOFk/6YZYTuyY3aJVT19OgcTlOFShS7i8g9S3F3QdlzNW04zWbI8
ws/zkQstHeUkaAmDclKUkOLuq0tG04SgfN7ImHNZ+FjO8ACSQagoliSIGvc3kpAYB5Nht5IM59Hc
DJGRClguc21qLMg4+jbXWAO7oK2luB0dwH5TPWptnaqxZ3MkQ86qgphcNw5MPtmjw1Q6GV1yRlOf
mI8FVl4FGLJJzJrfduphXuVm56ZSmhtmRqiKdea3LX7dIKfHAZblROFbATD20L7tfD+wEi+oekAd
GtTdOSClAUBbAABtAQC0BQ7YJZPBHs4wDlvUjfFei0pvEFSSlW1Mg6u2TEVtmb42WBzgOLRNjWde
eddTvMnSymoBWKm+VkWEePbwToI0NLRKXOtIb1lktlt/ntshEUex20tzo42C6rcc4KDW1jFb5scA
jvSWJWa7tfllKXdNfa6pek15Cx5ri/W1w7c3oP2xaTth9WwprDPbbSY1KMTI8EEZ+zoB7w1A25DZ
y5/UTQY3/X1Z7jeHFQSF3UPgFmhL0120GIuk+1FhwXzj1gN/8hvIAicB1L0VJyF3yIh8l1MmzZ37
Ubup051hIvMkuGDtDdDWlqeO9zyqsGW2KNeSx1qRDMVu31MiPTLhOLbjnAaeq1Ksr4WvcEDc293d
nMk/0LYN1tHb7u/l7rxPvMDaQ2GHmgRaLBIA2gIAaAuAtgAA2gIAaAsAoC0A2gIAaAsAoC0A2gIA
aAsAoC0A2gIAaAsAoC0A2qIKANAWAEBbAAjB/nKXM+Fs8fOfYNYmF0a4AJInwxECMfpcVFpGklO5
AzdHW+5tXRjCuTA3ee0iBFloNBdryz4OgLYB1lp8OW8Lzpn6xrjb70k0UklzSm2lfoZQfPhoeUhM
cHWw5zPvDxqBuc4TLIZvGzZvjjEUhqdwPqUINNhjZYy5EMb54M8YXgycF+o4Nw6qjPzAblrAzVrb
EGu1k2AjZuLEEGkgnTB+mHXQi8lDScdtqYinBWAkIemX8pS/KvoAYgjHOTP2ru7KJdICbmkkgc3g
TYqB3YNcDD/2wQqsjaYF3Jy11ebrvMW59QwPUMuxdtau8osN97hPsoRnPGXpOcbCQNuwNTMsZz+a
YI4zWLzRu2LwB7oDwR8vurAorz1dO7A67qUF3BTuYXIs4KreDWZcBADQFgBtAQC0BQDQFgBtAQC0
BQDQFgAsTYK71F1oy4GKolYws35qY2qtG5172dqmE+GtK0zmbJZhcg0/I0Enh0vkQIostAKheVbe
0rIqJ/cWFS2fJHU0ii1yXou1GazuV2MvTJjyr3AiZ2sJ9wnW6gS9HCiYYmidTWct+hb8eHO12qo9
beP2o68jt+nLNlUVvs8yi32lDWYivJEtXdsCkjlQfsKVaz2d2FtTAX5Mq9OWLkZCBuwHC5vTBUtM
BXeBCu8aZWRb+gjObj7UripqJPdmKsA6moTTvNtA4SYr2ZoYfIQii5sXfmLpbGmVoV94uJjojKq0
g3X4sRUnIc7HwOrN/THJSK59PdQmfCqYf93E8teINyJhgdUraUvullWnnoGiJk+v2kMNSzQVSU38
T6wZ7OC+YzgoanDjPvwmPAQ9jlR1gKIsifnkkmDt1dZWuwHmFqmdkJNgHCe5it2VfeeqNPe88MlQ
6mQ30iJHD4GSvqqOE8pBnx221NAs2Uxet8bXBL5u2BoShlVusNOGrxuAa/wWeUt1dAJNNgaaderG
3ARYWwC0BQDQFgBAW+CIXbIMKVIfLiCybT/8MpnBIASk2gmzXL3tUIFFeltPVlemt+3zu2m9LWXd
xJDItv3wi8wMIKsnzLL1topgRXpbX1Gbr7c1LEYrva3C1mS3p2CdDtrakZSdoDEhsm2uvJ3MQAWQ
66h5pr8DmYyZHUhf4sjz5nYhLrv9MatYhqtoG/xGYVQ00ezKr8KLiQBUvT1k3XHyHt+0RFXUfKtL
E9Y2cn4Detvhuyrj5bj6L1jqLvitvA+XySe+xdJSvW2ec01hqslFehZbeys1w7c1702rL8eWYyMV
XGyunZqlt52yhYHUbldPcrqiIo9iRTPoRYWNoMT1qMDum9M13p8yM8TCneKDKDeIKIOTLS82c/wt
dfj21LhB3zbHZ70prWem3takYq7eNqQT9vS2gSx8Ne4tAXrbHXnb0NtmOgnApsYs1nJkDtQlAxo5
JDM7htDbAgBoCwCgLQCAtsDuu2Sp8T9vHFJakxy2nuNWZkzpOSfnifDpWXO9yW+HA+V6W2PiUMxv
W0bblMAgLjc1ozab43YyxZk5T4RPz5rrTU07HijW2xoDWJua33bEG7alYSdvNnEaKt0W3Brz26qz
qdmu6rf7ZsLFrFTDHPSmpp0jgqTigO0lxaH034oc38D8tmP1+GaLzC8ZSHG4DUO3iKArQYkDMz4N
kukCUDubkNOU3kSOb2l+WzJm/hoEt+5VUWhKO3I9tcp+QkaAYh8vZ9a4CVciNHFqVb2txDSiGbTN
uJsu0Tcjvy27wXmT8lJZljP0tpKuKcCqRNlGaYwPYGURW0otSBtjW9u3nJdqud5WYjbQAty3LY9V
d5LlC27lRlhbe37bjFRljQvL0/0CIWtrij4DT0/jtHfWEYZWH7iV0wOsLea3zUm1it42cjZLb4v5
bYH1By2gty1zEoBt8HbRaPv3bYEtgGhe95HaGdtX7/6rr7/7akuV9BZ04kAaf/af/8PHf/qbL//T
3Yt/Gzj7/Z/C2gKbw6/e+cdfvrhsvPjgydubsbhml4xf/if0nnB9bh46yftIfWR+2R6D9afOYRfw
21XhuXkJzVM1rl1YV2zWQjRaIAFu5zYmZ+Rvn+02+ZBnfXo8ev3S2H385s3rrXXJzhcvhjpybpy3
qY9cYqkKPG9YVadPBaLWR1/6wCU0S1Ud16eHLTHRFpzwZvrCPy26mvUrVVW5Y24qurTPHr36tGPt
nTryuy/p8YMtWFvXtRVD21WtmGuLyk3jqoPb5tdof92hflvw9sZWLJ9q6mSWFRLXFKTNJY/49meP
X7K7M2vPfy/N3/f/6w+2NZLAuVvzXOj232+aFpnbkfnU07YtcTnfTapVC9fkMf2Tu59+eaboxda6
fx/9wdfvbYi2wiWuCNqH2H3s6cxXu9W1vYO8VHnU582shSybGQnU5pI7/IsfJk7+03e35CT0vBOT
NWhVleCma3XxMc4dsOVpK6zSVE51gk9epgW1cMWTXrTsE3300dcevfpc+Qb2H/239Z2Ek2tLi6tZ
LNPhyr+XC5ZG1cb8TPNYmw7VyFF4/eLBd35z8QsuPq3+PXu267PWGkngjiea95DjtuugK7A33guR
SOXD6w6ATZRe0cmtgkwacZ7ko5e3deASmbPgAE494j5/8d2nvT/Ler/27u9+7cUPtmCdQuO2nR+g
/o2DguamOtPfHT6MHapfYwRoHLddYHRPj4CKJqmGkuW6edoVZdVCLNXR3RLmuK2wqk3Xu24k7tkx
VpM6/t//XA68vfvX//71vBGTprRtN+zUeKzmOEhWVJohzer4wenB35yZ++RvffCwuFALOAktuizF
AUHc2axthddfffa1p9/87i+eP9xOLUFvC1zXzKC3BQDQFgBtAQC0BQDQFgBtAWDjMDQJzlx0MnvV
7oW+dK6djTc5LbBH2m589VzZJL29rxkMJ0HfUCnVfCzdlnOY6RPnMMGQewC4ehBra97Qy+TUzhy3
5o410y01mT7cL1XddgHWHoy2yVtrT3ZLuycCwbc9HG1tf1ImHM3md7+VKYdvezza2nPcUsqytncS
QC8g2SWL998l05PdypbdfP9hjvlfgaS1HR743ZpBuiPkTH5rr6+xWxcRvu0BaEvO/8lYfcT6cYMs
ceupSXrg7BGdBAAAbQEAtAVAWwAAbQEAtAUADW+F8wKdrYfAgp3jGLAK0C3RFwxiBHbC9C/rKBLJ
X2g8ka5VwFRpJMNb353Q9mpQiMjWOumMggtG6gYjKZpOJF1JVsuIp6uVbWaBw6Xp/oG1O3MSXMWt
KamVshfdGopbM5gOP1CJhmhKqUsTrLcDWOklGkjZY0GnDmoextr6ilu92a236ShuDTs5yGJd3c3g
P0hToENRUpmOyiiECEZySD5N6m4VYR08Xhoweie0lXmPf1OwTSFaBG442b8U9449NdmYHUVZNfqo
FCZqbGlail/E5Z/Eq9890HZczVtOMzm5wHllD/nKKPbjIj/FQA8T2HKXjKYJQfm8Cdz7yMN8Yi3k
uAdc4CTkxqr9FRCwxEhCYhxMht1KMpxHczNEMErkGRhD8yNFCD7POMKkHoK2luJ2dABHD7HbshxF
Y88YlmJZclYVpOt7dZv6wOhkBuzjkHB0mEonY/u2aV9hLHAfD4TeJmbNbyvpmtN1MpmdG74eq4p1
5rctft0gs3pAC6LwrQAYe2jfdr4fWIkXVD2gDg3q7hyQ0gCgLQCAtgAA2gIH7JLJYA9nGIct6sZ4
r0WlNwgqyco2qsH1p6Et09cyDHkdm7apm3vlXU+93U9rZf1paAv1tSoFiGcP7yRIQ0OrxLWO9JZF
Zrv157kdEnEUu700N9ooqFZ7YbCzR7e2jtkyPwZwpLcsMdutoyg0lbumPtdUvaa8hQm1TY6+Vv2A
vsembYo0zjFvtttMagSVs64zbEVwJh1jeG8A2rKg2cuf1E0GN/19mf8Ud5xh75s0ALSNPFaz/ULb
FZVRu0oZ5C9jpASLQdu8rr/98PZU2zJpTX1JrSSf1EUfIQCgLfM+vZIUci8js9268lgrkqHY7dJV
3zUGRmEtya2dTrG+FgMKB8S93d3NmfwDbdtgHb3t/l7uzvvEC6w9FHaoSaDFIgGgLQCAtgBoCwCg
LQCAtgAA2gKgLQCAtgAA2gKgLQCAtgAA2gKgLQCAtgAA2gKgLaoAyMM7T16BtsC+8OobX/3lew9A
W2BXrP2j5y/ZJ1/7aiPFMT6B5N3/xy/a9LdtXB08H+F9iC6o4JftMVh/6hx28Y/iuC7SUMBaqRqJ
i0im1umhEsyKCSVthx8Kz1RMIzdunbYjW4Xgta47iAdvv+h+nzz60L2WtT+BFKL/M0nsVDa/BOgr
sQtt30Z1KhC1MWuH8guzFHVS5c61WafVcX162BJTDUK4CYuh5u1rMK/Nq2crjabs+dYPe9beffbL
e5uwtqeILeCmcR3qzjW/RmPrDvXbgq9wHY3um/MEYvFGzeZYITFReJ5xbQtYu/f/7xcXzr5kL+9e
3P3tTzbp2/atV/TPOcPKWHeKc55h/5YhrMgp0txUxTJkiRU+eW1LPZ+f/Tl7ef7p/15+8HTrXbIz
ZyNU6OnMq7PlCqhHJa9qd0XEmotpI51ZMX3CEddGWNW99KNmwJd3m+shnqbq1Kouwc3ewaU7cO6A
rUtbZXKMxy2vYIW4uIYYBRVjOFelbgAXy7CWffXuvc87H6H7+3ufbJ22fn2IxTtcWe5n/cclD46l
bMsl58PoTmtn4ZP33vk/Z7/27CGwu99ugbWFq0Aq2zBWlL6xgi9SgWHLxqpnLex+Z1biZqicdtQ9
ykQ0fc4ca2qF6nogLa48iI+/9c6Lzrd9/I3fbNRJ6BwB0fFQmO5ZN0zbe44qiNX/Mo+tMJSnS90k
+/BwsJdpqGKiZdUJ26X2rsE6ELhC3r7Kf/7g6afnnyd//eE2HrEFMy7mNus1bO5RkKy7tAlvXO2v
3n3Onj5/uNpwRsFIwswxH7D2Srs+j7Vt8fCL998LsHb71hYAShvTBqwtAGwFoC0A2gIAaAsAoC0A
2gLAajDekqkVaIYRMWOBvIlBssar0KgV+GovGzIkiDV09k1b2uYtlCN3q5ZuXJYdHDiIkyClVKsz
dlvOYaZPnMMEQ9a3tW1AsLX7t7a2HSK17K4kxzxZpopCIWtTq5kZJ6xXdhzaJilD0lz0lpYhGHMX
0K1kxmFqD0lb2/GTsRNNWBVxRfdgxoF1aWt3WSh1z+EmAit3yaL2ths0Gv1blrC+ALCwtR0e+JfO
lrGeuOkHOD5BF3Jnvm3zEgOL0Zac/xMzetvmjxuEtR2mapEBwcc9rpMAAKAtAIC2AGgLAHsBPoE8
JCqNoWckk5NT/dLA2gI7xMljc77ONtQc3DjjGLAKcBkGDgcxAjtB+pd15MTRscjcm0rXKGCqNBLv
/fZC26tBQbtuSW98hasOMmrKfMK4+8TGdCRZLWMqXVMJFC9N9w+s3Rlte7vU3TwlNxg3L3ZIaRX6
E4aBvOzJMfxApX57MF+S0QTXySlKl5lPoWtIpdWYR33bIBdLRi5Xmgna+opbvdnz1zkxWjZST2xP
dzP4D9IU6OR581Iz33INQuzNSPeSlmZtojS7NraH7JJFaCvzaoFkqnoo+HR1XqWSZ1Dj1zlmR8kL
omgQJT8IqBAofhFseHIAW3cShm8NDf7KPLsvr7MM1zZHmmzspV9gEIOQfHe+LU0TgvJ5E7j36Yd5
hCxmpIwgpU8fr0sHNeb+RhIS42AyeEKS4TyamyGGUYqjksKWPION84zj8UwqLZYMrVKaU8IZtHW0
2kPstixH0diTljXMULXSMAoxbpkDrJbkN9bDyktXH0g8+8mYPoH27NtGR8Pz/B4ZmjBjTnerfJYL
K0ZkKH/Wy11J15yu14udlZu8ifcI0dHwvKZoVFI6wlRychxTz76fZoxYt6T45a48YwnW5j86ZJPW
cGA6V4xQf8KivBjFb8moQoi67hmVJ3u71KW6Eag6F/JiQEoD7BCgLQDaAgBoCwBTXTIZ9ImzhkEC
3UFX4uIOghoirFCu4yF/4K5MXxsctzz+cEJs1Lo4es3SlMeIFf4eTYw+yDlzF7u0DenHKZWvO8+j
OY44aMny9LXhcUtoDY7nJKi5avU0t+YUtnKYJzk0260/z+2QiHlySFdOszZvbLysQQGHchJYyMDR
qPSWFLBolp0LvM6wlLumPtdUvQa8hfhDRUY/6cl7+AzPIND3YLT1b3L0mDfbLRWRx2aioyzXU+T5
zo3h+oJ+oK1l9vLtmIw/sDPmZUyIyvtt34rTFc4+cFDfls7ofzK9RhWhoyBR5JS7E3KpZ6wAkV/K
WwK/YHbk4Z/asQ5XzZAXHZ52EnKF/eR/0iWT1tQfmJCBqQ/LPnqHtfUhakUXmakuu9D5/RAVO42X
+hlpSJb0y9wztsmRh1mRdMKkhyQkCxhZFVJ6hUkIvmJxvBRuySXuTCBXppKrjd5ujkfGcJeD6hTv
Dw7hzcOc6wizM+TMydpJNp1Jan7b0GS3LPwtI1mbgUlx7Ulwyey/UcKAunHS5jUWx0nhlmwzF/2f
u93v6iPDVndQqFAqxHBGjDtW1HkZuok7yaYzYXt8uVvDlT2+se0NVX/PBQ/cfWH+iCKPQITOl2Wo
IwfdkUmP47S/O0KbSGIfvm2yc3NmV1a4dNR5GUb6X7nlODHg4E5CktvGk7q0WUSdhKJYdozcjh0U
YEdnbmflRMikTdg5nh4guy5D7p82fiabEKztoV0F3j2YzSe0cUg/s81wbLCIl4NWuO5wfzT4uC/I
0Eq8O2wlm86EYVpmYDXv5RrASQB2CFhbYIeAtQVAWwAAbQEAtAVAWwAAbQEAtAVAWwDYFv4/FHdG
ppXVUJYAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-10-25 15:22:35 -0500" MODIFIED_BY="James Tacklind" NO="2" REF_ID="CMP-001.07" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotics (classes) versus placebo, outcome: 1.7 Bacteriuria (with pre-biopsy enema).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAAIACAMAAABATt+2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-02-10 09:52:22 -0600" MODIFIED_BY="James Tacklind" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.2 Bacteremia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAAHwCAMAAABkNNwyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-10-25 15:29:16 -0500" MODIFIED_BY="James Tacklind" NO="4" REF_ID="CMP-001.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotics (classes) versus placebo, outcome: 1.8 Bacteremia (with pre-biopsy enema).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArYAAAGACAMAAABvFtHzAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-04-04 22:50:11 -0500" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.3 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq4AAAIgCAMAAABzmxucAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-08-06 14:40:27 -0500" MODIFIED_BY="James Tacklind" NO="6" REF_ID="CMP-001.09" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotics (classes) versus placebo, outcome: 1.9 Fever (with pre-biopsy enema).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr0AAAGwCAMAAACTjC2pAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-04-04 22:49:54 -0500" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.4 UTI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq4AAAEgCAMAAABCcwEBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-10-25 11:16:05 -0500" MODIFIED_BY="James Tacklind" NO="8" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.5 Hospitalization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq4AAAFgCAMAAABNKwttAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-08-06 14:39:28 -0500" MODIFIED_BY="James Tacklind" NO="9" REF_ID="CMP-001.06" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.6 Adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq4AAAFQCAMAAABJUQzAAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-04-13 09:55:16 -0500" MODIFIED_BY="James Tacklind" NO="10" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Antibiotic versus Enema, outcome: 2.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArAAAACwCAMAAADABa2tAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-04-13 10:02:17 -0500" MODIFIED_BY="James Tacklind" NO="11" REF_ID="CMP-002.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Antibiotic versus Enema, outcome: 2.2 Bacteremia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsIAAACgCAMAAAAxb/qTAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2010-04-13 09:55:56 -0500" MODIFIED_BY="James Tacklind" NO="12" REF_ID="CMP-002.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Antibiotic versus Enema, outcome: 2.3 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsIAAADACAMAAAA5m/XJAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2010-10-25 15:27:46 -0500" MODIFIED_BY="James Tacklind" NO="13" REF_ID="CMP-003.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Antibiotic versus Antibiotic + Enema, outcome: 3.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAACwCAMAAAAc/NmaAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2010-04-04 22:49:44 -0500" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-003.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Antibiotic versus Antibiotic + Enema, outcome: 3.2 Bacteremia.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtQAAACgCAMAAAAb3ws8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2010-10-25 15:27:05 -0500" MODIFIED_BY="James Tacklind" NO="15" REF_ID="CMP-003.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Antibiotic versus antibiotic + enema, outcome: 3.3 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAADACAMAAAAX3tRbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-16" MODIFIED="2010-10-25 15:26:02 -0500" MODIFIED_BY="James Tacklind" NO="16" REF_ID="CMP-004.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Short-course treatment versus long-course treatment, outcome: 4.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAACwCAMAAACFBAAvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-17" MODIFIED="2010-10-25 15:25:22 -0500" MODIFIED_BY="James Tacklind" NO="17" REF_ID="CMP-004.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Short-course treatment versus long-course treatment, outcome: 4.3 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAADACAMAAACOJg3uAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAS5klEQVR42u1dzc7kRhX1fOnhTliAwpAQUIREkFjlFXiDihSJHY/A
hiWvwA6egh1SFrViyyYPwA5BgEUQmXwCskjmkkHQtst2/bvK7bLL7XOUyddtV926Lp+6vlU+dj+h
BgBOgAd0AQCmAwCYDgCHwqUWR0T7P3n9I91dcg3zsurz0B2+cfz6p36f1h+VHc4RvL9U01fXgxde
TotzxJz++GVkn9YfEt4fNqZPA78nvYoRelBXnSTG8HH9N5WTSb04VlatSNGsZ3ylES/MrrCcF21/
mMUqiu31el9Pni6EdnW79oXqjDZOjB1n7BqGhwzt8Z+KvsjQijB33GR8PbqolmyqtJ0hhv7YzqH7
8L6WmN4N9q4T5HzU9/SvzIwPUmt3deOLc11pNGjmurKRFSdy9XtfTUzvumdhX8jhiiAKdGZR43YH
GA1O/SFl7dPq+r1/qLCzvKmNmKuqcp0FvVnUeNaYEmaD1r66149q974Wps8EzIFkRjGhVZZpdvxX
3VLGF3eFNMlzJFTr/UM9EUGjVPfV7jG1bfpjl9YreSO3sIpoNm40vmZY9LfUuSS0JaktHLon75+c
WeElZP23lAAwfd0VAwBMB4A7ABReAJgOAGA6AIDpAFAfdN2LWui09OCxZbihxnzJOdgqZmOfTK8o
/N4sNZ9ovb8tqK9Zukpto5mhdDNJRLSqTTNpLBv/udAElp12R7sDMMkxC+CwjutMHyTiIuOwg6Ly
fMg428LV9K4RK5tPtT7fnMjsCjnb833Hy4Ey7q7tUbPjF8+pHRXEUhu0/Rk3FNvj0Y0lG031rRcd
9d4yPmKn6o1Wo5fYzvThpH4Ol11ufsb6EB6E54iboUnrJM6EFFVZ6AJ5GQ6Vo/VuU1GeH9RxI09X
t2uNfERYDg6yca2GcRnXVN+TuNsskHKtmFTkUhEnXrMv0JeVSWVzzKdYn1TZ0ycxHvQNZ3ESyHua
FaJmJW9Njj+Ylx63eRlRojk15FyqEJcrCrslaXVb4iVUiHLmZY7OS4YP2rzQm+ddfXO0Ib5T0F+E
N6TOUR2/uJlL1lGLdR5otnvDPnaZo/r0BpHVzPtD1MKM3EgB3YAhhomfU17oiwHdKkLOBGtV3h/E
8YvvCpzL9TKBw2kncUglcPYG8z7rslc7ioSHppwRIeKTZRGwKHd8kvyYjj9YWboTmmJLP1oNYYQz
EemexJUU05uVJJ6FzTv9knBO9cc7nDMwTgnUU0+N8fyTlkgZIuNthPRHc/zBzECVEntY5ZRWoLMS
MK2GnK5afnG3NC5rgTzd24zyJ07GqaFInr7Y/Kx1XxeZnedc/GSTM+8wu3VYjzP8Ft5zVOJ6e0jH
07SMWR6EVd/n0oIvUL+nJFBCVnqslTt+SeJ51vmSUH0v7AcQvSCgTwcAALgdP6nEjwtiOlAWlTAM
ql3gHADTgXMAM1KgGF6NOTJiOgBsNSM1vnE4wnM/tfD+2QKJTbGaA+V6llZeWefQRItVp6idYy9R
tGuN5nlwX23hvj2yzpBmjrXmxsrEDa7WYaYzBc8H9yfL+2cToic2paiW61lieXOQ+weCycq+lyId
azWvPpFuTXOOzZbMuqSxvaU6EI7pE99VaBlDA90eEG9CJmvLmR8oR/PN081j23Nq4u5vGHs6xAVZ
H6YV2+aG+sXfx0OPqY/rxNuN0hzawDr7cxcOjft8p7w1yMt4tnKbDXNKuWqxzZjeXjXbviJ/rAue
LaqSwrzXCNHHfded3P6XnjcvcNz0varAU2mevny2WBl6du1yMSF/dk9p7Ety3CH2HoHn0EynGGnj
mSlvRaTFfFvFfDRLZ2fHtFKS3D+U4g6H0ngQOogHq5+Cp2S266vKXbiseT9HiaxYscAoZ7RU/RX2
0uKD679K117URdTsS+7nOWq786d4qsB58yzKnJXxetM4GpatJqPdBChmfqrjc3za6xudzl5iZDAe
QA1QOWI382hhxU1Ry6MjUANUT/V7WSWoM3sBagEt2oX8BTEdANMBAEwHADAdAA43I42uxO6sUJ9d
NTPkTavr003xVOAmqX0HlUeJech9W5iuq809wnTdTVeKz9oG6NNjTI+KEndWqHNagYV+zZY3rAec
YdvTsVJQn+4I0zVHPMJ0w02PFF+zVLE+/VWzx5rfxQ5JxGOY6NXpSQr1DSI6JxWgos1HZSyDaHfc
maB2odkN0aMzlae88YlKG0u/dba81ixf7qdVmD7a0tXpDVVxt43KdUF+8xQrQ75it3YhJSV0G8sA
0tpy75G+2iVuXmKHQM2cQr1CjUXZBHWB9bg+nRvKmpB49rI2yJiKd8FdzEjzrktNbY8baeltTdaj
+vQV3CXtOdINuqAQ50rjwcdybmWhC1Y/gKXrRotCOs7HUqZ3sx7rIfSjEZ2PZZ1vILpjgrfogvvI
Xoas2ys4jynUK8pdlvmVWD7DrBV8A/p0R5huCOUd6bnaa/DdMQF9uhfQpx8w40m6ukKfPpenA3eR
iCGHqWIeDCRkSot2ZZU57YwUAMB0AADTAQBMB4D6ZqSWXM68gc3aOu0eSvVU88Pby3MX2TjLuv8V
Wta+SUCeok/X9MA+Vbvn5aLa+63d83Io7csrm4qFmR5jiE77PZTq6eaD93hnKZxu3f/2dFu8PgnI
E/TpGsmn17B7pO7OafC9r71uffr+Md0MFjycJe2LpSTyUGBvjI/9cGY1zrAeHwR02/vqjDg+J3Wn
wPvaq4rn8137WmKwoZWZPgQF0iMEHURQpO6IZ9aiLOvRgeGVOSf03WCTfQL3mOLXzesqy1zmnXm1
wei8eLPQZcGtqFo2NU8vm0TNWOeAtiWoT79Jo6Kij5EA5bzB+sTZC/kuN3Xkezm/c1Q8OmXyKMI+
8znSRd4Yai/rebtD59BbtEFz3OGTy9cT31/OlDEN4Cqfa7kfPKTMIvg4RN9Enx54f/lNPRB/J3rS
EWO1JTemE2tXXPJNeDxKdS67oJ6a0NJ+XrCzOK59ntWnJ02KjOJW/0OfHgf06dVmSNCnb5K9AAdP
xJDK7DDrBRZlSot2ZZXBjBQAwHQAANMBAEwHgF3xxH5VK2e+QH2z1azU35gedbtUwHxUi+/sHDdE
lsyZArXN96fzpOJ1zpj9kvXx1bEVoNNuVbHuoflAMzej/Xr0rVazOJ2wTE22X5xj3d9Rzs5pQ1Cf
PrUbf3+6+mQemKNZZ20H9OlhpluxiWkQhcZk6aPWtPC6Vo7gnIqap1AjtKB1p11KGWxO3WWi/JIR
Z8BrSypRaaYTE1tvTyf1LMacU8W1SZRxKij/rFOe9ezcINQ3lD8k3br2bzkUZXymx6/KUfeWGSkZ
D2t5nmUJkrme+xRlnytT1kONsG+KQNzFgVSvOP8JWGQqy7OX0he10jGn1PVlSYaS+XQELZG/L5i6
nw0P3hgxt06QUWev0M47DD4ODbPVyJem7eJ6As/l8sHlUoXkJOU3MTipm6u6gu7ySAOvcD1ZwWs8
zpHKdPPt6dM3ryzdW2dPim+hT/c3wtprFEjTi8f06RO/faYd6blvOCRJ3IE0fTp6cZep9Y05DPTp
CdmLlZSA6JVR/UhLBBVnL/GZPbDdVOOWc4LzZgEKLwBMBwAwHQDAdAAA0wEATAcAMB0AwHQAANMB
AEwHwHQAANMBAEwHADAdAMB0AADTgfvCy+++8Y23/719u/j1F6AsjKfrXr7Lnzx/bJrnX3v24ivE
dOBO8c6b73/8SXMlevP494/p+Tsvd4rpovu/dMeiUBuvW0RfoisqRft5LNbvupbd5xFZzTOpO13C
utD7SesjZ/fQJ3o/BY03rvdCVTd3G83rX/paYmyzqpj+9PK1T61dbz579rc9YrqU/T+d99YJEW2B
nuZdafNUq12eqlsQvWt+9EIUtK4dqtFbzu7hk0wxrn+ajEt3t9G8/kX1frehEpoPePq9N+hfnzbP
1Vf198UXf/zm2083cuESCDFCD+Fjr1tBXhux3ab+s9yD6dJycVvrIjmyhY2vct3xXm92n4O+/q3/
fHyl92Pz2OXo+t9rmP/pR396tkue3kcJ2V9xjeihFxJits+3jup6IFs9gxLxMLlucwu9lynnZnP8
/vW3Xn7yWZubB/795s/vv/X9nWeksgl1Wj8CRE39ql3jC1uXDu/lfLSN9pMyJ+cGVOAUScMJJ7Xa
GT//31yJj/67+9qL3e+K+iqbv0Z8IWu7VPZTQ1nUeiaZZvtpnPKrRFxGA48Rf0R1xLbx41+++ME7
os/Nvf9+8e6Lxw0mppccok/rLtViWrQoQfcy1wvhLuT4vTeXdw6Daxb+qz98+Y82L28TFuPvm1+n
XzdbpOmZv7Wk5p3jqZlOhxRi1ym/MFbn5MqkFAtWLpOnDY5xr/ft8q3W+1ZnV7fYYuG9pvnRlw8v
us+Pattj8+1nn33++VYuuEyXolsXa6kr9dyyWz7vk0JVxJh+6tt26PWx+SJrD6Z14/C9Pad2+/op
lMdLu7zTtt770t0b2lAL/to0H/6MH8fvz4l+996G7WeoAVLjRu3x5UCIdmU8OxO13Tnq8PKHX3zV
LTB+59lfnm3rR47uJTHxFSD6ekyPrOHLpTV3ZPoVT59/2dA/v9rcDyi8gG2Zvheg8ALOATAdANMB
AEwHADAdAMB0ANgH2j1S9Wtnw7Lj9NNpcz+iVvj3AHvzXPpHqvBTlKdheqU/38ojD4t6h181PGH2
wszqF5O7T9bmZtrBjb9kgVCLgAusFtN1bjERkxlI9S/D566MU3JVbERxJgT1E89IPSy7EkJjNG3J
SSTSwLoxPZS8ciSrJT52goFRdG6mdzmJN2aTJ/zzkddGGGw/c/biBO82co+5+rYrF2V5SESY9J4u
pg+ZSDvXbKaJmp6gWMlKV7IpHHMZCzDAakwn6/80/KdlLOQrUpKEtMV0F8Po7NkLAIDpAACmAwCY
DgDbA09MnwEFlmiTTaa3XdZLxHTgHLg4AyBdl+4bQXadcW1eFWiX5/1FtMJWkf5WLQUqDeIsx1nd
DI92NQdj3nCtImZgBabfDPJePQxFGDn3U6ciozrS5Zjv+zh6jMHkbZqnDaSXC3rT/Qei3z/T++jX
nW8laRk/ttFO6WH6HVoYbr/xWH5gH7EeJO3gPHfHpq9n85huG4eTFPkkN4x4R5O8p5czTHcV6tPH
nvLWjjF+0qDztuVgQ2LDum4sgWVqhA11PdkGuX1FjhGtD1tbE9Ej3txTSD/tjDTAdE7rKYM3blHv
ZZ/Mv+Q7xIB4ZmyOnFivO54iGmD/9cR3EM1wfQLuMHsZHk3WKM9pVxpeK0wkj2sKPhGySqwg/wQb
uLM8PYFDGXmzhy5GvpBKp4SUJ5CHDIsvlFELz9udZO0lstjI/hSZtERY/+jjF2WEXI5NKVPyUZoh
+v3nKLSjSarESy/TDYX6mMz2H5Vm3cyptW/a2l+T9NQdj+vcUwvTYrYhkW88DQbXAg0zZkORwTUa
7v25mzEQvGmRn5+x751At+aOt73Ux6gduCuzSA3A6+fFy63ktsZnvCUUvGmRP5j1WxkJldMa4PGW
yJJTY9QO3ZXJVgPwFVsQPf0CxUUG0HlGQNHKORG97EFk3yOlFUrslQiOpcH2Nc4VrdYAbXAQUHgB
5wCYDoDpAACmA8CxEH5/ujmxzVuNcu6js7M4rckJfbMKfTdZW2b16NOKagPpbd+9480F86bFTaZK
eXlb7dABPvHTz96UeVw2032PaERvk3JjvdXX2MJxPbqms2ywrAiEsxf1LvTpNer6K9J5eHW/723q
7nvUByP6zsEuh4m+BjtBccCfvVjBUX9Ex5KqN5G3qZsMM5Tuup5dV4m7aYzv0sI+/kZFX8NlDIwH
5u4c0cw2U4tOyVmWX57eBAnr2zR/CwhPggJxpnPu9IDDtEx4I2+UjUrhteThOpAcmGE65YZEMrOV
IN0oYbyQ33bg/eYMTqdCtP+T2bXk/JYSzS9sJT97SX3chth5moKjMdtdD2GKjYMps+G5VAoz0jjk
qZv3rb1Qr1ZUf0bmkiFi1L9pn8kSOhqVJsM0LeJwp47k4JSSHYvBQcfDOwuMAwDhrWgpRB9hhfo8
fpm2jOW6v9M30X4TjWe7Y2EytKx5s82+vcm1BU2H35/ue5l643/0mYyPnpeumy9ZJ336Gnt4yHgx
O81FcttTJDWhtGBIDfTP/ddpy/Cp32h+mwoHLVg7spv3eSCMgrlNH08NAD36LcFcJRFSeMgg7TRD
OkmHjOcjMpKo5DdvNyOXNh3L06umesHSJ8jTRbSM0MgYoo2IEWqoJ25rvlmz6aMyHbg5e4kOBxVt
ZXABRM4NqLaevLH5Zu2moWU8Idm7+CftTWbEFWl2IhZCJpKan2lvQdOI6WfLYUR3ldcv99qmUPai
f+tJ2laKWAjlIanN+zzQSi1oGr8UABwq81oMxHTgOCnXLQYQ04FzADNSAEwHADAdAMB0AADTAQBM
BwAwHQDAdACYx/8B83nKaPF1cecAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-18" MODIFIED="2010-10-25 15:20:41 -0500" MODIFIED_BY="James Tacklind" NO="18" REF_ID="CMP-004.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Short-course treatment versus long-course treatment, outcome: 4.4 UTI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAADQCAMAAACN8A91AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-19" MODIFIED="2010-10-25 15:19:47 -0500" MODIFIED_BY="James Tacklind" NO="19" REF_ID="CMP-004.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Short-course treatment versus long-course treatment, outcome: 4.5 Hospitalization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAACgCAMAAACG0gK0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-20" MODIFIED="2010-11-06 20:04:01 -0500" MODIFIED_BY="[Empty name]" NO="20" REF_ID="CMP-005.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAADACAMAAABlEbbtAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-21" MODIFIED="2010-11-06 20:04:11 -0500" MODIFIED_BY="[Empty name]" NO="21" REF_ID="CMP-005.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.3 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAADACAMAAABlEbbtAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-22" MODIFIED="2010-08-06 10:59:38 -0500" MODIFIED_BY="James Tacklind" NO="22" REF_ID="CMP-005.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.4 UTI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAADQCAMAAABmx7R2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-23" MODIFIED="2010-11-06 20:04:30 -0500" MODIFIED_BY="[Empty name]" NO="23" REF_ID="CMP-005.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.5 Hospitalization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAACwCAMAAABuM7ssAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-24" MODIFIED="2010-10-25 15:18:07 -0500" MODIFIED_BY="James Tacklind" NO="24" REF_ID="CMP-006.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsgAAAFQCAMAAACVqHj3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-25" MODIFIED="2010-10-25 15:17:30 -0500" MODIFIED_BY="James Tacklind" NO="25" REF_ID="CMP-006.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.3 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsgAAAFQCAMAAACVqHj3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-26" MODIFIED="2010-10-25 11:23:03 -0500" MODIFIED_BY="James Tacklind" NO="26" REF_ID="CMP-006.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.4 UTI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAscAAAFQCAMAAABkoyN6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-27" MODIFIED="2010-10-25 15:16:29 -0500" MODIFIED_BY="James Tacklind" NO="27" REF_ID="CMP-006.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.5 Hospitalization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsgAAAFQCAMAAACVqHj3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-28" MODIFIED="2010-10-25 11:23:45 -0500" MODIFIED_BY="James Tacklind" NO="28" REF_ID="CMP-007.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 7 Sulfonamides versus other antibiotics, outcome: 7.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtMAAAHACAMAAABXgBSrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-29" MODIFIED="2010-10-25 15:13:18 -0500" MODIFIED_BY="James Tacklind" NO="29" REF_ID="CMP-008.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsYAAAFQCAMAAACLYUhEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-30" MODIFIED="2010-10-25 12:02:51 -0500" MODIFIED_BY="James Tacklind" NO="30" REF_ID="CMP-008.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.2 UTI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsgAAAFQCAMAAACVqHj3AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-31" MODIFIED="2010-10-25 15:15:02 -0500" MODIFIED_BY="James Tacklind" NO="31" REF_ID="CMP-008.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.3 Sepsis.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsYAAAFQCAMAAACLYUhEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-32" MODIFIED="2010-10-25 15:14:31 -0500" MODIFIED_BY="James Tacklind" NO="32" REF_ID="CMP-008.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.4 Hospitalization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsIAAAFQCAMAAACCiug+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-33" MODIFIED="2010-08-26 20:15:40 -0500" MODIFIED_BY="[Empty name]" NO="33" REF_ID="CMP-009.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 9 Oral versus systemic antibiotic administration, outcome: 9.1 Bacteriuria.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArcAAACwCAMAAAAi2bbUAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-34" MODIFIED="2010-08-06 11:01:30 -0500" MODIFIED_BY="James Tacklind" NO="34" REF_ID="CMP-009.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 9 Oral versus systemic antibiotic administration, outcome: 9.2 Fever.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAACwCAMAAADqtVwCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-35" MODIFIED="2010-08-06 11:01:37 -0500" MODIFIED_BY="James Tacklind" NO="35" REF_ID="CMP-009.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 9 Oral versus systemic antibiotic administration, outcome: 9.3 UTI.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAACwCAMAAADqtVwCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-36" MODIFIED="2010-04-04 22:49:24 -0500" MODIFIED_BY="[Empty name]" NO="36" REF_ID="CMP-009.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 9 Oral versus Systemic antibiotic administration, outcome: 9.4 Hospitalization.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAACgCAMAAADpY16ZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-37" MODIFIED="2010-10-17 21:14:16 -0500" MODIFIED_BY="[Empty name]" NO="37" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-38" MODIFIED="2010-10-17 21:14:16 -0500" MODIFIED_BY="[Empty name]" NO="38" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASMAAAN+CAIAAADRzfp6AAApnElEQVR42u3dvW4d1ffG8SPRULhw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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-07-19 20:31:59 -0500" MODIFIED_BY="[Empty name]"/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>